annual report corporate website brochure us meeting global challenges products commitment innovation health access medicines responsibility therapy areas community mission research development would better future investors like know media centre careers gsk wwwgskcom corporate annual responsibility review report human access medicines interview research innovation chairman ceo ethical conduct focus patient annual employees year vaccine human rights growing brands report environment powering performance community investment performance highlights business operating review summary remuneration report interview corporate governance chairman ceo summary financial statements financial summary shareholder information description business chairman ceos corporate governance closing letter remuneration report operating financial review prospects financial statements notes financial statements investor information feel better live longer head office registered office glaxosmithkline plc great west road designed cgi london brentford middlesex tw gs printed midas press uk paper used united kingdom production document made pulps harvested tel sustainable forests also using sawmill residues wwwgskcom forest thinnings elemental chlorinefree feel better live longer glaxosmithkline annual report discovering important medicines eradicating diseases improving quality peoples lives making medicines available greater number people matters people jp garnier left sir christopher gent rightthanks efforts employees around world successful year gsk best year ever financial standpoint also made substantial progress pipeline innovative medicines vaccines jp garnier chief executive officer interview sir christopher gent chairman jp garnier chief executive officer year success progress gsk delivered excellent financial performance year vaccine turnover billion grew constant exchange landmark year gsks vaccines business sales rates cer earnings per share eps p growth increased company made number cer putting gsk top tier global significant strategic acquisitions acquisition id biomedical pharmaceutical companies terms performance important move gsk says jp strengthened position global flu vaccine marketand increased figures confirm excellent growth key products ability prepare respond potential flu pandemic efficiency global operations says jp pharmaceutical industry making gsks performance driven sales key pharmaceutical products sales seretideadvair avandia coreg lamictal positive improvement peoples lives valtrex continued impressive growth says jp noble purpose develops medicines also saw good performance number newer vaccines save lives make products including avodart enlarging prostate boniva people feel better bonviva osteoporosis requip restless legs syndrome show great promise future sir christopher gent chairman patients gsk also acquired plant marietta pennsylvania looking strong growth seen key products give us access tissue culture technology vaccine vaccines business expected continue manufacturing acquisition corixa gives us valuable anticipate eps growth around cer adjuvant technology enabling us boost human immune response vaccines pipeline progress gsk continues meet challenge increasing research gsk also made good progress pipeline new vaccines development rd productivity discover new medicines expect five major vaccine launches next five years faster economically companys pipeline one says jp perhaps exciting cervarix cervical cancer largest promising industry projects expect file approval europe march clinical development end february usa end year including new chemical entities nces product line improving access medicines extensions ples vaccines gsk continues seek new ways improving access anticipate good news gsks latestage medicines people need least able pipeline developing fast pace eight major new obtain challenge particularly acute developing assets scheduled enter phase iii doubling world gsk offering many medicines latestage pipeline says jp vaccines notforprofit prices years gsk annual report however addressing challenge something gsk tragedies year brought home extent alone work gsk organisations bill pharmaceutical industry making positive melinda gates foundation highlights benefits public improvement peoples lives says sir christopher private partnerships provide way companies noble purpose develops medicines vaccines save asgsk private sector work together typically gsk lives make people feel better provides rd technology manufacturing distribution human expertise partners governments help fund continue meet challenges improving productivity development delivery costs rd ensuring patients access medicines even gsk entered three groundbreaking publicprivate poorest parts world thisreporthighlights partnerships develop vaccines biggest causes work done implement strategies meet death developing world today aids malaria challenges behind one human story tuberculosis thank employees efforts commitment passion individually publicprivate partnerships use teamwork helped us make gsk success today respective strengths partners also appreciate great support employees receive bring best families work gsk importantly model works grateful significant contribution tachi yamada chairman rd executive director retire june reaching patients welcome moncef slaoui succeed tachi gsk introduced strengthened number effect stjune would also like thank jack initiatives aimed improving patients understanding gsks ziegler president gsk consumer healthcare retired medicines programmes help gain access company january welcome successor john initiatives include gskspioneering clinical trial registerwhich clarke wealso thank dr lucy shapiro retire non expanded contain summaries clinical trials executive director companys annual general meeting end may welcome tom de swaan joined board january new nonexecutive director usa gsk placing emphasis education patient directtoconsumer advertising providing people advice gsks programmes industrys partnerships prescriptions assistance help people gain access medicines need initiatives seeking differentiate gsk company finding solutions healthcare challenges society faces believe well way achieving says sir christopher abroader contribution sir christopher gent jp garnier gsk 's global community investment activities chairman chief executive officer valued million equivalent group profit tax year saw number natural disasters including asian tsunami guatemalan hurricane new orleans floods earthquake struck parts india pakistan gsk quick respond help victims tragedies thanks go employees response crises makes proud lead organisation committed compassionate people respond effectively help people real need says jp disasters alone gsk contributed morethan million cash donated medicines vaccines valued million towards relief efforts gsk annual report contents report directors financial summary description business corporate governance remuneration report operating financial review prospects financial statements directors statements responsibility independent auditors report consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements financial statements glaxosmithkline plc investor information financial record shareholder information taxation information shareholders glossary terms index annual report approved board directors onst march published onrdmarch website glaxosmithklines website wwwgskcom gives additional information group information made available website constitute part annual report gsk annual report financial summary growth cer turnover operatingprofit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders earnings per share p p diluted earnings per share p p dividends per share p p net cashinflow operating activities net assets history development company glaxosmithkline plc public limited company incorporated th december english law shares arelisted london stock exchange new york stock exchange th december company acquired glaxo wellcome plc smithkline beecham plc english public limited companies way scheme arrangement merger two companies glaxo wellcome smithkline beecham major global healthcare businesses gskplcand subsidiary associated undertakingsconstitute major global healthcare group engaged creation discovery development manufacture marketing pharmaceutical consumer healthrelated products gskhas corporate head office london also operational headquarters philadelphia research triangle park usa operations somecountries products sold overcountries principal research development rd facilities uk usa japan italy spain belgium products currently manufactured countries major markets groups products usa france japan uk italy germany spain business segments gskoperates principally two industry segments pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare overthecounter medicines oral care nutritional healthcare group multinational business operates many countries earns revenues incurs costs many currencies results group reported sterling therefore affected movements exchange rates sterling overseas currencies average exchange rates prevailing period used translate results cash flows overseas subsidiary associated undertakings joint ventures sterling period end rates used translate net assets undertakings currencies influence translations us dollar euro japanese yen order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates cautionary statement regarding forwardlooking statements group 's reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give group 's current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factorsincluding document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pagestoof annual report gsk annual report srotcerid eht fo troperdescription business description business discusses strategy activities resources andoperating environment business identifies developments achievements following headings strategy strategyand business drivers business drivers build best product pipeline industry achieve commercial operational excellence improve access medicines best place best people best work global manufacturing supply corporate responsibility community investment annual report review products competition report annual report glaxosmithkline plc year pharmaceutical ended st december prepared accordance united consumer healthcare kingdom requirements regulatory environment summary report year annual review intended regulation investor needing full detail annual report intellectual property produced separate document responsibility environment health safety annual review includes joint statement chairman discussion groups management structures corporate chief executive officer summary review operations summary governance procedures set corporate governance pages financial statements summary remuneration report annual review issued shareholders annual report remuneration report gives details groups policies issued shareholders elected receive documents directors remuneration amounts earned directors available glaxosmithklines corporate website wwwgskcom senior management pagesto discussion groups operating financial performance financial resources given operating financial review prospects pagesto gsk annual report srotcerid eht fo troper mission global quest improve quality human life enabling people feel better live longer spirit undertake quest enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency report glaxosmithklinethe groupor gskmeans glaxosmithkline plc subsidiary undertakings company means glaxosmithkline plc glaxosmithkline share means ordinary share glaxosmithkline plc p american depositary share ads represents two glaxosmithkline shares throughout report figures quoted market size market share market growth rates relate months ended th september later available gsksestimates based recent data independent external sources valued sterling relevant exchange rates figures quoted product market share reflect sales gskand licensees brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline associated companies exception baycoland levitra trademarks bayer bonivabonviva trademark roche entereg trademark adolor corporation usa hepsera trademark gilead sciencesin countries including usa integrilin trademark ofmillennium pharmaceuticals micropump trademark flamel technologies natrecor trademark scios janssen navelbine atrademark pierre fabre mdicament nicoderm atrademarkof sanofiaventis elan novartis glaxosmithkline certain countriespritor trademark boehringer ingelheim andvesicare trademark yamanouchi pharmaceuticals japan south korea trademark astellas pharmaceuticalsall used certain countries license groupstrategy business drivers glaxosmithklineis addressing key challenges face corporate responsibility pharmaceutical industry society whole working tomeet challengesand implement thesebusiness driversgsk recognises responsibility support improving productivity research development delivery better healthcare education underserved ensuring patients access new medicines communities connect business decisions ethical social environmental concerns gsks commitment theseisoutlinedon strategies meet challenges focus several business pagestowith information available corporate drivers responsibility report available website build best product pipeline industry wwwgskcom group aiming create best product pipeline industry benefit patients consumers society includes developing focused portfolio strategy support pipeline manage full life cycle compounds launch prescription medicines becoming overthecounter products appropriate strategy includes selective licensing efficient execution development commercialisation supply chain processes gsks rd organisation measures productivity number innovation products creates also commercial value theseproducts ability address unmet needs consumers includes patients healthcare professionals budget holders regulators perspective constitutes valuable new product details given pages achieve commercial operational excellence gsk links research commercial operations closely order maximise value portfolio compounds developed tested marketing campaigns sales efforts planned appropriate within markets group aims build strong relationships patients consumers ultimate users medicines common approaches management processes business functions used internationally diverse talented management team order create sustain competitive advantage markets details given page improve access medicines gsk created extensive programmes designed improve healthcare people limited access medicines developed developing worldthese set improve access medicines section report page best place best people best work single greatest source competitive advantage organisation people groups ambition tobethe place great people apply energy passion make difference world skills intellect key components successful implementation groups strategy work environment supports informed empowered resilient workforce group values draws diverse knowledge perspectives experience styles global community details given page gsk annual report srotcerid eht fo troper description businessbuild best product pipeline industry research development pharmaceuticals cedd responsible assessing safety development characteristics lead compounds preclinical screens gsks strategic intent become indisputable leader may involve using animals allows selection industry success depends bedrock groups best candidate new medicine achieved business vibrant productive research development cedds responsible demonstrating compound rd function develops new ways help patients satisfied proof therapeutic concept midstage clinical trials supporting existing products decision made whether information available justifies focus thepatient compounds progression latestage drug development rdsfocuson patientinvolvesseekingthe views patients largescale clinical trials conducted register commercialise families understanding important aspects product disease impact lives information conjunction discussions key opinion leaders used compounds entered clinical trials first time shape drug development programmes new medicines agsk research facility focusing new therapies treatment likely benefit patients neurodegenerative illnessessuch alzheimers diseasewas opened finding candidate compounds singaporein two components needed early stages finding new application experimental medicine major opportunity medicines targets shown affect mechanisms industryan important tool field clinical imaging important pathological processes human disease compounds enables visualisation changes body made response able modulate behaviour specific targets administration new medicine worldclass imaging many diseases arise complex interactions gene experts wererecruited usaand uk gsk prepared variants environmental factors within gsk genetics research open clinical imaging centre hammersmith hospital aims take advantage identifyinggenes influence london addition rd established global common diseases large unmet medical needs major patient collaborations academic imaging centres make aleader burdens insightshelp search fortargets known application imaging drug discovery development relevance disease hence greater chance delivering converting candidates medicines benefit patients preclinical development pcd includes wide range activities discovery research dr produces lead compounds may throughout entire drug development process also involves influence targets whichform basis drug discovery efforts enhancement existing products devising convenient gsks centres excellence drug discovery cedds formulations early development process metabolism dr performed million assays provided cedds safety compounds evaluated laboratory animals highquality new lead compounds investment dr testing humans testing required animals highly regulated focused increasing quality quantity lead see animals research page compounds available pcd researchers investigate appropriate dosage forms example selecting best candidate molecules tablets inhalers develop formulations enhance drugs fundamental steps turning lead compound drug effectiveness ease use patient processes candidate optimising potency efficacyandsafety supporting analytical methods drug synthesis product demonstrating validity therapeutic hypothesis early formulation delivery scaled meet increasing supply clinical trials resulting candidate requirements leads technical transfer processes methods manufacturing new product supply process steps helped rapid informed decision making creative partnership rd global manufacturing supply solutions issues inevitably arise phase development ensures robust product developed largescale commercial gsk hasdesignedthe ceddswhich focused specific disease manufacturing launch areasto nimble entrepreneurial seven cedds based europe usa provide focus development process major functional components clinical medical biomedical data regulatory biopharmaceuticals stevenage uk safety integrated single management organisation cardiovascular urogenital diseases upper merion usa worldwide development wwd metabolic viral diseases research triangle park usa microbial musculoskeletal proliferative diseases including cancer gsks medicine development centres mdcs provide focus upper providence usa latestage development responsible creating value neurology gastrointestinal diseases harlow uk delivery full product development plans managing dayto psychiatry verona italy day operational activities latestage development portfolio respiratory inflammation stevenage uk ensuring strong partnerships cedds global commercial strategy gcs gsk annual report srotcerid eht fo troper description businessbuild best product pipeline industry continued mdcs based major usaand uk sites aligned extending use existing products following therapeutic areas product launched important establish additional ways patients helped cardiovascularmetabolic investigating whether illnesses may treated infectious diseases including diseases developing world product development additional convenient dosage ddw forms developments reflect feedback patients musculoskeletalinflammationgastrointestinalurology medical professions others result continuing research neuroscience psychiatryneurology disease causes oncology respiratory examples importance lifecycle management gsk include new indication restless leg syndrome requipand monthly teams responsible maximising worldwide dosing boniva simplify administration prevention development opportunities product within remit osteoporosis line extensionsaddsignificantvalue totheproduct information needed support registration safety portfolio recent examplessuch augmentin esxr seroxatpaxil programmes pricing formulary negotiations available crand wellbutrin xl achieved sales millionin needed commercial input global commercial strategy ensures regional marketing needs integrated development productivity plans early stage challenge increasing rd productivity continued programmes identify associations diseases genes addition rd investigating new ways operating enableit helped point areas researchmorelikely produce new ways respond variety external pressures industrysuch helping patients increased automation screening provided increasing regulatory stringencyso thatit ispositioned ensure higher quality lead compounds quickly thateffective new medicines reach patients soon possible progress portfolio communicated investors media gsk believes pharmacogenetic research correlates regular intervals year amajor presentation genetic data response medicine help reduce pipeline vaccine portfolio held june oncology supportive attrition improve productivity rd collecting dna samples care portfolio november details gsks product clinical studies identify pharmacogenetic information help development pipeline given pagesto predict patients response information intended define patient groups likely gain benefit treatment suffer managing portfolio side effectas compound progresses development improved productivity compounds progressed clinic ultimately pharmacogenetics promises provide later phases development progress however puts demands physicians information help select medicine rd resources important look objectively dose likely benefit patient portfoliokey projects reaching significant milestones reviewed month product management board pmb rd taken several approaches improving responsible determining asset met criteria passing productivity clinical trialsincluding increasing use countries next phase development outside western europe usaand introduction direct electronic data capture new clinical trials gsk continues identify compounds companies improvements productivity continue going forward would enhance portfolio create innovative collaborations ensure group regarded partner choice large clinical trials sponsored gsk irrespective take small companies place conducted according international standards good clinical practice applicable laws regulations protocols specific centre excellence external drug discovery reviewed external regulatory agencies relevant created small internal management team responsible countries required protocols considered ethics delivering compounds clinical proof concept establishing review committeewhose remit covers site study managing longterm strategic collaborations biotechnology take place safety data routinely collected throughout development companies small midsized pharmaceutical companies programmes reported national regional regulatory academic institutionsthe group committed funding two agencies line applicable regulations years collaborations option renew additional three years gsk global safety board responsible internally approving pivotal studies investigating issues related patient safety inlicensing arising development programmeduring gsk took inlicensing comarketingcopromotion agreements concluded step making information clinical trials widely easily available extending clinical trial register public website development commercialisation vertexpharmaceuticals clinical trials data published regulatory authorities incs vx nav nachannel blocker plus backup molecules continue informed data generated may pain preclinical reassuredofthe safety efficacy gsks productsthe clinical trial development promotion allergan incs botox japan register enhance ability clinicians make informed clinical china judgements benefit patients development commercialisation renin inhibitor program preclinical vitae pharmaceuticals inc gsk annual report srotcerid eht fo troper description businessbuild best product pipeline industry continued exercise optionfor theravance incs inhaled muscarinic gskmade number ofinvestments thatstrengthen antagonist beta agonist programme preclinical vaccinecapabilities exercise options human genome science incs significant increase flu vaccine manufacturing development lymphostat b completed phase iia rheumatoid arthritis capacity systematic lupus erythematosus mapatumumab trail r acquiring idbiomedical north american developer vaccines monoclonal antibody various cancer indications phase ii infectious diseases producer influenza vaccines discontinuations sites canada usa million rd carries risk failure lead compounds showing positive investing million extending german vaccine facility activity validated target may proveinsufficiently safe purchasing vaccine rd manufacturing site usa introduce humans orimpossible manufacture commercial acquiringus based corixa corporation developer innovative scale also compounds may show expected benefits vaccine adjuvants approximately million patients large scale clinical testing discontinuations occur entering three groundbreaking publicprivate partnerships despite extensive predictive testing develop vaccines three biggest killers developing worldaids malaria tuberculosis latestage projects terminated phase iii included aplaviroc hiv avandiafor psoriasis gsk expects launch five major new vaccines within next five years lamictal xrfor schizophrenia ahumanpapillomavirusvaccinepreventingcervical cancer usa eu launch vaccine rotavirus induced research development vaccines gastroenteritisand strengthening presence international majority gsks vaccine rd activities conducted markets biologicals headquarters rixensart belgium theseincludeclinical vaccine pneumococcal disease development regulatory strategy commercial strategy scaling improved vaccine influenza vaccine production packaging support functions vaccine combinations meningitis scientists devoted developing new vaccines costeffective convenient combination vaccines prevent strength gsks vaccine pipeline expected provide infections cause serious medical problems worldwidegsk opportunities gsk todeliver new vaccines many years come also targeting therapeutic vaccines may prevent relapse diseases developing world cancer patients continued investment research diseases disproportionately vaccine discovery involves many collaborationswith academia affect developing world essential longterm thebiotech industry worldwide allows identification new improvement health people live regions part vaccine antigens expressed yeast bacteria gsks response challenge operates drug discovery unit mammalian cells purified high level dedicated finding new medicines diseases based tres cantos spain work undertaken tres cantos focuses malaria followed formulation clinical lots vaccine tuberculosis together work elsewhere group may involvemixing antigens selected novel proprietary adjuvants hivaids vaccines means gsk addressing prevention designed stimulate goodimmune response first treatment three world health organizations step evaluate safety efficacy candidate vaccine top priority diseases preclinical setting usually involving animal model candidate vaccine tested clinical trials healthy individuals evaluate gsk currently clinical programmes relevance developing safety andeffectivenessin inducing immune response protect world eight aimed producing vaccines medicines body frominfectionencountered later natural settingphase diseases disproportionately affect developing countries iii largescale field trials healthy individuals follow establish publicprivate partnerships ppp remain essential fund research safety efficacy cross section populationphase iii commercially viable market potential product results obtained clinical trials data regarding gsk leader working ppp continues collaborate closely development quality largescale production process many governments academic centres united nations agencies facilities combined regulatory file submitted global funding bodies area maximise expertise authorities various countries vaccine knowledge dual benefit encouraging research made available development accelerating access medicines developing world example gsk announced partnerships launch post marketing studies considerable size set global alliance tb drug development aeras global assess vaccination programmesimpact monitor vaccine tbvaccine foundation international aids vaccine initiative safety phase iv gsks malaria falcipain inhibitors project chosen medicines vaccine manufacturing particularly complex requires use malaria venture project year award living microorganisms sophisticatedqualityassurance andquality control procedures place ensure quality safety vaccinesand commonly includes animal usedue biological nature health authorities maysubject vaccines second controlto guarantee highest quality standards gsk annual report srotcerid eht fo troper description businessbuild best product pipeline industry continued animals research gsks submissions regulatory authorities usa eu ethical regulatory scientific reasons research using animals first time approvals remains small vital part research development new usa europe medicines vaccines gsk uses animals submission alternative numbers required test group approval strives exceed regulatory standards care use animals uses undergoes internal external review assure standards latestage pipeline expected expand vast majority experimental methods use animals eight major assets anticipated enter phase iii development also gsk actively engaged research develop validate tests gsk anticipates seven products approvedandor either avoid use animals research reduce numbers launched seven product filings planned details needed animals used research unnecessary pain developments expected see gsk outlook suffering scrupulously avoided page gsk understands use animals research purposes gsks policy obtain patent protection significant products commands high level public interest glaxosmithkline public discovered developed rd activities patent protection policy position care ethical use animals research new active ingredients available significant markets information reports available website protection also obtained new pharmaceutical formulations wwwgskcomor secretariat manufacturing processes new medical uses special devices administering products research development consumer healthcare key rd aligned closely new consumer healthcare v vaccine operating model structure global brands mirrors p pharmaccine commercial structure rd teams paired commercial compounds shionogiglaxosmithkline pharmaceuticals llc joint teams located principal centres consumer healthcare venture rd weybridge uk parsippany usa inlicense alliance relationship third party colocation sites termed innovation centres focus date first submission rd identification rapid development novel date first regulatory approval maa first eu approval letter products bring benefits consumers overthecounter al approvable letterindicates ultimately approval given otc oral care nutritional healthcare markets subject resolution ofdeficiencies maa marketing authorisation application europe gsks pipeline nda new drug application usa phase evaluation clinical pharmacology usually conducted volunteers charton rightshows new chemical entities nceandproduct phase ii determination dose initial evaluation efficacy conducted line extensions ple projects clinic small number patients end february gsk hadnearly pharmaceutical vaccine phase iii large comparative study compound versus placebo andor established projects development clinic comprising treatment patients establish clinical benefit safety nces ples vaccines compared since number projects late stages developmenthas increased maturity late stage pipeline expected lead increase registrations coming years content drug development portfolio change time new compounds progress discovery development development market owing nature drug development process many compounds especially early stages investigation may terminated progress development phase nces multiple indications counted nces later phases counted indication competitive reasons new projects preclinical development disclosed project types may identified gsk annual report srotcerid eht fo troper description business pip eline la e stage pipeline growth nces phase iii nces phase registration ples nces phase ii vaccinesbuild best product pipeline industry continued estimated filingdates compoundproduct type indication phase maa nda cardiovascular metabolic high affinity nicotinic acid receptor dyslipidaemia hma agonist p kinase inhibitor atherosclerosis also rheumatoid arthritis chronic obstructive pulmonary disease copd factor xa inhibitor prevention stroke atrial fibrillation p kinase inhibitor atherosclerosis also rheumatoid arthritis copd rilapladib lipoproteinassociated phospholipase atherosclerosis lppla inhibitor peroxisome proliferatoractivator receptor dyslipidaemia ii ppar delta agonist ppar alpha agonist dyslipidaemia ii odiparcil indirect thrombin inhibitor prevention thrombotic complications cardiovascular ii disease darapladib lppla inhibitor atherosclerosis lliii arixtra synthetic factor xa inhibitor treatment acute coronary syndrome iii coreg cr beta blocker hypertension congestive heart failure oncedaily submitted na sdec metabolicprojects ppar pan agonist type diabetes glucagonlike peptide agonist type diabetes melanin concentrating hormone antagonist obesity radafaxine noradrenalinedopamine reuptake inhibitor obesity also fibromyalgia neuropathic pain depression sodium dependent glucose transport sglt type diabetes ii inhibitor ppar pan agonist type diabetes ii sglt inhibitor obesity ii denagliptin dipeptidyl peptidase lv dpp iv inhibitor type diabetes ii solabegron beta adrenergic agonist type diabetes also overactive bladder ii avandamet xr ppar gamma agonist metformin type diabetes extended release iii avandia simvastatin ppar gamma agonist statin type diabetes iii avandaryl ppar gamma agonist sulphonylurea type diabetes fixed dose combination approved smay adec infectious diseases oral pleuromutilin treatment ofbacterial infections oral pleuromutilin treatment bacterial infections phospholipid antiendotoxin emulsion sepsis ii farglitazar ppar gamma agonist hepatic fibrosis ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na chlorproguanil dapsone antifolate artemisinin treatment uncomplicated malaria iil na artesunate cda etaquine aminoquinoline malaria iii altabaxretapamulin topical pleuromutilin bacterial skin infections submitted snov antivirals dna antiviral vaccine hiv infection brecanavir aspartyl protease inhibitor hiv infection ii relenza neuraminidase inhibitor influenza prophylaxis submitted snov snov musculoskeletal inflammation gastrointestinal urology oxytocin antagonist threatened preterm labour gselective oestrogen receptor modulator treatment menopausal symptoms vitronectin integrin antagonist agerelated macular degeneration potassium channel opener overactive bladder relacatib cathepsin k inhibitor osteoporosis osteoarthritis also bone metastases calcium antagonist osteoporosis parathyroid hormone agonist osteoporosis tyrosine kinase inhibitor psoriasis pde iv inhibitor topical atopic dermatitis corticotrophin releasing factor crf antagonistirritable bowel syndrome also depression anxiety dutasteride testosterone alpha reductase inhibitor testosterone hypogonadism fixed dose combination solabegron beta adrenergic agonist overactive bladder also type diabetes endothelial cell adhesion molecule inhibitor inflammatory bowel disease ii selective inos inhibitor rheumatoid arthritis also migraine ii p kinase inhibitor rheumatoid arthritis also atherosclerosis copd ii dual alpha integrin antagonist vla inflammatory bowel disease also multiple sclerosis ii p kinase inhibitor oral rheumatoid arthritis also atherosclerosis copd ii casopitant nk antagonist overactive bladder also depression anxiety ii chemotherapy induced postoperative nausea vomiting mepolizumab antiil monoclonal antibody eosinophilic esophagitis also asthma nasal polyposis ii rosiglitazone xr ppar gamma agonist rheumatoid arthritis also alzheimers disease ii avodart alpha blocker alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fixed dose combination iii avodart alpha reductase inhibitor reduction risk prostate cancer iii enteregentrareg peripheral muopioid antagonist opioid induced gi symptoms iii mepolizumab antiil monoclonal antibody hypereosinophilic syndromealso asthma nasal polyposisiii enteregentrareg peripheral muopioid antagonist post operative ileus approvable aljul bonivabonviva bisphosphonate treatment postmenopausal osteoporosis approved sapr ajan ivinjection gsk annual report srotcerid eht fo troper description businessbuild best product pipeline industry continued gsk annual report srotcerid eht fo troper description business estimated filing dates compoundproduct type indication phase maa nda neurosciences presynaptic mixed ht antagonist depression anxiety histamine h antagonist dementia endothelin antagonist stroke gap junction blocker migraine epilepsy neuropathic pain dualacting cox inhibitor acute chronic pain conditions including neuropathic pain schizophrenia endothelin antagonist stroke nk antagonist depression anxiety noncannabinoid cb agonist inflammatory pain crf antagonist depression anxiety also irritable bowel syndrome radafaxine noradrenalinedopamine reuptake inhibitor fibromyalgia neuropathic pain also obesity selective inos inhibitor migraine also rheumatoid arthritis ii triple htnoradrenalinedopamine reuptake depression attention deficit hyperactivity disorder ii inhibitor glycine antagonist smoking cessation ii dual alpha integrin antagonist vla multiple sclerosis also inflammatory bowel disease ii transient receptor potential vanilloid acute migraine ii trpv antagonist ht antagonist dementia ii mixed htdopaminergic antagonist schizophrenia ii casopitant nk antagonist depression anxiety also overactive bladder ii chemotherapy induced postoperative nausea vomiting radafaxine noradrenalinedopamine reuptake inhibitor depression also obesity ii rosiglitazone xr ppar gamma agonist alzheimer 's disease also rheumatoid arthritis ii talnetant nk antagonist schizophrenia ii vestipitant paroxetine nk antagonist selective serotonin reuptake depression anxiety ii inhibitor dualacting cox inhibitor acute chronic pain iii lamictal sodium channel inhibitor bipolar disorder acute treatment iii na lamictal xr sodium channel inhibitor epilepsy oncedaily iii requipextended release nonergot dopamine agonist restless legs syndrome iii requipmodutabxl nonergot dopamine agonist parkinsons disease oncedaily controlled release submitted sdec hour formulation trexima ht agonist naproxen migraine fixed dose combination submitted na saug wellbutrin xl noradrenalinedopamine reuptake inhibitor seasonal affective disorder submitted sdec wellbutrin xl noradrenalinedopamine reuptake inhibitor depression approved aaug oncology thrombopoietin agonist thrombocytopaenia kinesin spindle protein ksp inhibitor cancer elacridar oral bioenhancer cancer relacatib cathepsin k inhibitor bone metastases also osteoporosis osteoarthritis casopitant nk antagonist postoperative nausea vomiting ii also overactive bladder depression anxiety casopitant nk antagonist chemotherapy induced nausea vomiting ii also overactive bladder depression anxiety ethynylcytidine selective rna polymerase inhibitor solid tumours ii iboctadekin recombinant human il immunomodulator immunologicallysensitive cancers melanoma renal cell ii ispinesib ksp inhibitor nonsmall cell lung cancer tumours ii pazopanib vascular endothelial growth factor vegf solid tumours ii tyrosine kinase inhibitor vestipitant nk antagonist postoperative nausea vomiting ii eltrombopag thrombopoietin agonist thrombocytopaenia iii hycamtin topoisomerase inhibitor ovarian cancer firstline therapy iii hycamtin topoisomerase inhibitor small cell lung cancer secondline therapy oral formulationiii tykerbtycerb erbb epidermal growth factor receptor breast cancer also renalhead neck cancers iii egfr dual kinase inhibitor hycamtin topoisomerase inhibitor cervical cancer secondline therapy submitted sdec arranon guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas approved aoct hycamtin topoisomerase inhibitor small cell lung cancer secondline therapy approved ajan anovbuild best product pipeline industry continued gsk annual report srotcerid eht fo troper description business estimated filing dates compoundproduct type indication phase maa nda respiratory pde iv inhibitor inhaled asthma copd allergic rhinitis muscarinic acetylcholine antagonist copd p kinase inhibitor oral copd also atherosclerosis rheumatoid arthritis novel glucocorticoid agonist asthma muscarinic antagonist beta agonist copd longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist muscarinic acetylcholine antagonist copd ii longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist p kinase inhibitor oral copd also rheumatoid arthritis atherosclerosis ii glucocorticoid agonist asthma copd combination longacting ii beta agonist also allergic rhinitis glucocorticoid agonist asthma copd combination longacting ii beta agonist mepolizumab antiil monoclonal antibody asthma nasal polyposis also hypereosinophilic syndrome ii eosinophilic esophagitis avamysallermist glucocorticoid agonist allergic rhinitis iii seretideadvair beta agonistinhaled corticosteroid copd mortality claim iii seretide beta agonistinhaled corticosteroid asthma initial maintenance therapy submitted saug na ariflo pde iv inhibitor oral copd approvable aloct seretideadvair beta agonistinhaled corticosteroid asthma noncfc inhaler approved ajun aloct oct paediatric vaccines hibmencytt conjugated neisseria meningitis groups cy disease ii haemophilus influenzae type b disease prophylaxis menacwytt conjugated neisseria meningitis groups c wy disease ii prophylaxis globorix conjugated diptheria tetanus pertussis hepatitis b haemophilus lll influenzae type b disease neisseria meningitis groups ac disease prophylaxis streptorix conjugated spneumoniae disease prophylaxis children lll priorixtetra live attenuated measles mumps rubella varicella prophylaxis submitted sapr rotarix live attenuated oral rotavirus induced gastroenteritis prophylaxis submitted sdec menitorix conjugated neisseria meningitis group c diseasehaemophilus approved adec influenzae type b disease prophylaxis vaccines hiv recombinant hiv infection prophylaxis l pneumoniae elderly recombinant pneumoniae disease prophylaxis l pneumoniae paediatric recombinant pneumoniae disease prophylaxis l pgcvax varicella zostervirus recombinant varicella zoster prevention l tuberculosis recombinant tuberculosis prophylaxis iii dengue fever attenuated tetravalent vaccine dengue fever prophylaxis epsteinbarr virus recombinant ebv infection prophylaxis flu improved inactivated splitadjuvanted influenza prophylaxis flu intranasal fluinsure inactivated splitadjuvanted influenza prophylaxis hepatitis e virus recombinant hepatitis e prophylaxis mosquirix recombinant malaria prophylaxis cervarix recombinant human papilloma virus infection prophylaxis lll fluviral inactivated split influenza prophylaxis lll simplirix recombinant genital herpes prophylaxis lll flu pandemic inactivated wholealuminium salt adjuvant influenza prophylaxis submitted sdec pharmaccines p recombinant treatment prostate cancer l recombinant treatment breast cancer lii mage recombinant treatment nonsmall cell lung cancer melanoma llachieve commercial operational excellence gskundertakes range activities maximise commercial consumerhealthcare marketing excellence potential intellectual property introducing innovative products structure ofthisbusiness redesigned order focus many markets possible accelerating processof bringing brands growth opportunities brands new products market increasing brand recognition ensuring sales multiple marketsa new team called future group patients access new medicines pharmaceutical created develop global approach support global consumer healthcare businesses focus ways improve brands brands large marketed several existing performance commercial operational excellence territories generally one lead marketone anchor market initiativessome team leads development lead market brands remaining valuable localbrands managedthrougha new modelwhich worldwide pharmaceutical sales force excellence retains local responsibility brand communications gskssales force always ranked high surveys healthcare innovation local enterprise brands also supported globally professionals worldwide sales force excellence wsfe aims regionally ensure application best practice cross improve customer satisfaction even pollination innovation time available physicians learn new medicines maintaining high standards clinical studies precious wsfe initiative sales gsk expects employees meet high ethical standards aspects representatives strengthen product knowledge learn deliver business conducting activities honesty integrity patientspecific treatment options efficiently adhering corporate responsibility principles complying effectively research shows sales visit highly effective applicable laws regulations gsk audits operations ensure representative engages physician dialogue around patient types relevant standards expected marketing practices supports message visual aids illustrate clinical results reached exceeded group introduced single global sales call model focuses commitment gsk code conduct reinforced year treating patient dialogue gsk senior management certification programme medicine appropriate effective administer managers certified complied performance safelyall field people groups key markets trained integrity principles new approach entire sales organisation isnow involvedin wsfe bring cultural change patient advocacy raises ethical standards helps build longterm trusting patient advocacy initiative demonstrated significant progress relationships healthcare community since inception rationale strategy centres enhancing access groups medicines connecting pharmaceutical marketing excellence patient groups ensure informed disease treatments large numbers patients suffering effects disease well improvinggsksreputation patientcentric group continue unable benefit innovative medicines treatments one gsks goals provide accurate balanced initially launched usprogramme itisnowa critical initiative information groups products allow many people strategic plans throughout world patientadvocacy teams possible benefit gsks medical advances example within usa europe shared best practices established processes europe around patients suffering chronic obstructive optimise interaction patient groups patientadvocacy pulmonary diseasecopdare diagnosed leaders summits held usa europe canada receive regular maintenance drug therapy gsks marketing initiative patient advocates attending gsk sponsored meetings implements programmes overcome barriers proper diagnosis throughout world two diabetes summits held minority treatment programmes begin show effects legislative groups usa hopes developing base societal costs disease decrease extent gsk product future legislation awareness activities chosen patients treatment group benefit well vision factory marketing codes gsk introduced vision factory initiative global manufacturing gsk committed ethical responsible patientcentred supply identifying improvements productivity cost marketing groups pharmaceutical marketing promotional reduction increase operational excellence activity policy governs marketing activities apply manufacturing operations ensure product quality patient safety employees suppliers contractors agents policy requires paramount marketing promotional activities based valid procurement scientific evidence comply applicable laws regulations gsknonproduction operations supported number third policy supported regional marketing practices codes party purchases worldwide covers areas including media europe gsks international region japan usa codes travel rd itand marketing purchases managed apply ethical standards reflect differences market procurement behalf internal customers covers structures national healthcare systems regulations assurance supply service quality cost innovation widely incorporate principles industry codes practice recognised industry analysts global best practice leader european federation pharmaceutical industries associations procurement works collaboratively business develop international federation pharmaceutical manufacturers associations implement sourcing strategy ensures gsk receives best value japan pharmaceutical manufacturers association pharmaceutical buying goods services research manufacturers america marketing codes gsk annual report srotcerid eht fo troper description businessimprove access medicines access healthcare developing world much achieved sustainable progress occur significant barriers stand way better access access healthcare developing countries remains major healthcare tackled shared responsibility sectors global challenge global community problem rooted society governments international agencies charities academic poverty lack political continues demand significant institutions pharmaceutical industry others mobilisation resources true spirit partnership gsk continues play vital role commitment rd access medicines thedeveloped world diseases particularly prevalent developing world programme preferential pricing antiretrovirals arvs anti programmes usa malarials vaccines community investment gskis working provide meaningful access medicines people programmes willingness seek innovative solutions limited financial resources without prescription drug voluntary licencing arrangements insurance gsks uspatient assistance programs provided million worth medicinesvalued wholesale acquisition cost preferential pricing programme toqualifying low income us residents gsk offered vaccines key organisations vaccination programmes developing countries preferential prices uninsured americans qualify medicare years group also sets single notforprofit price medicaid gsk pharmaceutical companies created arvs antimalarials wide range customers together rx access programme qualified individuals offering least developed countries un definition subsaharan africa reductions usual pharmacy cost onmore medicines well country coordinating mechanismprojects fullyfunded launched together rxaccess global fund fight aids tb malaria us cardholders whosaved millionin presidents emergency plan aids relief pepfar gsk participates partnership prescription assistance ppa gsk committed contributing health improvements largest nationalprogrammededicated helping people need sustainable manner prices arvs antimalarials access prescription medicinesppa matched one million therefore set levels profit made direct costs us patients need programs providing significant help gsk covered allowing supply sustained long required us pharmaceutical companies launched program gsk shipped developing countries overmillion partnership healthcare physician patient advocacy tablets preferentiallypriced combivirand million tablets organisations preferentiallypriced epivir programmes countries offer notforprofit prices requires sustainable framework group also introduced orange cards providing discounts combining gsks commitment preferential pricing certain gsk prescription medicines eligible patients bulgaria commitments governments developed world avoid lithuaniaand ukraine nature discounts varies price referencing preferentially priced medicines help countries depending needs patient way prevent product diversion gsk taken steps minimise healthcare system operates threat diversion retrovir syrup epivirsolutioncombivir epivir preparing flu pandemic tablet trizivirare available special access packs group committed everything support countries differentiated red opposed traditional governments health authorities around world planning white combivir epivir tablets registered across responses possible global influenza pandemic gsk first number international markets gsk company company submit mockup dossier emea apply registered arvs european unions antidiversion pandemic influenza vaccine marketing authorisation eu regulation also continued encourage allows accelerated final registration pandemic countries take necessary steps ensure introduction declared gskis also developing hn prototype pandemic strict enforcement appropriate antidiversion measures vaccine clinical trials testing vaccine hn flu innovative solutions strain taking place increase performance gsk shown industry leadership granting voluntary licences prototype pandemic vaccine gsk developed innovative seven generic companies manufacture supply arvs adjuvant may allow loweramounts antigento used public private sectors subsaharan africa essential formanufacturing large number dosesin event pandemic looking ahead gskwill continue build products pricing partnership commitments help improve healthcare developing world however significant increase funding global community still needed also important maintain incentives rd protection intellectual property gsk annual report srotcerid eht fo troper description businessbe best place best people best work glaxosmithkline people group committed employment policies free discrimination potential existing staff grounds glaxosmithkline committed creating best place best age race ethnic national origin gender sexual orientation faith people best work deliver groups business strategy disability gsk committed offering people disabilities group employs people countries access full range recruitment career opportunitiesevery recruitment talent management leadership effort made retain support employees become disabled development working group attracting best people industry critical enhancing communication employee involvement sustaining gsks performance groups recruiters usaand good internal communication important achieving gsks business uk arefocussedon proactive identification talented external objectives well creating open inclusive work environment candidates key jobs acting internal headhunting function range communication channels keep employees annual performance development planning pdp process uptodate gsks news enable give feedback ensures employees set objectives aligned corporate include strategies set behavioural goalsand create development plan pdps mygsk global intranet site provides news updates reviewed throughout year culminating end year qa section employees put questions directly chief review factored compensation decisions executive officer senior executives questions annual talent management cycle identifies highest performing answered month behind news section gsk people business function individuals given feedback intranet gives groups position important issues linked development needs key talent developed press stories gsk exceptional management leadership programmes detail spirit gsks internal magazine reaches around employees see groups corporate responsibility report exposure top throughout world four times year management programmes chief executive forum confidential feedback mechanisms enable employees raise via stretch assignments pool successors identified concerns include gsks integrity helpline vicepresident positions critical roles organisation group conducts global leadership survey gls every two years performance reward last gls conducted among reward systems designed support culture high managers gauge opinion critical issues culture performance attract retain best people performance confidence groups future results showed significant based pay share awards share options align employee interests improvement items compared results accomplishment business targets compared global benchmarks managers rate highly fostering alignment personal goals glaxosmithkline mission business ethics reputation fostering environment ethics integrity survey performance integrity central operating gsk managers proud part glaxosmithkline recent global leadership survey showed believe would gladly refer friend family member work gsk people department show commitment performance integrity enhance managers leaders skills programme leadership surveys many business areasconduct surveys ethical decisionmaking run attended bypeople employees gauge levels engagement satisfaction training area planned motivation business function developed action plans address areas improvement based results gls pdp process includes assessment well employees surveys implemented gsk spirit principles used define groups culture significant impact bonus payments group also consults employees changes affect potentially reducing zero employee found discusses developments businesses european followed spirit also affect future career development employee forum similar committees incountrieswhere way group holds employees accountable delivering nationalpractice performance high standards integrity protect enhance health wellbeing gsks reputation healthy employees healthy ways working contribute togsks diversity sustained performance global policies employee health gsk diversity initiative focuses improving performance supported mandatory standards integrate employee health responding diverse needs employees customersand external safety environmental requirements standards stakeholders third annual multicultural marketing diversity applied groups facilities operations worldwide awards entrants usa uk continental europe commitment flexible working flexitime tele highlighted innovative activities demonstrated business impact conferencing remote working flexible work schedules recognises global management population wasmaleand employees work best environment helps integrate female details diversity measures see work personal livesduring groups employee employment practices section corporate responsibility report health management function personnel todaysmanaging health work awardin uk recognition impact promoting healthy workplace gsk annual report srotcerid eht fo troper description businessglobal manufacturing supply gsk large portfolio products ranging tablets new product global supply toothpaste inhalers complex capsules different new product global supply focuses ensuring pack sizes presentations appropriate technical competencies exist support rapid successful new product introduction works closely rds manufacture medicines begins development development team also ensures secure supply key therapeutic active ingredient bulk active selected formulation brands sold across many markets global distribution global manufacturing supply gms develops manufacturing division focal point developing introducing new processes full scale volume production active compounds secondary manufacturing technologies gmsit coordinates primary manufacturing sites converting active compounds primary supply operations ensure alignment two finished dosage formulation responsibility secondary divisions full value stream approach introducing new manufacturing sites products eight sites six countries new product gms operates single global network sites countries global supply year gms produces around tonnes bulk actives operational excellence four billion packs packaged delivered sale gmshas developed set measures uniform way working countries throughout world also supports drive business improvement activities mainly focused new product line extension launches year increasing quality products supplied customers extensive adopting leading edge practices developing people gms leadership education carried reinforce culture expects derive benefits continuous improvement staff involved solving problems rigorous controlled structured way provided secure source supply high quality products capability improve significantly performance accelerate compliance regulatory requirements customer expectations delivery benefits across manufacturing network best class cost since formation gsk merger rationalisation operational organisation excellence initiatives reduced number manufacturing sites supply divisions foursupply divisions sites grouped together based external suppliers upon common business drivers areas expertise commercial manufacturing spends billion many external suppliers activities support four divisions described every year including purchase active ingredients chemical intermediatesandpartfinished finished products gms takes primary supply andantibiotics appropriate steps protect supply chains disruption primary supply antibiotics focuses ensuring supply high resulting interrupted external supply appropriate stock quality competitively priced bulk actives driving levels contracting alternative registered suppliers improvements primary technologies processes also supports delivery maximum value antibiotics franchise vaccines supply chain combined primary secondary approach cost competitive europe vaccine manufacturing located primarily rixensart supply response market opportunities customer needs wavre belgium three sites france germany sites eight countries primary supply andantibiotics hungary gsk strengthened global production network north america three major acquisitions us based corixa consumer healthcare supply corporation produces important component many consumer healthcare supply focuses delivering high quality gsks vaccines development vaccine production site competitivelyproduced products offering capability rapid marietta pennsylvania id biomedical flu vaccine new product introduction highly innovative competitive manufacturing facilities canada asia new vaccine production business far shorter time frames pharmaceuticals facilities built india singapore gsks vaccine division new technologies become fundamental platform lowering also hastwo joint ventures china russiamanaging vaccine costs providing flexibility operations sites supply chain involves anticipating market needs using flexible countries consumer healthcare supply approach able meet fluctuations demand based regional pharma supply forecasts different markets firm orders health regional pharma supply focuses several key activities supply authorities mass vaccination campaigns products key one regions supply products bulk filling packaging carefully balanced stocking important particular market tailoring vaccines helps manage shortterm increases demand packaging meet specific local requirements key focus increasesresult fromdisease outbreaks increased demand regional pharma supply team reducing costs gsk public owing disease awareness campaigns compete effectively markets sites countries regional pharma supply gsk annual report srotcerid eht fo troper description businesscorporate responsibility community investment commit corporate responsibility uk gsk contributed million continuing corporate programme charitable activities supporting gsk committed connecting business decisions ethical social organisations health medical research science education arts environmental concerns thus corporate responsibility environment addition group companies uk integral embedded part way gsk business provided million charitablepurposes gsk published set corporate responsibilityprinciples corporate programmes north america focused improving provide guidance standards group committed public education access better healthcare children sets approach ten areas standards ethical conduct seniors funding ofalmost millionin additionthe groups research innovation products customers access usbased businesses donatedmillionto regional community medicines employment practices human rights community activities investment caring environment leadership advocacy engagement stakeholders groupreports annually gsk operate single charitable foundation community progress upholding principles corporate responsibility investment programmes number country based report available website wwwgskcom foundations grants made foundations included investment total partnership success gsk works partner underserved communities global health programmes developed developing world supports programmes eliminating lymphatic filariasis innovative sustainable bring real benefits groups effort help rid world disabling disease communities group engages numerous external lymphatic filariasis lf continued close partnership stakeholders funds communityled initiatives around world governments ofcountrieswhere disease endemic donates medicines support humanitarian efforts community partner organisations gsk committed donate based healthcare much antiparasitic drug albendazole required treat one billion people risk countries community investment million albendazole treatments worth million wholesale gsks global community investment activities valued acquisition cost donated countries since global million equivalent group profit tax elimination programme started cumulative total comprised product donations million cash giving million albendazole treatments donated million inkind donations million costs programme reaching million people million manage deliver community programmes gsk opened new million manufacturing facility cape town countries south africa produce albendazole product donations cash giving follows positive action hivaids positive action gsks pioneering global programme working productdonations communities affected aids started supports communitybased organisations deliver effective hiv aids education prevention healthcare services positive action worked partners support programmes countries programme also supported participation community involvement regional international aids conferences glaxosmithkline african malaria partnership since partnership supported three behavioural gsks cash giving targeted primarily health education development programmes working eight african countries initiatives programmes targeting nearly two million people focus particularly young children pregnant women encouraging breakdown cash giving effective prevention measures prompt treatment antenatal malaria management extending programme group announced threeyear grant malaria consortium new initiative mobilising malaria increased sustained advocacy activities uk europe african countries programme aims increase awareness malaria mobilise resources gsk annual report srotcerid eht fo troper description business patient assistance programs million albendazole lf million humanitarian product donations million health education arts culture environment corporate responsibility community investment continued phase education initiatives phase initiative personal hygiene sanitation education gsks efforts improve public science education included initiated gsk providing education thousands threeyear grant national board professional school children kenya ugandazambia nicaragua peru teaching standards increase number science teachers improve health hygiene fight infectious diseases pursuing certification north carolina philadelphia areas group committed three year funding gsk led group companies come together extend programme bangladesh partnership save create us business education network ben ben new children usa business coalition staffed center corporate citizenship humanitarian product donations us chamber commerce dedicated harnessing gsk donated essential productssuch antibiotics power business community address issues facing us nonprofit partners including americares map international education system project hope support humanitarian relief efforts gsk continued support innovative scheme postdocs community healthcare december medicines donated research education inspire developed partnership groupwere among first shipped support south asia imperial college london specialist schools academies tsunamirelief efforts gsk continued donate life trust million donation four years inspire places saving medicines tsunamiaffected countries affected postdoctoral researchers specialist science schools assist disasters including hurricanes usa science teaching total value groups international humanitarian science summer free librarybased science education product donations wasmillion excludes albendazole donated programme philadelphia area teaching basic scientific concepts part groups commitment lymphatic filariasis continued receive support grant science across elimination programme product donations valued wholesale worldisan awardwinninginternational education programme acquisition cost wholesale list price including uses webbased resources promote discussion science issues discounts standard industry method teachers children schools community initiatives countries grant made gsk dedicated strengthening fabric communities bringinggsks total contribution programmeto live work providing health education initiatives five years support local civic cultural institutions improve employee involvement quality life gsk employees encouraged contribute local gsks contribution improve healthcare includes new grant communities employee volunteering schemes support million three years childrens health fund expand varies around world includes employee time cash referral management initiative rmi sites philadelphia donations charities employees volunteer matching including delaware valley community health center rmi gifts programme ensures continuity specialistmedical care highrisk children usa group matched thanemployee often homeless retiree gifts value ofovermillion group also matched annual impact awards recognise excellence work non million employee donations gsks annual profit community health organisations across uk united way campaign gsks give program provided grants greater philadelphia area usa charities receive organisations us employees unrestricted awards work dealing diverse issues volunteered domestic community violence sexual health services young gsks making difference programme uk provided grants peopleand bereavement counselling services almost nonprofit organisationsandregistered medical research provided four uk charities based employee involvement medical charities alzheimers research trust british liver trust meningitis uk samantha dickson research trust childhood brain tumours part gsks support arts group sponsored popular gardens glass chihuly kew innovative exhibition work dale chihuly contemporary glass artist royal botanic gardens kewnearlondon gsk annual report srotcerid eht fo troper description businessproducts competition pharmaceutical products antivirals combivir combination retrovirand epivir consolidated glaxosmithklines principal pharmaceutical products currently position two reverse transcriptase inhibitors directed nine therapeutic areas analysis sales cornerstone many multiple antihiv product regimens physician therapeutic areas description principal products acceptance clearly demonstrated value placed minimising setout pill burden faced patients ziagenis reverse transcriptase inhibitor products potency ease turnover therapeutic area use resistance profile allow play significant role respiratory variety highly active well tolerated andsimplified hiv treatment central nervous system regimens antivirals antibacterialsantimalarials triziviris combination combivirand ziagen combining three anti metabolic hiv therapies one tablet twice daily administration vaccines epzicomkivexa approved use usa europe oncology emesis combination epivirand ziagenthat taken one tablet cardiovascular urogenital oncedaily dosing hivaids combination least one antihiv drug lexivatelziris protease inhibitor treatment hivthat well tolerated convenient agenerase sales werehigher cer termsand sterling terms supersedes lexiva may taken twice daily daily boosted ritonavir products formulations may approved zeffixhas approved marketing usa europe china indications markets available markets treatment chronic hepatitis b respiratory valtrexis treatment episodic genital herpes well long seretideadvair combination sereventand flixotide offers along term suppression reduction transmission genital herpes acting bronchodilator antiinflammatory single inhaler zoster shingles cold sores chicken pox valtrex supersedes approved treatment asthma copd zovirax also used treat herpes infections flixotidefloventand becotidebecloventare inhaled steroids antibacterials antimalarials treatment inflammation associated asthma copd augmentinis broadspectrum antibiotic suitable treatment sereventis longacting bronchodilator used treat asthma wide range common bacterial infections particularly copd ventolinis selective shortacting bronchodilator used effective respiratory tract infections augmentin esis treat bronchospasm extra strength suspension specifically designed treat children recurrent persistent middle ear infections augmentin xris extra flixonaseflonaseand beconaseare steriod intranasal preparations strength tablet form adults combat difficult treat infections treatment perennial seasonal rhinitis zinnatis oral antibiotic used primarily communityacquired central nervous system cns infections lower respiratory tract seroxatpaxilis selective serotonin reuptake inhibitor ssri treatment depression panic obsessive compulsive disorder post malarone oral antimalarial used treatment traumatic stress disorder social anxiety disorder premenstrual prophylaxis malaria caused plasmodium falciparum dysphoric disorderand generalised anxiety disorder lapdapis effective well tolerated therapy treatment wellbutrin antidepressant available usa malaria developed publicprivate international markets normal sustainedrelease sr daily collaboration formulations imigranimitrexis ht receptor agonist used treatment ofsevere frequent migraine cluster headacheand become reference product sector naramigamergeis newer migraine product lamictal well established treatment epilepsy also indicated bipolar disorder requipis specific dopamine dd receptor agonist indicated treatment ofparkinsons disease first approved product restless leg syndrome rls gsk annual report srotcerid eht fo troper description businessproducts competition continued metabolic oncology emesis avandia potent insulin sensitising agent acts zofran used prevent nausea vomiting associated underlying pathophysiology type diabetes chemotherapy radiotherapy cancer available bothoral injectable forms also approved use avandametis combination avandiaand metformin hci prevention treatment postoperative nausea vomiting first medicine targets insulin resistance decreases glucose production one convenient pill hycamtinis second line treatment ovarian cancer forsmall cell lung cancer avandarylis fixeddosed combination avandiaand amaryl sanofiaventis product bexxar treatment patients cd follicular non hodgkins lymphoma without transformation whose bonvivaboniva oncemonthly oral bisphosphonate disease refractory rituximab relapsed following treatment osteoporosis launched usa several chemotherapy eu markets cardiovascular urogenital vaccines coregis alphabeta blocker proven effective gsk markets vaccines worldwide gsks hepatitis vaccines intreating patients mild moderate severe heart failure heart range havrix protects hepatitis engerixb attack hypertension gsk sole marketing rights usa hepatitis b canada generic versions product available canada twinrixis available combined hepatitis b vaccine levitrais pde inhibitor indicated male erectile dysfunction protecting diseases one vaccine available gsk copromotion rights usa adult paediatric strengths gsk received european markets approval fendrix vaccine prevent hepatitis b patients renal insufficiency including highrisk groups pre avodartis ari inhibitor currently indicated benign prostatic haemodialysis haemodialysis patients years age hyperplasia large clinical outcome study underway examining onwards efficacy prevention prostate cancer fluarixis indicated prevention certain types influenza arixtra fraxiparine acquired part distributed countries approved usa divestitures required merger sanofiand aventis fluarixis first vaccine receive fda approval agencys arixtra selective factor xa inhibitor indicated prophylaxis accelerated approval regulations deep vein thrombosis may lead pulmonary embolism infanrixis gsks range paediatric vaccine combinations infanrix hip fracture surgery knee replacement hip replacement surgeryand provides protection diphtheria tetanus pertussis abdominal surgery also indicated treatment deep vein whooping cough infanrix pentapediarix provides additional thrombosis pulmonary embolism protection hepatitis b polio infanrix hexafurther fraxiparine lowmolecular weight heparin indicated adds protection haemophilus influenzae type b prophylaxis thromboembolic disorders particularly deep vein cause meningitis gsk launched boostrixin usa thrombosis pulmonary embolism general surgery vaccine adds protection pertussis whooping cough orthopedic surgery treatment deep vein thrombosis routine tetanusdiptheria booster administered teenagers prevention clotting hemodialysis gsk also markets priorix measles mumps rubella vaccine integrilin gp iibiiia inhibitor approved eu typherix vaccine protection typhoid fever varilrix prevention early myocardial infarction patients unstable vaccine varicella chicken pox addition group angina nonqwave mi markets range vaccines prevent meningitis umbrella name mencevax gsk recently received approval uk new hibmenc vaccine menitorix gsks meningitis category includes betnovate thehigher potency dermovateand vaccine portfolio wil complimented new meningitis conjugate newer cutivate antiinflammatory steroid products vaccines near future used treat skin diseases suchas eczema psoriasis relafen nonsteroidal antiinflammatory drug treatment arthritis part paediatric franchise gsk also developed vaccine zantac treatment peptic ulcer disease range rotavirus induced gastroenteritis since launch mexico ofgastric acid related disorders rotarix licensed several additional countries worldwide among number latin american countries including brazil thephilippines singapore first asian countries gsk annual report srotcerid eht fo troper description businessproducts competition continued pharmaceuticals competition antivirals gsk pioneer hiv market launching azt retrovir pharmaceutical industry highly competitive gsks principal epivirin today available combivirin single competitorsrange small tolarge international pharmaceutical tablet cornerstone hiv combination therapy launches companies substantial resources companies ziagen agenerase trizivir lexiva epzicom broadened major products mentioned thegroups portfolio hiv products major competitors hiv pharmaceuticals may subject competition products market include gilead bristol myers squibb abbott merck pfizer period patent protection patent valtrexhas strengthened groups position antiherpes area generic versions manufacturers generic products typically gsks valtrex zovirax compete novartis famvir donot bear significant research development education valtrexis market leaderwhilst zoviraxfaces competition marketing development costs consequently areable offer generic acyclovir hepatitis b market gsks zeffixwas first products considerably lower prices thebranded competitors antiviral market gileads hepsera second group research development based pharmaceutical company secured marketing rights hepserain key markets normally seek achieve sufficiently high profit margin sales volume period patent protection repay original antibacterials antimalarials investment generally substantial fund research forthe generic versions augmentinand ceftinzinnatare available future competition generic products generally occurs patents usa augmentinalso faces generic competition various major markets expire increasingly patent challenges made prior european countries augmentin xr augmentin es compete patent expiry claiming innovator patent valid andor broad range branded generic antibiotics infringed generic product following loss patent malarones safety profile convenient dosing regimen protection generic products rapidly capture large share helped put product strong position versus mefloquine market particularly usa malaria prophylaxis gsk believes remaining competitive dependent upon metabolic discovery development new products together effective major competitor avandiais takeda chemicals actos marketing existing products within pharmaceutical industry copromoted eli lilly usa introduction new products processes competitors may monthly bonivabonvivacompetes mercks weekly fosamax affect pricing levels result changing patterns product use proctor gamblesanofiaventiss weekly actonel generic fosamax assurance productswillnot become outmoded alendronate available markets uk canada notwithstanding patent trademark protection addition increased government pressures physicians vaccines patients use generic pharmaceuticals rather brandname vaccine market dominated four key players gsks major medicines may increase competition products longer competitors include sanofipasteur sp merck wyeth protected patent hepatitis market engerixb havrix compete vaccines produced sp merck respectively comvax recombivax hb respiratory hepatitis b vaqta avaxim hepatitis within gsks respiratory franchise driven growth seretideadvair paediatric vaccine field infanrixsmain competitor sps range gaining patients competitor products cannibalisation dtpabased combination vaccines although infanrix hexa sereventand flixotideflovent major respiratory competitors combination available hexavalent paediatric combination singulair merck especially usa europe symbicort europe astrazeneca spiriva pfizer boehringer ingelheim oncology emesis cns disorders zofranpresently provides gsk leadership position anti major competitors usa paxilare generic forms well emetic market competitor companies include roche sanofi generic fluoxetine generic form eli lillys prozac zoloft aventis recently mgi merck major competitors pfizer forest laboratories celexa lexapro effexor diverse cytotoxic market include bristol myers squibb sanofiaventis wyeth principal competitors usa wellbutrin pfizer novartis gsks cytotoxic portfolio led hycamtin generic forms bupropion generic forms ssris effexor currently holds relatively small market position xr wyeth product paxil cr oncedaily wellbutrin xlhelp retain strong presence antidepressant market given cardiovascular urogenital availability generic paroxetine bupropion usa gsk markets coregin usa major competitors toprol generic competition seroxatpaxilhas also commenced xl generic betablockers avodartcompetes directly mercks uk number markets proscar within bph market group copromotion rights usa levitra faces competition pfizers viagra lillyicos cialis gsk annual report srotcerid eht fo troper description businessproducts competition continued consumer healthcare products oral care leading oral care products toothpastes mouthwashes glaxosmithklines principal consumer healthcare products three aquafresh sensodyne macleansand odolbrand names major areas analysis sales areas isset range toothbrushes sold aquafreshand dr best names addition denture care products available principally polident poligripand coregabrand names nutritional healthcare otc medicines oral care leading products category lucozadeglucose energy nutritional healthcare sports drinks ribena blackcurrant juicebased drink rich vitamin c horlicks range milkbased malted food chocolate drinks sales werehigher cer terms higher sterling consumer healthcare competition terms gskholds leading global positions key consumer product major productswhich necessarily sold marketsare areas worldwide third largest oral care otc category product medicines nutritional healthcare holds leading position uk india ireland overthecounter medicines analgesics panadol environment consumer healthcare business dermatologicals zovirax operates become ever challenging abreva consumers demanding better quality better value improved gastrointestinal tums performance citrucel respiratory tract contac retailers consolidatedandglobalisedwhich hasstrengthened beechams negotiation power smoking control commit competitors finding conditions equally challenging nicorette competing aggressively across elements marketing nicoderm cq mix niquitin cq nicabate cq cycle times innovation reduced natural wellness support abtei main competitors include major international companies oral care aquafresh colgatepalmolive johnson johnson pfizer procter gamble dr best unilever wyeth addition many companies macleans compete withgskin certain markets odol odol med major competitor products otc medicines polident usa metamucil laxative pepcid indigestion private poligrip label smoking control products sensodyne uk lemsip cold remedy nurofen anadin analgesics nutritional healthcare lucozade nicorette nicotinell smoking control treatments ribena horlicks oral care major competitors colgatepalmolives colgate procter gambles crest overthecounter medicines nutritional healthcare major competitors horlicksare ovaltine leading products panadol widely available paracetamol milo malted food chocolate drinks competitors acetominophen analgesicnicorettegum usathe nicoderm ribena primarily local fruit juice products lucozade niquitin cq nicabaterange smoking control productstums competes energy drinks calciumbased antacidcitrucellaxativecontacfor treatment coldsabtei natural medicines vitamin rangeand zovirax abrevafor treatment cold sores gsk annual report srotcerid eht fo troper description businessregulatory environment regulation pharmaceuticals recent government healthcare reforms countries france spain germany may restrict pricing reimbursement gsk operates within highly regulated environment regional countryspecific laws regulations define data required show usa recent legislation healthcare reform crossborder safety efficacy pharmaceutical products well govern trade acceleration generics market increased patient testing approval manufacturing labelling marketing drugs contributions increased focus pricing currently regulatory requirements major factor determining government price controls private sector whether marketable product may successfully developed purchases federal law requires pharmaceutical manufacturers amount time expense associated development pay prescribed rebates certain drugs order eligible reimbursement medicaid federal healthcare europe pharmaceutical firms regulators managing programmes transition following implementation new medicines legislation end significant changes implemented medicare number areasincluding approval procedures post marketing us medicare program federally funded healthcare requirements manufacturing controls active ingredients insurance program benefiting senior citizens certain disabled excipients labelling requirements pharmacovigilance processesand americans included coverage prescription medicines increased emphasis involvement availability information new benefit medicare program dramatic patients eu change program since inception coverage voluntary includes brandname generic drugsand open climate change continue expectation new million americans medicare coverage paediatric regulation finalised stimulating industry research paediatric indications via intellectual property incentives number competing private organisations provide new benefit premiums subsidised government benefits must satisfy european medicines agency emea published final minimum standard outlined federal law law provides version road map strategic plan incentives manufacturers negotiate prices withprivate plans additional driver change covering areas new technologies provide government price controls government innovative development approaches enhanced provision provides additional help million peopleonmedicare agency advice development process limited incomes resources qualifying beneficiaries usa safety issues prescription drugs primary focus pay reduced premiums deductibles low copayments fda congressional oversight committees since recent prescriptions withdrawal several products market safety reasons value money gsk working closely fda assess impact isincreasingly necessary demonstrate value money current development programmes asin new products particularthe impact drug budget expenditure europe evaluation benefit risk continues important burden disease treatedmust apparent consideration approval new drug fda markets requirement satisfy healthcare purchasers fdahas introduced new focus called critical path initiative value money becoming additional hurdle product intended tofacilitateinnovation drug development hopefully acceptance regulatory tests ofsafety efficacy allowing rapid development approval needed quality may delay bringing effective improved medicines medicines initiative investigate use pharmacogenomics market reduce effective patent protection time surrogate markers efficacy among things manufacturing innovations tools rapidly developing many markets especially usa europe becoming producing safe effective drugs unmet medical needs difficult even significantly improved therapy obtain pharmaceutical industry including gsk collaborating premium price existing medication valuebased pricing may fda national institutes health number areas difficult apply circumstances although usa still including use biomarkers possible price products reflect value possible predict whether extent groupsbusiness new health information source launched us affected future legislative regulatory developments relating government includes electronic labelling approved specific pharmaceutical products price prescription drugs posted within one day fda approval action immediate accessbyphysicians patients gskis providing regulation consumer healthcare labellingto thefdafor products new electronic format new regulations fda implemented mid consumer healthcare industry subject national regulation completely change format prescribing information usa testing approval manufacturing labelling marketing products many countries high standards technical appraisal gsk well placed manage effectively changes external involve lengthy approval process new product launched regulatory environment national regulatory authorisation also required approve switch price controls products prescription otc requirements include long manycountries prices pharmaceutical products controlled term experience quality safety efficacy product law governments may also influence prices control wide patient population data confirm relevant national healthcare organisations may bear large part condition selflimiting easily diagnosed consumer cost supplying products consumers gsk annual report srotcerid eht fo troper description businessregulatory environment continued intellectual property paxilseroxat patent commercial form paroxetine due expire cusa europe litigation relating intellectual property key business asset gsk effective legal validity infringement patents protecting product protection intellectual property critical ensuring reasonable ongoing usae generic competition commenced return investment rd intellectual property protected usa europe certain markets paxil cris protected patents trademarks registered designs copyrights domain formulation patent due expire generic name registrations patent trademark rights regarded manufacturer applied fda approval generic form paxil particularly valuable cr asserting noninfringement patente many cases generic manufacturers launch attempt launch requip patent ropinirole due expire ausa generic versions patented drugs prior normal patent expiry beurope patent relating use ropinirole arguing relevant patents invalid andor parkinsons disease due expire usa b infringed product significant litigation concerning europe litigation challenging validity patents ongoing challenges summarised noteto theffinancial statements usae legal proceedings retrovir patents zidovudine patents covering patents pharmaceutical formulations containing zidovudine medical gsks policy obtain patent protection significant products use expired usa expire europe discovered developed rd activities patent protection new active ingredients available significant markets seretideadvairthe patent specific combination salmeterol protection also obtained new pharmaceutical formulations xinafoate fluticasone propionate due expire manufacturing processes new medical uses special usa beurope application reissue us patent devices administering products filed gskewith us patent trademark office uspto january uspto issued final office action patent position respect active ingredients significant rejecting application gsk seek reconsideration products follows rejectione uk patent revoked ukcourts patents avandiaand avandamet patent rosiglitazone due individual ingredients expired uk usa expire ac usa b europe patents patent salmeterol xinafoate expire commercial form active ingredient rosiglitazone maleate sereventthe patent salmeterol xinafoate due expire due expire usa b europe litigation usa europe patent expired except france challenging validity patents protecting products b italy b ongoing usae trizivir patent method treatment using combination avodart patent dutasteride due expire lamivudine zidovudine abacavir expire usa beurope usaand europe combivir patent specific combination lamivudine valtrex patent valaciclovir due expire zidovudine due expire usa beurope usa beurope litigation challenging validity coreg gsk exclusive licensee us patent carvedilol patent protecting product ongoing usae due expire ac wellbutrin sr wellbutrin xl andzybanthe patent active epivir patent lamivudine due expire ac ingredient expired generic competition usa beurope sustained release srand instant release ir forms usa flixotidefloventand flixonaseflonase patents fluticasone europe regulatory data exclusively provides protection propionate expired eu usa generic competition markets usa wellbutrin xlis protected formulation flixonaseexists euand fda recently approved generic patents expire litigation relating validity version flonasein usae infringement ofthese patents ongoing usae imigranimitrex patent sumatriptan due expire ziagen patent abacavir due expire acusa c usa generally b europe except b italy beurope litigation challenging validity patent protecting product zofran patent ondansetron expired usa ongoing usae europe except france b italy b patent use lamictal patent lamotrigine due expire ac treating emesis expires litigation challenging validity usa litigation challenging validity patent usa emesis use patent ongoing usae settlede europe corresponding patent expired generic competition exists including patent term restoration hatchwaxman act b including extension term national european supplementary protection levitrad gsk copromotion rights uspatent certificates c including granted pending extension term paediatric exclusivity vardenafil due expire usa registered trademark bayer ag e see notetofinancial statements legal proceedings lexivatelzir gsk exclusive licensee patent fosamprenavir due expire usa b europe gsk annual report srotcerid eht fo troper description businessregulatory environment continued trademarks ehs management gsks pharmaceutical products protected registered gsk takes systematic approach managing ehs risks impacts trademarks major markets may local variations framework information programmes based global examplein usa trademark paxilis used instead seroxat ehsstandards guides management key aspects impacts advairis used instead seretide risks throughout organisation trademark protection may generally extended long ehs audits trademark used renewing necessary gsks trademarks part governance responsibility gsk conducts ehs audits pharmaceutical products important maintaining brand sites assessing performance ehsstandards identity product upon expiration patent assigning quantitative performance scores sites audited achieved audit scores better consumer healthcare trademarks particularly important part continuous improvement process progress business brand orientated many products monitored actions arising issues raised audits patent protection part commitment corporate responsibility pro responsibility environment health safety active management gsk manufacturing supply base suppliers also assessed representing priority environment health safety ehsis key element corporate suppliers process evaluated management key ehs risks responsibility group high priority responsibility impacts well human rights issues based groups ehs highest level corporate group reporting requirements priority suppliers recommendations made general counsel overall responsibility providing improvements needed governance leadership ehs issues head group makes regular reports corporate executive team cet ehstargets audit corporate responsibility committees board part ehs plan targets set every five years directors within businesses operations managers end first fiveyear target period targets set responsible ehs supported sitebased ehs environmental measures one measure occupational health occupational health staff safety ehs strategy plan progress towards meeting targets tracked every year gsk strategic planning process ehs looks forward final data showing level achievement targets years reviewed every year plan aligned gsk published website wwwgskcom significant progress business drivers includes management performance made towards achievingeightof ehs targets measures targets progress made areas plan progress due outsourcing processes contract particular success incorporating ehs selection manufacturers hazardous waste disposed proportion management contract manufacturers key suppliers waste recycled targets achievedthe targets developing maintaining open effective dialogue achieved products transferred facilities without external stakeholders providing ehsdata decision making appropriate recycling systems place recycling systems new products processes ensuring safety health maintenance new products coming concerns properly addressed gsks facilities minimise risk manufacturing avoid disruption product supply areasforadditional gsk selects measures performance improvement based focusare driver safety occupational chemical exposure machine potential adverse impact people environment business guarding pharmaceuticals environment patient excretion continuity business reputation measures selected energy conservation use hazardous chemicals similar reported companies recommended manufacturing global reporting initiative longterm multistakeholder strategic focus international undertaking develop disseminate globally plan provides area special focus year applicable sustainability reporting guidelines focus completing core programmes programmes sustainability essential prevent injury illness harm environment work towards eventual sustainability gsk addressing ensure continuity gsks business economic environmental social issues research manufacturing common operating locations operations different risks sales distribution medicines sustainability starts may different core needs therefore different core healthcare solutions found rd continues sustainable programmes programme complete must solutions manufacturing sales rd considering improving management system place acceptable audit scores acceptable operational efficiency new products futurethe ehs plan progress ehstargets excellence proposes investigating use renewable resources need operate maintain programmes monitor overall balance impact society environment performance continually look improvements progress group seeks dialogue external stakeholders considers strategic focus area may seen audit scores progress views developing approaches sustainable development targets information ehs programmes performance may found website gsk annual report srotcerid eht fo troper description businessgsk annual report srotcerid eht fo troper corporate governance section discusses glaxosmithklines management structures governance procedures contains companys reporting disclosures corporate governance required combined code corporate governance financial reporting council combined code including required statement compliance company reports compliance uslaws regulations apply board corporate executive team governance policy dialogue shareholders annual general meeting internal control framework committee reports combined code us law regulation gsk annual report srotcerid eht fo troper corporate governance continued board dr ronaldo schmitz aged appointed rd may nonexecutive director dr schmitz sir christopher gent aged formerly nonexecutive director glaxo wellcome plc appointed st june chairman sir christopher chief nonexecutive director legal general group plc member executive officer vodafone plc retirement july board directors rohm haas company cabot nonexecutive director lehman brothers holdings inc corporation member financial reporting councila senior adviser bain co chairman advisory board reform dr lucy shapiro aged appointed rd may nonexecutive director dr shapiro dr jeanpierre garnier aged formerly nonexecutive director smithkline beecham plc appointed rd may chief executive officer dr garnier ludwig professor cancer research department appointed executive director smithkline beecham plc developmental biology director beckman center became chief executive officer april non molecular genetic medicine stanford university school executive director united technologies corporation member medicine nonexecutive director anacor pharmaceuticals board trustees eisenhower exchange fellowships inc holds phd molecular biology holds phd pharmacology university louis pasteur france mba stanford university usa tom de swaan aged appointed st january nonexecutive director mr de swaan lawrence culp aged member managing board abn amro appointed st july nonexecutive director mr culp chief financial officer st december retire president chief executive officer danaher corporation prior board abnamroonst may nonexecutive joining danaher held positions accenture previously director financial services authority member board andersen consulting institute international finance chairman board sir crispin davis aged netherlands opera member board royal appointed st july nonexecutive director sir crispin concertgebouw orchestra chief executive reed elsevier plc prior chief sir robert wilson aged executive aegis group plc joined guinness plc appointed st november nonexecutive director sir robert member main board group managing nonexecutive chairman bggroup plc economist group director united distillers spent early career procter previously executive chairman rio tinto gamble dr tachi yamada aged julian heslop aged appointed st january retiring st june chairman appointed st april chief financial officer mr heslop joined research development dr yamada nonexecutive director glaxo wellcome financial controller april january subsequently executive director smithkline beecham plc following merger appointed senior vice president prior joining smithkline beecham chairman operations controller prior joining glaxo wellcome held senior department internal medicine university michigan medical finance roles grand metropolitan plc school physicianinchief university michigan medical sir deryck maughan aged center trustee rockefeller brothers fundand member appointed st june nonexecutive director sir deryck advisory board quaker bioventures inc managing director kohlberg kravis roberts co formerly moncef slaoui aged chairman ceo citigroup international salomon chairman designate research development dr slaoui senior vice brothers inc nonexecutive director reuters group plcas president worldwide business development appointed well serving boards directors carnegie hall lincoln board effect th may succeed dr center nyumedical center also international advisory yamada chairman research developmentonst june dr board member british american business inc board member slaoui joined gsk biologicals engineered ofthe trilateral commission served vice chairman new development robust vaccines pipeline phd molecular york stock exchange biology immunology universit libre de bruxelles sir ian prosser aged appointed rd may senior independent director sir ian directors formerly nonexecutive director smithkline beecham plc mr john coombe formerly chief financial officer retired chairman chief executive bass plc ultimately board st march chairman demerged intercontinental hotels group plc details membership board committees may found chairman world travel andtourism council page london stock exchange listed advisory council nonexecutive deputy chairman bp plca nonexecutive director sara lee corporationanda member cbi presidents committeegsk annual report srotcerid eht fo troper corporate governance continued corporate executive team cet david pulman president global manufacturingandsupply jp garnier dr pulman responsible global manufacturing supply chief executive officer organisation global procurement joined glaxo chief executive officer dr garnier responsible responsible north american supply network manufacturing management group oversees operational aspects strategy logistics current appointment group including establishing policies objectives initiatives directs longterm strategy formerly chief executive david stout officer smithkline beecham joined group president pharmaceutical operations mr stout responsible forallpharmaceuticals vaccinesoperations rupert bondy worldwide including usa europe international japan senior vice president general counsel globalmanufacturingand supply joined smithkline beecham mr bondy responsible legal matters across group together president uspharmaceuticals current environmental health safety issues insurance security appointment january lawyer private practice joining smithkline beecham chris viehbacher president uspharmaceuticals ford calhoun mr viehbacher responsible us pharmaceuticals joined chief information officer wellcome responsible gsks european dr calhoun responsible information technology global pharmaceuticals business current appointmentin function enables key business processes across parts group doctoral postdoctoral training microbiology andrew witty genetics biomathematics computer science joined smith president pharmaceuticals europe kline french mr wittyisresponsible groups pharmaceuticals operationsin europe joined glaxo andwas senior vice president asia john clarke pacific current appointmentin president consumer healthcare mr clarkesucceededmrziegler president consumer healthcare tachi yamada st january hejoined beecham progressed chairman research development roles australasia south africa far east japan canada dr yamada leads groups complex business drug discovery ukfrom john president consumer development creating new medicines research joined healthcare europe appointed president futures group smithkline beecham nonexecutivedirectorand became chairman rd pharmaceuticals marc dunoyer president pharmaceuticals japan jennie younger mr dunoyer appointed president pharmaceuticals japan march senior vice president corporate communications joined group senior vice president community partnerships regional director japan current appointment mrs younger responsible groups internal external communications image partnerships global communities russell greig joined glaxo wellcome director investor relations president pharmaceuticals international appointed current position dr greig leads pharmaceutical operations outside usa japan europe covering countries joined moncef slaoui group senior vice president worldwide business chairman designate research development development rd prior current appointment march dr slaoui succeed dr yamada chairman research developmentonst june join cet th may joined group inand currently senior vice president worldwide julian heslop business development chief financial officer mr heslop became chief financial officer st april head members finance function mr heslop responsible activities mr coombe retired chief financial officer st march financial reporting control tax treasury investor relations mr ziegler retired head theconsumer healthcare business finance systems internal audit real estate joined glaxo st january wellcome financial controller april mr ingram continues work parttime vice chairman dan phelan pharmaceuticals acting special advisor group senior vice president human resources attending cet meetings capacity mr phelan responsible benefits compensation recruitment organisation development leadership development succession planning human resource information systems employee health management lawyer private practice joining smith kline french corporate governance continued governance policy board appraises approves major financing investment contractual decisions excess defined thresholds additionthe board corporate executive team board evaluates monitors performance group directors listed board page whole includes board responsible groups system corporate engaging board meetings ceo executive governance ultimately accountable groups activities directors members cet appropriate financial strategy financial performance operating performance gsk external issues material chief executive officer ceo responsible executive groups prospects management group assisted cet cet meets evaluating progress toward achievement groups financial times per year otherwise necessary members business objectives annual plans responsibilities listed corporate executive team monitoring reports received directly various committees significant risks facing group board comprises three executive nine nonexecutive directors whilst board considers nonexecutive directors board overall responsibility succession planning independent character judgement determined ceo executive directors board given ceo one nonexecutive director dr shapiro considered broad authority operate business groupand ceo independent combined code dr shapiro accountable reports board business performance considered independent due remuneration cet members make regular presentations board areas receives group member glaxosmithkline responsibilityand board meets cet members scientific advisory board sir christopher gent appointed annual basis discuss collectively groups strategy primary board deputy chairman determined board element induction process new nonexecutive directors independent upon taking chairmanship board undertaken members cet nonexecutive directors st january accordance combined code encouraged separate informal discussions excluded determination whether least half discretion cetmembers board independent nonexecutive directors neither dr shapiro sir christopher gent hold positions board committee board metsixtimes member attending independence required combined code follows board considers mr culp sir crispin davis sir deryck number meetings number name held whilst board member meetings attended maughan sir ian prosser dr schmitz mr de swaanand sir robert sir christopher gent wilson independent accordance recommendations dr jpgarnier combined code mr j heslop date publication throughout majority dr yamada board members excluding chairman independent non mr l culp executive directors sir crispin davis sir deryck maughan sir christopher gent succeeded sir christopher hogg st january sir ian prosser chairman throughout dr garnier ceo dr r schmitz chairman leads board represents board ceo dr l shapiro cet members necessary board meetings ceo sir robert wilson manages group implements strategy policies mr jcoombe adopted board chairman chairmen board committees communicate regularly ceo cet addition six scheduled meetings board also met members division responsibilities role quorate basis ontwooccasions chairman ceo set writing agreed board appears full website business environment development sir ian prosser senior independent director sid throughout ensure board kept uptodate important matters including legal governance regulatory developments presentations made regular basis external board process internal advisers board authority accountable shareholders ensuring company appropriately managed achieves independent advice strategic objectives sets board discharges responsibilities board recognises may occasions one annual programme meetings includes directors feel necessary take independent legal andor approval overall budgetary planning business strategythe financial advice companys expense agreed board reviews companys internal controls risk management procedure enable explained corporate policies approves governance structure code ethics governance section companys website gsk annual report srotcerid eht fo tropercorporate governance continued indemnification directors nominations committee qualifying third party indemnity provisions defined section nominations committee reviews structure size b companies act force benefit composition board appointment members directors formerdirectors held office board cet makes recommendations board appropriate committee also monitors planning succession company secretary board senior management committee consists company secretary responsible board available entirely nonexecutive directors majority individual directors respect board procedures company independent meets least year otherwise secretary simon bicknell appointed may necessary nominations committee report given page barrister joined group secretary board committees corporate responsibility committee corporate responsibility committee consists entirely non boardcommittees executive directors provides boardlevel forum regular board established number ofcommittees provides review external issues potential serious impact sufficient resources enable undertake duties executive upon groups business oversight reputation directors members audit remunerationnominations management committee also responsible governance corporate responsibility committees although may invited oversight groups worldwide donations community attend meetings director member corporate support committee meets formally three times year administration transactions financial results committees otherwise necessary membership thesecommittees shown table financial results committee corporate audit remuneration nominations responsibility financial results committee reviews approves behalf sir christopher gent c c board annual report form f annual review mr l culp convening annual general meeting together sir crispin davis preliminary quarterly statements trading results director sir deryck maughan member committee quorum meeting sir ian prosser three members quorate meeting must include dr r schmitz c chairman chairman audit committee ceo dr l shapiro chief financial officer cfo committee meets necessary mr de swaan corporate administration transactions committee sir robert wilson c corporate administration transactions committee reviews mr de swaan succeed dr schmitz chairman audit committee approves matters connection administration groups september business certain corporate transactions committee consists keyc chairmanm member directors cet members company secretary following summary role terms reference committee meets necessary committee current full terms reference eachcommittee evaluation board board committees directors may obtained company secretary corporate performance evaluation board committees governance section companys website directors undertaken chairman audit committee implemented collaboration committee chairmenwith audit committee reviews financial internal reporting support company secretary board considered review process system internal controls management risks conclusionsatits meeting december agreed number external internal audit process committee also proposes minor improvements procedures operating methodology shareholders appointment external auditors senior independent nonexecutive director sir ian prosser directly responsible remuneration oversight work undertook performance evaluation chairman committee consists entirely independent nonexecutive discussion directors excluding chairman directors meets least four times year otherwise december necessary audit committee report pages remuneration committee dialogue shareholders remuneration committee determines terms service financial results announced quarterly remuneration executive directors members cet assistance external independent advisors evaluates company reports formally shareholders twice year makes recommendations board overall executive halfyear fullyear results announced fullyear results remuneration policythe committee consists entirely independent included companys annual report annual review nonexecutive directors meets least four times year otherwise issued shareholders companys halfyear results necessary information remuneration directors given published national newspaper shortly release ceo remuneration report pagestothe chairman cfo give presentations fullyear results institutional investors company ceo responsible evaluating making analysts media recommendations board remuneration non executive directors gsk annual report srotcerid eht fo tropercorporate governance continued webcast teleconferences release first second donations political organisations eu political third quarter results institutional investors analysts expenditure media annual report annual review quarterly results agm may shareholders first authorised company available companys website make donations eu political organisations incur eu political expenditure provisions political parties annual general meeting agm takes place london elections referendums act year formal notification sent shareholders least one month authority since renewed annually although advance meeting business presentation made company make intend make payments shareholders directors able attend available formally donations political parties within normal meaning theagm informally afterwards questions committee expression definition legislation eu political chairmen ordinarily attend agm respond shareholders organisation wide may extend bodies company questions mr culp unable attend thecompanys agm may subsidiaries might wish support including concerned due commitments resolutions agm policy review law reform representation business decided poll required companys articles association community special interest groups concerned results poll announced london stock exchange environment donations made eu political posted companys website details agm organisations group made donations noneu set section annual general meetingsee political organisations totalling ensure nonexecutive directors aware understand views major shareholders company donations made usa board place process focusing sectorspecific issues well canada usa largest recipient political donationsand general shareholder preferences atitsmeeting julythe board reflects us political system candidates sponsored received external review ofshareholder opinion solely donations individuals ngos companies ceo cfo maintain dialogue institutional shareholders parties performance plans objectives programme line us law corporate donations gsk made regular meetings federal level candidates political parties state groups investor relations department offices london local levels donations accepted practice usa philadelphia acts focal point contact investors major employer heavily regulated industry important throughout year gsk engage fully political process donations one ways gsksupports candidates seek chairman meets regularly institutional investors hear environment appropriately rewards highrisk highinvestment viewsand discuss issues mutual importance industries believe free market principles intellectual chairman remuneration committee meets major property rights shareholders discuss executive remuneration policy non situation similar canadaand donations follow executive directors including new appointees available meet guidelines rest world donations rare major shareholders requested low value companys website gives access current financial business also gsk political action committee pac usa information group gives political donations pacs employee organisations share buyback programme allow employees contribute fund political donations atotal billion spent company buying employees decide upon recipients pac donations shares cancellation held treasury shares total donated political organisations gsk billion spent programme covers purchases pac company shares cancellation held treasuryshares accordance authority given shareholders annual general meeting companys agm agm held pm wednesday th may may company authorised purchase maximum queen elizabeth ii conference centre broad sanctuary ofmillion shares million shares representing westminster london swp ee business transacted issued share capitalwere purchasedand held treasury meeting include shares see noteto thefifnancial statements share capital receiving adopting glaxosmithkline 's annual share premium account report exact amount timing future purchases extent approving remuneration report repurchased shares held treasuryshares rather remuneration report pages sets cancelled determined company dependent remuneration policies operated glaxosmithkline disclosures market conditions factors directors remuneration including required companies act directors remuneration report regulations resolution proposed approve remuneration report gsk annual report srotcerid eht fo tropercorporate governance continued retirement election reelection directors internal control framework also relies following drslaoui mr de swaanhave beenappointeddirectorssince overseeing reporting risk compliance issues agm offerthemselves election boardmr risk oversight compliance council rocc culp sir crispin davis dr schmitzwill retire offer rocc council senior executives authorised board reelection board article companys articles assist audit committee oversee risk management associationdr shapiro retire conclusion agm internal control activities group membership comprises several offer reelection cetmembers heads departments internal reappointment remuneration auditors control risk management audit compliance responsibilities resolutions proposed reappoint pricewaterhousecoopers rocc meets regular basis review assess significant llp auditors authorise audit committee determine risks mitigation plans rocc responding group remuneration policy referred provided business units special business framework risk management upward reporting significant company seek authority risks mitigation planning identification manager overall responsibility management given risk requirement make donations eu political organisations incur eu political expenditure risk management compliance boards rmcbs risk management compliance boards rmcbs allotordinaryshares company established major business units membership often give directors authority disapply preemption rights comprises members senior executive team respective allotting newshares connection rights issues otherwise business unit augmented specialists appropriate rmcbs maximum current issued share capital oversee management risks considered important purchase ordinary shares maximum respective business units including risks designated current issued share capital significant glaxosmithkline whole thus increasing number risks actively managed across group internal control framework rmcb regularly reports status regarding significant risks board recognises responsibility present balanced rocc understandable assessment groups position prospects compliance functions structure accountability audit operated gsk follows number risk areas specific standards meet exceed board accountability reviewing approving adequacy requirements applicable law established specialist audit effectiveness internal controls operated group including compliance functions example corporate environment financial operational compliance controls risk management health safety global quality assurance worldwide regulatory board delegated responsibility review audit compliance assist dissemination implementation audit committee receives reports individuals identified standards committees report pages responsibility corporate ethics compliance cec management cet implement board policies risk rocc also supported corporate ethics compliance control cet responsible identifying approving department responsible supporting development monitoring enforcing key policies go heart implementation practices facilitate employees compliance group conducts business internal control framework includes laws group policy central direction resource allocation risk management key activities research development manufacturing marketing thrust groups compliance effort due diligence sales legal human resources information systems financial preventing detecting misconduct noncompliance law practice part framework comprehensive planning regulation promoting ethical behaviour compliance laws system annual budget approved board results regulations corporate responsibility levelsand effective operating units reported monthly compared budget compliance systems forecasts prepared regularly year cec managed corporate compliance officer extensive financial controls procedures selfassessment exercises reports directly ceo corporate compliance officer chairs risk activities reviewed groups internal auditors commercial rocc provides summary reports roccs activities financial responsibility however clearly delegated local groups significant risks cet audit committee business units supported regional management structure regular basisthe corporate compliance officersdirect reporting principles designed provide environment central leadership line audit committee provides mechanism bypassing coupled local operating autonomy framework executive management need ever arise exercise accountability control within group areas potentially significant risk group also attaches importance clear principles procedures details risks affecting group seenoteto thefifnancial designed achieve appropriate accountability control group statements legal proceedings risk factors pagesto policy risk management legal compliance mandates business units establish processes managing monitoring risks significant businesses group gsk annual report srotcerid eht fo tropercorporate governance continued effectiveness controls accordingly boardchosenot nominate one committee internal control framework operation whole member recent relevant financial experience defined year review continues operate date combined code audit committee financial expert approval report system internal controls designed defined bysarbanesoxley manage rather eliminate risk achieving business arriving conclusion board considered following points objectives provide reasonable absolute dr schmitz chairman committee since april assurance material misstatement loss prior appointment nonexecutive director audit committee receives reports areas significant risk company nonexecutive director glaxo wellcome plc group related internal controls following consideration served audit committee dr schmitz also reports audit committee reports annually board member executive board directors deutsche bank ag effectiveness controls controls may mitigate retired board charge eliminate risks addition areas groups investment banking dr schmitz formerly member business necessary take risks achieve satisfactory executive board directors basf including return shareholders investment rd acquiring cfo holds mba insead sir ian prosser new products businesses casesit groups objective cfo later ceo bass plc member institute apply expertise prudent management rather chartered accountants england wales sir robert wilson elimination risk directors review relates company began professional career economist chairman bg subsidiaries extend material associated group plc held senior management positions rio tinto plc undertakings joint ventures investments culminating appointment executive chairman retired board audit committee reviewed assessment risks internal control framework operates sir deryck maughan appointed member committee glaxosmithkline considered effectiveness system st january managing director kohlberg kravis internal control operation group year covered roberts co kkr chairman kkr asia chairman report date approval board process ceo citigroup international vice chairman citigroup inc followed board reviewing system internal controls prior creation citigroup chairman cochief accords guidance internal control issued turnbull executive officer salomon smith barney also chairman committee chief executive officer salomon brothers appointing mr de swaanto thecommittee effect committee reports st january board determined recent audit committee report relevant financial experience accordance combined code coming conclusion board paid particular attention mr audit committees role flows directly boards oversight de swaans role chief financial officer abn amro function authorised board investigate activity heretiredon st december board also considers mr de within terms reference committee written terms swaan audit committee financial expertas defined reference approved board committee sarbanesoxley reports regularly board performance activities assigned committees main responsibilities include committee supported company secretary attends reviewing corporate accounting financial reporting process committees meetings available financial resources monitoring integrity financial statements evaluating take independent professional advice considered necessary system internal control management risks overseeing meetings committee attended chairman ceo activities groups compliance audit functions cfo general counsel head global internal audit gia corporate overseeing compliance laws regulations ethical codes compliance officer external auditors practice committees oversight role requires address regularly committee worked structured programme relationships management internal external activities standing items committee required auditors understand monitor reporting relationships consider meeting together matters focused tiers accountability committee receives regular coincide key events annual financial reporting cycle reports members cet senior managers covering key compliance activities group including concerning external auditors reported committee critical rd manufacturing sales marketing ehs accounting policies practices used company alternative accounting treatments discussed committee members bring considerable financial accounting management resultant conclusion external auditors experience committees work members past employ material written communications management ment experience either finance accounting roles comparable restrictions access information experience corporate activities cfo reported financial performance company respect board haddetermined combined technical financial accounting matters qualifications experience committee members general counsel reported material litigation taken together modus operandi gave committee collectively financial expertise necessary discharge company secretary reported corporate governance responsibilities gsk annual report srotcerid eht fo tropercorporate governance continued heads groups compliance audit groups thecommittee also recommended board appointment reported audit scope annual coverage audit resources sir deryck maughan audit committee january dr results audits conducted throughout year schmitz remuneration committee mayin february corporate compliance officer reported activities committee recommended board dr moncef undertaken rocc slaoui succeed dr yamada chairman researchdevelopment retirement company st june company secretaryas chairman disclosure committee reported matters affected quality timely disclosure addition committee recommended board dr schmitz financial material information board serve term three years nonexecutivedirector public markets shareholders enabled committee remain chairman audit committee review clarity completeness disclosures september committee also made recommendation published annual financial statements interim reports quarterly board dr ralph horwitz appointed nonexecutive preliminary results announcements formal director following announcement dr horwitzs appointment announcements relating financial performance prior potential conflict interest disclosedand dr horwitz decided release board take appointment nonexecutive director company audit committee management internal auditors full board work together ensure quality companys corporate recruiting nonexecutive directors committee considers accounting financial reporting committee serves particular skills knowledge experience would benefit board primary link board external internal auditors significantly appointment broad selection criteria facilitates necessary independence management used focus achieving balance representation encourages external internal auditors communicate freely european uk us markets individuals ceo regularly committee committee met experience skills developed various sectors specialities collectively separately external auditors head particular focus placed upon recruiting newnonexecutive gia without members management present director recent relevant financial expertise join audit committeeprofessional search agencies engaged specialising committee primary responsibility making recruitment high calibre nonexecutive directors dossiers recommendation shareholders appointment reappointment potentialnonexecutive appointees provided committee removal external auditors annually assessing candidates shortlisted interview considering relevant qualifications expertise resources independence external qualifications auditors effectiveness audit process customised induction process conducted new making assessment committee considers papers nonexecutive directors focusing particular experience detail relevant regulatory requirements relating external auditors taking account different backgrounds process includes evaluates reports external auditors compliance meeting members cet senior executives visiting requirements external auditors provide nonaudit particular operational facilities group services committee ensures auditor objectivity independence safeguarded policy requiring preapproval committee continued keep review succession audit committee services expenditure audit non planning senior executive positionsincluding ceo audit services set pages chairman researchdevelopment guidelines set companys policy engaging appointingnew executive directors committee considers external auditors provide nonaudit services include ascertaining skills knowledge experience required particular skills experience external auditors make executive position committee consider potential external suitable supplier nonaudit services adequate safeguards internal candidates recommending board approve place objectivity independence audit new appointmentallnew directors offer election compromised fee levels relative annual audit fee companys next agm appointments announced publicly within limits set committee committee met full session andtwiceon company also wellestablished policies including code quorate basisall members present full meeting ethics available website helpline facility remuneration report reporting investigation unlawful conductno waivers remuneration report found pagesto code made committee met full sessionfivetimes andfivetimes combined code quorate basis full session attended members throughout company complied code provisions except sir robert wilson unable attend one meeting combined code except follows nominations committee report bin designing schemes performancerelated remuneration nominations committees terms reference include responsibility remuneration committee follow provisions proposing appointment board committee members schedule code item schedule states general committee made recommendations board basic salary pensionable companys position appointment ofmr de swaanas anonexecutivedirector explained remuneration report pagesto gsk annual report srotcerid eht fo tropercorporate governance continued c board satisfy least one member sarbanesoxley also introduced requirement ceo audit committee recent relevant financial experience cfo complete formal certifications confirming companys position explained pagesee pagefor reviewed annual report form f position st january based knowledge contains material misstatements chairman arrange chairmen omissions audit remuneration nominations committees available answer questions agm alldirectors attend based knowledge financial statements companys position explained pages financial information fairly present material respects financial condition results operations cash flows us law regulation dates periods presented annual report form f number provisions us law regulation apply gsk companys shares quoted new york stock responsible establishing maintaining disclosure exchange nyse form adss controls procedures ensure material information made known evaluated effectiveness nyse rules controls procedures year end results general nyse rules permit company follow uk corporate evaluation contained annual report form f governance practices instead ofthoseappliedin usa provided disclosed annual report form f changes company explains significant variations explanation internal controls financial reporting period covered ison companys websitenyse rules came effect annual report form f materially affected require company fileannualand interim written affirmations reasonably likely affect materially companys internal concerning audit committee companys statement control financial reporting significant differences corporate governance disclosed based recent evaluation sarbanesoxley act internal control financial reporting external auditors following number corporate accounting scandals usa audit committee significant deficiencies material congress passed sarbanesoxley actof sarbanesoxley weaknesses design operation internal control sarbanesoxley established new standards corporate account financial reporting reasonably likely affect adversely ability companies listed usa although companys companys ability record process summarise report corporate governance structurewasbelieved robust line financial information fraud regardless materiality best practice certain changes necessary ensure involving persons significant role companys compliance sarbanesoxley internal control financial reporting recommended securities exchange commission sec ceo cfo completed certifications gsk established disclosure committee committee reports filed sec part groups form f ceo cfo audit committee chaired company secretary members consist senior managers controls procedures finance legal compliance corporate communications group carried evaluation supervision investor relations participation groups management including ceo cfo effectiveness design operation external legal counsel external auditors invited attend groups disclosure controls procedures st december meetings periodically responsibility considering inherent limitations effectiveness materiality information timely basis determining system disclosure controls procedures including possibility disclosureof information ithas responsibility timely filing human error circumvention overriding controls reports sec formal review annual report procedures form f committee meteleventimes accordingly even effective disclosure controls procedures sarbanesoxley requires annual report contains statement provide reasonable assurance achieving control objectives whether member companys audit committee based upon groups evaluation ceo cfo concluded audit committee financial expert st december disclosure controls explanation details basis boards judgement procedures effective provide reasonable assurance matter refer page information required disclosed reports group files submits us securities exchange act accounting periods ending th july sarbanes amended recorded processed summarised reported oxley requires companys form f contain report stating requiredand accumulated communicated responsibility management establishing maintaining management including ceo cfo appropriate allow adequate internal control financial reporting assessing timely decisions regarding required disclosure effectiveness companys internal control financial reporting changes groups internal control although company required report compliance financial reporting materially affected form f management undertaken process ensure reasonably likely affect materially groups internal control position report compliance due date financial reporting gsk annual report srotcerid eht fo tropergsk annual report srotcerid eht fo troper remuneration report remuneration report sets remuneration policies operated gsk respect directors corporate executive team cet members together disclosures directors remuneration including required directors remuneration report regulations regulations accordance regulations following sections remuneration report subject audit annual remuneration nonexecutive directors remuneration share options incentive plans performance criteria performance share plans share options pensionsfor opinion thereon expressed remaining sections subject auditnorare pages referred within audited sections report submitted shareholders board approval annual general meeting referenced notice annual general meeting throughout remuneration report executive directors cetmembers referred executives references glaxosmithkline shares adss mean respectively ordinary shares glaxosmithkline plc p american depository shares glaxosmithkline plc ads represents two glaxosmithkline shares introduction remuneration policy executive director terms conditions remuneration nonexecutive director terms conditions fees directors senior management remuneration annual remuneration nonexecutive directors remuneration directors interests share options incentive plans pensions directors senior management directors interests contracts gsk annual report srotcerid eht fo troper remuneration report continued introduction remuneration policy remuneration committee committee responsible principles making recommendations board companys four core principles underpin remuneration policy remuneration policy within terms agreed policy glaxosmithkline determining total individual remuneration packages securing outstanding executive talent executives pay performance performance remuneration policy set thisreport finalised robust transparent governance structures undertaking extensive consultation process shareholders commitment leader good remuneration practice institutional bodies course pharmaceutical industry chairman remuneration committee continues formulating policy committee also decided regular dialogue institutional investors regarding gsks remuneration structure must support needs business remuneration policy competitive market place glaxosmithklines remuneration policy designed establish uk shareholder guidelines followed maximum extent framework remuneration consistent companys consistent needs business company would scale scope operationsmeets recruitment needs maintain regular dialogue shareholders business closely aligned uk shareholder guidelines global pharmaceutical companies primary pay comparator st december company second largest group pharmaceutical company world revenue operationson performance conditions would based measurable delivery five continents products sold overcountries strong financial performance delivery superior returns aroundof sales generated usa shareholders compared pharmaceutical companies high proportion total remuneration opportunity remuneration committee based performancerelated remuneration delivered sir robert wilson chairman committee since th medium long term may sir crispin davis mr culp members remuneration would determined using projected value committee throughout dr schmitz appointed method see benchmarking committee may board deemed members would one remuneration structure executive directors committee independent nonexecutive directors cet performance conditions applying accordance combined code equally longterm incentive awards committee met five times member exgratia payments made attending follows pay structures would simple consistent business needs number meetings number meetings held whilst attended name committee member committee member overall policy intended provide median total remuneration median performance poor performance result total sir robert wilson remuneration significantly pay comparator group median mr l culp opportunity earn upper quartile total remuneration sir crispin davis exceptional performance dr ronaldo schmitz strong alignment performance demonstrably threequorate meetings held approve formal grant interests shareholders provides executives share options performance share awards give effect unambiguous signals importance delivering success committees decisions companys shareholders exception company secretary employees commitment company involved conduct committee meetings dr committee apply policy consistent transparent garnier ceo senior vice president human resources basis significant changes measures used assess invited attend part meetings committee required performance discussed shareholders use deloitte touche llpdeloitte appointed comparators pay benchmarking committee use committee provide independent advice executive discretion ensure remuneration levels reasonable remuneration believes changes may cause concern amongst shareholders position discussed shareholders prior implementation deloitte provided consulting services gsk year provide advice executive remuneration matters committee towers perrin provides market data data analysis committeegsk annual report srotcerid eht fo troper remuneration report continued pay performance comparators following independent review committee made following table sets companies used pay deliberate conscious decision use projected value method performance comparison pay benchmarking purposes enables comparison market cap packages different structural characteristics provides company country insight value gearing different equity instruments abbott laboratories usa individual elements remuneration astrazeneca uk balance fixed base salary variable annual bristolmyers squibb usa bonus longterm incentive elements remuneration changes eli lilly usa performance chart shows anticipated normal glaxosmithkline uk range mix fixed variable pay different levels johnson johnson usa performance ceo typical case executive merck usa directors ed years ranges may higher lower novartis switzerland depending performance company individual pfizer usa roche holdings switzerland ceo ed sanofiaventis france scheringplough usa takeda pharmaceutical company japan wyeth usa base salary annual bonus longterm incentives merger aventis sanofisynthelabo reduced size comparator group companies glaxosmithkline base salary committee subsequently determined number reasons base salaries set reference median relevant market including focus operation market capitalisation executivesthis pharmaceutical pay comparator group actual suitable company add group salary levels reviewed annually may vary depending executives experience responsibility market value changes benchmarking usually take effect st april following market data reviewbase benchmarking purposes total remuneration incorporates base salaries dr garnier dr yamada increased salary annual bonus longterm incentives setting paythe respectivelywith effect st committee due regard executives pension arrangements april line stated policy relation base salary global pharmaceutical industry used primary pay positioning base salary mr coombe prior retirement comparator executivesas appropriate marketplace st march base salary appointmentfor companys senior executive talent first instance mr julian heslop succeeded mr coombe pay benchmarked publicly available remuneration data following market data review undertaken february companies base salary dr garnier dr yamada increased respectively mr heslops base provide context information reference made salary increased bytofollowing committees towers perrin annual global pharmaceutical pay survey review performance cfo since appointment role pharmaceutical human resources association phra ensure st april salary increases take effect st april global pharmaceutical industry benchmark subject scrutiny review committee also considers pay data global annual bonus businesses primarily consumer manufacturing sectors bonuses determined basis formal review annual performance stretching financial targets based profit prior determining annual longterm incentive opportunity interest tax subject detailed assessment committee considers range vesting levels may achieved individual business unit andgroup achievements objectives based different assumptions share price growth bonus payable financial performance less performance levels etc performance line expectations target performance individual performance objectives total remuneration targeted median comparator group increase decrease bonus level factor range longterm incentive opportunity set way provides zero bonuses subject upper limits positioning total remuneration median executives ceo range ensure stable benchmark developed reduce base salary ceos limit impact shortterm fluctuations incentive policies global annual bonus paid basis ontarget business performance pharmaceutical companies assessed number years together base salary provides annual cash line median valuation method pay comparator group projected value method used benchmark total remuneration case ceothe bonus targets set board method projects future value remuneration package setting objectives ceo board takes account different performance scenarioswhilst moderating impact strategies developed companyand set market fluctuations short term strengthening focus pageof annual report performanceremuneration report continued objectives set focussed particular building best historically performance period awards made fourth product pipeline industry delivering commercial operational quarter started st january following date award lti excellence addition formulating updating strategic awards made thereafter performance periodstarts plan vaccines business st january year award ie st january awards made february reasons commercial sensitivity specific objectives set strategic business drivers kept confidential following end compensation provided change awards cycle financial year board reviews ceos performance full disclosure ltiawards made executive directors generally againsttheset objectivesand committee february made remunerationreport determines bonus payable ceo makes recommendations summary details ltiawards made executive directors committee regarding performance level achieved february set outon pageof remunerationreport objectives executives recommendations considered committee determine resultant bonus performance share awards share options delivered us resident executives form adss awards delivered determining bonus awards committeetook form ordinary shares executives resident uk account excellent financial performance year countries awards made plans incorporate dilution encouraging progress building pipeline new products limits consistent guidelines provided association light low take levels response concerns expressed british insurers national association pension funds institutional investors relation nonperformance shareholder representative bodies current estimated dilution related match provided theannual incentive plan aip existing awards glaxosmithkline employee share schemes committee decided discontinue theaip aip us made since merger approximately companys share equivalent eligible employees could elect invest bonus gsk capital st december shares adss minimum period three years end committee assisted deloitte undertook review threeyear holding period participants including executives current performance measures used gskltiplans entitled matching award deferred shareholding extensive careful consideration committee concluded match subject performance conditions thisaip measures currently used lti plans remain open approximately senior executives participated appropriate relevant although case share option terms last deferral elections theaipwere plan agreed annualised growth eps achieve made respect bonuses earned although theaip vesting awards granted would increased closed gsk continue manage ongoing rpi rpi administration subsisting awards required theaiprules performance shares longterm incentives executives level performance shares vesting based executives eligible performance share awards share companys total shareholder return tsr relative options remuneration policy provides annual longterm performance comparator group see threeyear incentive lti awards normally made performance measurement period tsr chosen appropriate share award share option award comparative measure since focuses return shareholders committee considers performance shares provide stronger wellunderstood tested mechanism measure performance alignment shareholder value therefore remuneration policy allows comparison companies operating different places greater emphasis use performance sharesltiawards countries determined ontarget performance half tsr measured sterling performance period longterm incentive reward derived performance shares represents change value share together value annual grant ltiawards using one plan consistent reinvested dividends paid order remove impact practice pay comparator group leading uk varying tax treatments dividends different jurisdictions companiesltisfor cet provided basis dividends reinvested gross executive directors level annual lti opportunity result change lti award cycle eligible considered carefully yearonyear committee context employees performance share awards made market practice executives respect performance share awards granted align award cycles closely gsks financial year december february performance periods budgeting process committee decided change annual st january st december st january grant date forltiawards eligible employees fourth st december respectivelyif gskis ranked position seven quarter year first quarter year midpoint performance comparator group shares vest ranking point result shares change took effect thus lti awards would vesting gskis one top two companies otherwise made fourth quarter made shares vest determining vesting levels committee instead february change award cycle affect regard companys underlying financial performance performance period gsk annual report srotcerid eht fo troperremuneration report continued tsr rank companies percentage following introduction international financial reporting glaxosmithkline award vesting standards ifrs st january committee considered eps measurement basis either ifrsor ukgaap used share options performance share plan awards prior see eps performance conditions performance periods straddled ifrs conversion date committee agreed purpose measuring eps growth determining whether vesting targets achieved ukgaap would used grant performance period st january st december two three years would reported tsr measured prorata basis glaxosmithklines performance ukgaapthis would require cergrowth restated falls two comparators level vesting determined ukgaap basis ifrs would used grant actual relative level tsr rather simple ranking performance period st january stdecember two three years would reported ifrs provide closer link shareholder returns payments executives notional dividends reinvested paid result change lti award cycle eligible proportion vesting award receipt dividends employees share options granted executives incorporated benchmarking award levels addition forshare option grantsin vesting increases straightline performance shares earned executives sold except basis eps performance hurdles set meet related tax liabilities two years following end followinggraph vesting period committee believes aligns interests executives longterm interests shareholders vesting table performance share awards granted december performance period st january st december given page b share options share options allow holder buy shares future date share price prevailing time grant share options granted managers glaxosmithkline including executives thevestingof share options granted executives linked achievement compound annual eps growth performance period committee considered eps key measure performance business also fully reflected business measures extended throughout group ensuring organisational alignment setting eps targets committee considers companys internal projections analysts forecasts glaxosmithklines eps performance condition substantially consistent uk performance well analysts forecasts pharmaceutical shareholder guidelines expectations demanding industry compared operated global pharmaceutical following key principles govern use eps performance companies consistent policy providing pay measure performance performance adjustments considered major items performance measured overperiods ofthree financial yearswhich adjustments judgement committee commence basis set page performance purpose adjustments ensure performance retesting performance condition met three measurement fair reasonable participants year period options lapse shareholders pensions discretion exercised committee disclosed executives participate glaxosmithkline senior executive pension shareholders annual report plans pension arrangements structured accordance committee set basis decision considers plans operated executives country appropriate make adjustment executives likely retire benefits normally payable age details individual arrangements executive directors set page response future pensions regime uk committee carefully considered impact change legislation decided following gsk annual report srotcerid eht fo troper rpi pa egatnecrep gnitsev exceptional superior baseline threshold rpi rpi rpi pa pa pa eps targetremuneration report continued company continue fulfil obligations existing sharesave plan sharereward plan inland revenue pension arrangements approved plans open uk employees terms mr compensation provided participants adversely heslop member sharesave plan contributes affected new pension regime month provides option buy shares end threeyear savings period line opportunity coming decisions committee took account available uk employees following mr heslop also contributes per monthto buy shares new executive hires benefit plus match sharereward plan company matches number shares opportunity base pay defined contribution plan bought month uk contribution equal base salary plus bonus cash balance plan usa executives also receive benefits including healthcare uklegacy final salary plans grandfathered existing medical dental personal financial advice life assurance employees new entrants allowed capped cash value benefits received executive directors employees benefits excess cap currently provided shown page unfunded arrangements capped employees usa benefits cap executive director terms conditions provided nonqualified plan remuneration share ownership requirements executive director contracts align interests executives shareholders policy regarding executive directors contracts subject executives required maintain significant holdings shares extensive review change policy provides glaxosmithkline requirements important part framework contracts executive directors appointed since aligning interests executives shareholders ceo going forward required hold shares value four times base salary key aspects glaxosmithklines contractual framework executive directors required build shareholding value three times base salary members cet required build aspect policy shareholding value two times base salary top notice period calendar months executives group required build shareholding value termination one times base salary executives required continue satisfy employing company shareholding requirements minimum twelve months executive following retirement company termination payment x annual salary order shares qualify share ownership requirements x annual ontarget bonus must held personally executive spouse mitigation required minor children earned deferred one benefits governed benefits policy share programmes operated company unexercised share including options included calculation st december healthcare medical dental dr garniersholding wasadssdr yamadas personal financial advice adss mr heslops ordinary shares dr life assurance contributions garniers dr yamadas holdings excess share vesting longterm rules relevant equity incentive ownership requirements mr heslop december build holding value three times base salarymrcoombe 's incentives plan shareholdingat st december excess share pension based existing arrangements ownership requirements following retirement board terms relevant pension plan st march noncompete clause months termination remuneration elements notice date executives participate various legacy glaxo wellcome dr garniers target bonus salarydr yamadas salaryand mr smithkline beecham allemployee share plans either uk heslops salary usa glaxosmithkline plans replaced imposition month noncompete period executives considered vitally important company order protect groups intellectual property light noncompete clause competitor practice committee believes would appropriate provide mitigation contracts reviewing level severance payments committee considered investor dti guidance however determined line competitive practice appropriate provide payment salary target bonus termination approved shareholders glaxosmithkline glaxo wellcome smithkline beecham appropriate gsk annual report srotcerid eht fo troperremuneration report continued following independent review remuneration undertaken glaxosmithkline makes annual contributions dr garniers dr garniermr coombeand dr yamada agreed changes annual salary bonus dr yamadas annual salary previous contractual terms without compensation come bonus fund increases interest rate based yield broadly line new contractual framework including year treasury bonds company liability beyond making reduction contractual notice period calendar months annual contributions however order honour certain aspects old contractual prior usemployees including dr garnier dr yamada terms number individual features moved final salary pension arrangement current retained cash balance structure employees us cash balance plan dr garniers casethese include entitlement reimbursement contributions based combined annual salary annual bonus excise tax change control related payments life insurance mr heslop participates glaxo wellcome defined benefit plan benefit funded company age following provisions accrual rate th finalpensionable salary per annum relating vesting longterm incentives benefits accrued glaxo wellcome uk pension pre awards arrangements augmented trustees plans termination company cause reflect distribution surplus augmentation apply retirement resignation good reason ie resignation due element mr heslops pension earnings st march elected retained director company merged company result change control provided entitlements resignation occurs within days first addition contractual provisions outlined event anniversary change control options vest full thatexecutive directorsservice agreements terminated remain exercisable full option termand performance shares employing company following would apply vest end performance period subject case awards glaxosmithkline annual investment performance timeapportioned plan provided agreement terminated cause deferred amount income gains thereafter automatically distributed soon administratively practicable awards provisions applybut options subject termination resign retire termination cause performance testing circumstancesand options deferred amount distributed end performance share awards made months prior termination minimum threeyear deferral period notice date lapse line policy applicable us senior executives dr garnier additiondr garnier dr yamadaare entitled receive one dr yamada entitled receive continuing medical dental years worth pension contributions termination insurance dr garniers contract executed rd march took following merger participants legacy share option effect st january contract expire st october schemes elected exchange legacy options options last day month reach th glaxosmithkline shares receive additional cash benefit birthday dr yamadas contract executed th july equal grant price original option took effect st january dr yamada retire additional benefit triggered new option exercised board company st june mr coombes contract lapses qualify additional cash benefit participants executed rd march took effect st january retain options least second anniversary expired st march effective date merger mr heslops contract executed th march took outside appointments executive directors effect st april mr heslops contract expire st outside appointments must approved chairman january last day month reaches behalf board companys policy remuneration th birthday earned appointments may kept individual termination payments made respect part executive director notice period extending beyond contract expiry dates individual pension arrangements uk plan provides pension based twothirds final salary age us cash balance plan provides annual contribution interest sum accumulated cash balance plan contractual promise provide specific levels retirement income gsk annual report srotcerid eht fo troperremuneration report continued nonexecutive director terms conditions fees nonexecutive directors appointment nonexecutive director provided letter nonexecutive directors glaxosmithkline service appointment agreed serve company contracts instead letters appointment company aims nonexecutive director conclusion annual general provide nonexecutive directors fees competitive meeting following third anniversary appointment companies equivalent size complexity fee structure case extended term three years mutual nonexecutive directors follows agreement nodirectors serve term longer three years without per annum offering reelection shareholders standard annual cash retainer fee following table shows date letter appointment supplemental fees nonexecutive director senior independent directorthe auditcommittee nonexecutive date letter chairmanand scientificmedical experts director appointment chairmen remuneration mrl culp corporate responsibility committees sir crispin davis nonexecutive director undertaking sir deryck maughan intercontinental travel meetings per meeting sir ian prosser automatic share allocation dr r schmitz enhance link directors shareholders dr l shapiro glaxosmithkline requires nonexecutive directors receive mr de swaan significant part fees form shares effect sir robert wilson st october least nonexecutive directors total fees excluding chairmanare paid form shares tsrperformance graph allocated share account nonexecutive directors may also following graph sets performance company relative take opportunity invest part balance fees ftse index company constituent share account performance comparator group since merger th exchange rate december graph prepared accordance fees paid usdollars converted rate regulations indication likely vesting awards usbeing exchange rate applied th july granted companys incentive plans new fee arrangements approved board nonexecutive directors entitled compensation appointment terminated chairman sir christopher hogg retired chairman effect st december sir christopher gents letter appointment board dated th may agreed serve company deputy chairman st december st january chairman conclusion annual general meeting following third anniversary appointment may extended term three years mutual agreement received fees rate per annum plus allocation glaxosmithkline shares value per annum whilst deputy chairmanand receives per annum plus allocation glaxosmithkline shares value per annum chairman directors senior management remuneration following tables set directors glaxosmithkline plc remuneration earned interests shares glaxosmithkline plctheir interests share options incentive plans pension benefits members cet company secretary known senior management also participate remuneration plans executive directors aggregate remuneration interests directors senior management also provided gsk annual report srotcerid eht fo troper gsk total return index gsk pharma peers return index ftse total return indexremuneration report continued annual remuneration total total fees annual deferred annual fees annual annual salary benefits bonus bonus remuneration salary benefits bonus remuneration footnote current executive directors dr jp garnier abc mr j heslop dr yamada abc totalcurrent executive directors former executive director mr j coombe bcd total executive directors current nonexecutive directors mr l culp sir crispin davis sir christopher gent sir deryck maughan sir ian prosser dr r schmitz dr l shapiro e sir robert wilson total current nonexecutive directors former nonexecutive directors dr barzach f sir christopher hogg sir roger hurn sir peter job mr j mcarthur mr mchenry sir richard sykes total former nonexecutive directors total nonexecutive directors totalremuneration remuneration directors us payroll reported dollars amounts converted sterling average rates foreachyear following merger participants legacy share option schemes elected exchange legacy options options glaxosmithkline shares granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses market value qualify additional cash benefit participants retain options least second anniversary effective date merger yeardr garnier received dr yamada received nil relating options exercised page b dr garnier nonexecutive director united technologies corporation respect received form deferred stock units stock options grant price dr yamada member advisory board quaker bioventures inc respect received dr yamada previously member board directors diadexus inc respect received stock appreciation rights grant price amounts excluded table retained executive directors mr coombe member supervisory board siemens anonexecutive director hsbc holdings plc period st january retirement glaxosmithkline st march received stock appreciation rights grant price nil respectively c following merger dr garnier mr coombe dr yamada awarded oneoff special deferred bonus members cet awarded amount equivalent annual salary st december notionally invested glaxosmithkline shares adss th february deferred three years deferred bonus vested th february amounts paid equivalent value glaxosmithkline shares adss notionally acquired february plus dividends reinvested period dr garnier received dr yamada received mr coombe waived deferred bonus company made contribution pension plan enhance pension entitlements amount included table gsk annual report srotcerid eht fo troperremuneration report continued gsk annual report srotcerid eht fo troper mr coombe waived prorated bonus annual bonus company made contribution pension plan enhance pension entitlementsthese amounts arenot included within fees salary e dr shapiro member glaxosmithklines scientific advisory board received fees form adss included within fees salary f dr barzach received fees glaxosmithkline france healthcare consultancy provided included within fees salary none directors received expenses year requiring separate disclosure required regulations mr de swaan joined board nonexecutive director st january remuneration shown table nonexecutive directors remuneration total cash sharesadss total cash sharesadss fees salary current nonexecutive directors mr lculp sir crispin davis sir christopher gent sir deryck maughan sir ian prosser dr r schmitz dr l shapiro sir robert wilson former nonexecutive directors dr barzach sir christopher hogg sir peter job mr jmcarthur mr mchenry total table sets remuneration received nonexecutive directors glaxosmithkline accordingly include dr barzachs fees received glaxosmithkline france healthcare consultancy providedor dr shapiros fees received member glaxosmithklines scientific advisory board formation gsk nonexecutive directorshave required take least part total fees form shares allocated share account st october least nonexecutive directors fees except chairman see detailsmust taken fee allocation arrangementnonexecutive directorscan elect receive either part remaining cash payment form shares adss total value shares adss date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares adss shares adss notionally awarded nonexecutive directors allocated interest accounts included within directors interests tables page accumulated balance shares adss together notional dividends subsequently reinvested paid nonexecutive directors retirement upon retirement nonexecutive directors receive either shares adss cash amount equal value shares adss date retirementremuneration report continued table sets accumulated number shares adss held nonexecutive director relation fees received board members st december together movements account year number shares adss dividends nonexecutive directors share arrangements footnote elected reinvested paid current nonexecutive directors shares sir crispin davis sir christopher gent sir ian prosser dr r schmitz dr l shapiro sir robert wilson adss mr lculp sir deryck maughan dr l shapiro former nonexecutive directors shares sir christopher hogg sir roger hurn sir peter job dividends notionally reinvested end financial year payment made table sets settlement former nonexecutive directors share arrangements leaving board value awards value awards payments date leaving allocation leaving prior years sir christopher hogg ab sir roger hurn c sir peter job ab awards sir christopher hogg sir peter job nonexecutive directors share arrangements settled full transfer shares january b change value awards allocation leaving attributable dividends reinvested change share price dates award dates leaving c leaving board sir roger hurn elected receive settlement nonexecutive directorsshare arrangements quarterly cash payments gsk annual report srotcerid eht fo troperremuneration report continued directors interests following beneficial interests directors company shown register maintained company accordance companies act shares adss th february st december st january th february st december st january footnote current executive directors dr jp garnier mr j heslop bd dr yamada former executive director mr j coombe cde current nonexecutive directors mr l culp f sir crispin davis f sir christopher gent f sir deryck maughan f sir ian prosser f dr r schmitz f dr l shapiro f mr de swaan f sir robert wilson f one glaxosmithkline ads represents two glaxosmithkline shares includes equivalent number adss purchased glaxosmithkline stock fund within k plan b case mr heslop opening number shares shown st april c case mr coombe closing number shares shown st march includes shares purchased glaxosmithkline sharereward plan mr heslop totalling shares st december st april shares th february mr coombe shares st march st january e mr coombe left board st march therefore interests company onth february included table fincludes shares adss received part fees described nonexecutive directors share arrangements page dividends received shares adss converted shares adss st december also included directors interests interests abovementioned directors th february reflect changes end financial year date gsk annual report srotcerid eht fo troperremuneration report continued share options options adss granted footnote date grant exercise period grant price number exercised dr jp garnier dr yamada options shares granted date grant exercise period grant price number exercised mr jheslop ab mr jcoombe c na na na na aas part main option grant occured st february vestingperiod ofst january tost december dr garnier awarded ads options grant price part grant mr heslop awarded share options grant price dr yamada receive agrantof options due impending retirement glaxosmithkline b mr heslop joined theboard st april details cover period st april st december grant included table relates thesharesave plan cmr coomberetired onst march details cover period st january st march options outstanding st december earliest latest vesting lapse dates market price glaxosmithkline share year end given table mr coombe following vesting date lapse date weighted average dr jpgarnier grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total ads options st december vesting date lapse date weighted average dr tyamada grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total ads options st december vesting date lapse date weighted average mr jheslop grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total share options st december gsk annual report srotcerid eht fo troperremuneration report continued vesting date lapse date weighted average mr jcoombeto st march grant price number earliest latest earliest latest market price underwater period endvested options unvested options market price period end unvested options total share options st march lapse dates mr coombes options modified reflect retirement gskgrants share options executive directors senior managers annual basis initial grant made following completion merger march measurement period options granted march commenced st january measurement periods options granted november december commenced st january respectively directors hold options various share option plans referred noteto theffinancial statements employee share schemes measurement period options granted february commenced st january none directors interest option companys shares following merger directors elected exchange outstanding options legacy share option plans options overgskshares directors participants legacy schemes made election receive additional benefit cash sum equal grant price original option additional benefit given new option exercised lapses prior share options granted executive directors subject performance condition order options vest full business performance eps growth excluding currency exceptional items average least three percentage points per annum increase uk retail prices index threeyear performance period share options granted vesting increases straightline basis eps performance hurdles set following table annualised growth eps percentage award vesting rpi rpi rpi rpi respect grant performance condition met threeyear measurement period performance measured four financial years following date grant options performance condition met end four years option lapse options granted executive directors subject performance condition set extent performance conditions met end threeyear performance period option lapse retesting permitted grant market options exercised date number price price gain gain dr jpgarnier dr yamada mr j heslop average exchange rate year gain made dr garnier amounted eoi benefit paid dr garnier exercise options benefit included table page average rate year gain made dr yamada amounted eoi benefit paid dr yamada exercise options benefit included table page mr coombe exercise share options highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december prices onth february per glaxosmithkline share per glaxosmithkline ads gsk annual report srotcerid eht fo troperremuneration report continued incentive plans performance share plan awards dr jp garnier adss market additional vested price vested exercised ads vested number unvested deferred date market dividends unvested deferred granted performance period grant number price gain lapsed reinvested value awards deferred dr garnier vesting dr tyamada adss market additional vested price vested exercised ads vested number unvested deferred date market dividends unvested deferred granted performance period grant number price gain lapsed reinvested mr jheslop shares market additional vested price vested exercised shares vested number unvested deferred date market dividends unvested deferred granted performance period grant number price gain lapsed reinvested mr jcoombe shares market additional vested price vested exercised shares vested number unvested deferred date market dividends unvested deferred granted performance period grant number price gain lapsed reinvested st april total number performance share plans psp awards granted mr coombe performance period st january st december prorated reflect retirement end performance periodthepspawards performance period st january st december made st february market price per share per ads dr garnier awardedadssand mr heslopshares unvested average exchange rate year gains dr garnier dr yamada amounted respectively thepspis mediumterm incentive scheme introduced psp replaces ltiplan midterm incentive plan operated respectivelyby glaxo wellcome smithkline beecham terms psp number shares actually vesting determined following end relevant threeyear measurement period dependent gsks performance period described pages share awards previously granted annually november december theyaregranted february following year measurement period commences st january year granted ending three years st december threeyear measurement period awards performance period commencing st january ended st december based performance gskduring period award vested february forawardswith performance period commencing st january subsequent awards dividends reinvested psps awarded members cet dividends reinvested quarter payment made terms psp us participants may defer receipt part vested awards prior performance period beginning st january awards two parts half earned reference gsks tsr performance compared ftse company constituent half awardwill earnedif companys business performance eps growth excluding currency exceptional items average least three percentage points peryearmore increase uk retail prices index threeyear performance period awards gskis ranked top ftse based tsr performance shares part award vest th position ftse shares vest gskis ranked th position none sharessubject part awardwill vest th th positions vesting occur sliding scale gsk annual report srotcerid eht fo troperremuneration report continued following vesting table applies awards withperformance periodsfrom st january st december st january st december also applies awards made st february tsr rank companies glaxosmithkline percentage award vesting median median vested additional ads vested deferred dividends deferred participations reinvested participations midterm incentive plan adss dr jp garnier midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted final award adss made receipt award may deferred director dr garnier deferred receipt full amounts vested deferred awards together additional adss subsequently received dividend reinvestment arenot included directors interests table pagesince retained mtip paid average stock appreciation rights sars adss grant price dr l shapiro options exercised date number grant price market price gain gain dr l shapiro sars held dr shapiro hada grant price market price glaxosmithkline ads atst december dr shapiro member glaxosmithklines scientific advisory board sab dr shapiro member smithkline beechams sab completion merger glaxo wellcome along members sab received annual grants smithkline beecham sars general vested three years date grant expire years date grant grants sars sab members ceased sars entitle holder cash sum future date based share price growth date grant date exercise full provision made financial statements accrued gains sars date grant connection merger previously granted sars became immediately exercisable gsk annual report srotcerid eht fo troper performance comparator group theseawardscomprised companies glaxosmithkline aventis sanofisynthelabo comparator groupprior merger form sanofiaventis purposes calculating tsrover performance period awards granted december starting price shares two individual companies compared price merged company end performance period adjusted merger ratio dividends treated reinvested performance period tsr measured prorata basis glaxosmithklines performance falls two comparators level vesting determined actual relative level tsr rather simple rankingremuneration report continued pensions accrued annual pension benefits transfer values executive directors retirement set regulations require disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value changepensions executive directors disclosed currency pension payable personal change change contributions accrued transfer value accrued accrued accrued made transfer transfer change benefit change benefit benefit benefit scheme value value transfer year net accrued b year year value b inflation benefit b current executive directors dr jp garnier mr jheslop dr tyamada former executive directors mr j coombe adr yamadastransfer value st december hasincreased previously disclosed result adjustment employment contract dr yamadas accrued benefit st december decreased reflecting adjustment retirement age b change transfer value transfer value change accrued benefit shown net contributions made individual dr garnier dr yamada members employee us cash balance pension plan glaxosmithkline makes annual contributions calculated percentage employees base salary bonusthe fund increases interest rate set annually advance based year treasury bond rate provide cash sum retirement cash sum used purchase pension retirement based annuity rates applicable time neither entitlement spouses pension pension increases reducing initial pension normal retirement age plan years age drgarniers pension arrangements brought line terms service agreement assumed retirement age reduced similarly dr yamadas assumed retirement age hadbeen reduced transfer value cash sum dr garniers plan increased year result phased transfers previous scheme accumulation interest contributions paid company transfer value cash sum dr yamadas plan increased year result accumulation interest contributions paid company dr garnier dr yamada also members usretirement savings plan savings scheme open usemployees executive supplemental savings plan savings scheme open executives restore us government limits imposed retirement savings plan contributions plans invested range funds value accumulated funds paid retirement contributions paid two schemes company respect dr garnier invested gsk shares stock ownership account respect dr yamada contributions paid scheme invested gsk shares stock ownership account shares held accounts included within directors interests tables page mr heslops transfer value calculated basis actuarial advice accordance actuarial guidance note gn transfer value represents present value future payments made pension plan mr heslops annual accrued benefit increased excluding effects inflation transfer value less personal contributions increased year increase mr heslops pensionable salary primary reason increase transfer value mr coombes transfer value calculated basis actuarial advice accordance actuarial guidance note gn transfer value represents present value future payments made pension plan mr coombes transfer value increased accrued benefit fell decline due mr coombe opting receive lumpsum retirement mr coombe waived bonus company made contribution pension plan enhance pension benefits bonus special deferred bonus bonus gsk annual report srotcerid eht fo troperremuneration report continued directors senior management us reporting purposes necessary provide information compensation interests directors senior management asagroup group purposes disclosure group defined directors members cet company secretary respect financial year total compensation paid members group periods served capacity aggregate increase accrued pension benefits net inflationwas aggregate payment defined contribution schemes members group granted options sharesave scheme awarded shares adss reinvestment dividends performance share plan atth february thencurrent members group comprisingpersons ownedshares andadss constituting less issued share capital company group also held date options purchaseshares andadss shares andadss awarded performance share plan including shares adss vested deferred shares andadss legacy smithkline beecham midterm incentive plan including shares adss vested deferredadss awarded legacy smithkline beecham stock appreciation rights andshares awarded restricted share plan holdings issued various executive share option plans described noteto thefifnancial statements employee share schemes directors interests contracts except described noteto thefifnancial statements related party transactions end financial year director connected person material interest contract significance relation groups business group company directors remuneration report approved board directors signed behalf sir christopher gent chairman st march gsk annual report srotcerid eht fo tropergsk annual report srotcerid eht fo troper operating financial review prospects operating financial review prospects discusses operating financial performance financial outlook financial resources group results year prepared ifrs adopted use european union compared primarily results preceding year following headings financial trends ratios year results year st december compared year st december financial position resources st december outlookand risk factors year results year st december compared year st december reconciliation us accounting principles set note financial statements accounting presentation effect st january gsk moved reporting financial results accordance international financial reporting standards ifrs required european union regulation issued report prepared ifrs adopted use european union comparative figures presented basis except gsk taken advantage exemption permits financial instruments accounted presented uk gaap basis accordance ias ias st january full details major differences ukgaap apply gsk given innoteto financial statements ifrs transitioninformation prepared ifrs directly comparable prepared ukgaap data market share market growth rates gsk estimates based recent data independent external sources appropriate valued sterling relevant exchange rates figures quoted product market share reflect sales gsk licensees order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates annual report form f purpose usreporting requirements applicable firsttime adopters ifrs gsk hereby incorporates reference annual report form f five year record selected financial information pages thereof discussion year pages operating financial review prospects section thereof financial statements supporting notes pages thereofgsk annual report srotcerid eht fo troper operating financial review prospects financial trends ratios growth growth cer cer turnover pharmaceuticals consumer healthcare total cost sales selling general administration research development operating income operating profit profit taxation profitafter taxation year profit attributable minority interests profit attributable shareholders earnings per share pence p p p diluted earnings per share pence p p p research development pharmaceuticals consumer healthcare total net finance costcover netfinance costs cover times times times net finance cost cover profit tax plus net finance costsdivided net finance costs tax rate borrowings net debt gearing gearing ratio calculated net debt percentage oftotalequity exchange rates group multinational business operates many countriesand earns revenues incurs costs many currencies results reported sterling affected bymovements exchange rates sterling othercurrencies average exchange rates prevailing period used translate results cash flows overseas subsidiary associated undertakings joint ventures sterling period end rates used translate net assets undertakings currencies influence translations usdollar euro japanese yengsk annual report srotcerid eht fo troper operating financial review prospects year world economy world market pharmaceuticals gdp growth picked first part year impact global pharmaceutical sales increased billion higher oil prices later year saw leading indicators turn world market value growth downward business confidence weaken major countries geographic region bn total manufacturing trade strengthened year initial usa dip modest globalexpansion continued led usa europe china wheremomentum maintained contrast germany regions excluding japan indiahoweverus gdp growth slowed france fourth quarter annual rate compared uk reflecting slow consumer spending italy federal government spending us interest rates japan increased series rises asia pacific mixed views outlook us economy latin america gdp growth china exceeded expectations atand middle east africa also robust india continued expansion services canada information technology remained strong global trade arrangements total including china spotlight agreements eu china usaand growth us market slowed tobutit stillrepresents china textile imports world trade organisation global prescription pharmaceutical market comparedwith ministerial talks hong kong end yearmade decade ago modest progress towards agreement reduction trade th september gsk heldsecondposition world barriers pharmaceutical market market share behind pfizer japanese economy expanded strongly particularly fourth market share gsk hadeightofthe worlds top quarter driven recovery domestic demand underpinned pharmaceutical products avandia flixonase strengthening labour market saw fulltime employment expand imigranimitrex lamictal seretideadvair seroxatpaxil wellbutrin first time seven yearsboth business confidence exports zofran grew year part confidence stemmed continued reforms banking sector gdp growth year world market value growth similar rise forecast nikkei share index top five therapeutic classes bn total cer rose fouryear high strength betterthanexpected gdp cardiovascular data central nervous system alimentary tract metabolic oil prices higher commodity prices slowed growth antiinfectives bacterial eurozone nations economic forecasts zone viral fungal excluding downgraded yearwith increased concerns rising vaccines inflationthe european central bankraised interest rates respiratory first changein rates since june weak domestic demand theeuros lack resilience external events note data based months thseptember features theeurozone uk gdp growth recorded rate ofaround predicted bank pharmaceutical turnover england cut interest rates middle year growth rates included review turnover constant grounds economic growth subduedbut predicted growth exchange rates cer unless otherwise stated sterling growth would pick reflecting recovery domestic demand rates may found tables pharmaceutical turnover foreign trade therapeutic area pageand geographic region page exchange total pharmaceutical turnover million compared million increase cer sterling terms currencies influence groups results us turnoverincreasedprincipally due thestrengthof theeuro dollar euro japanese yen international currencieswithin groups portfolio turnover dollar strengthened pound new products first launched major market within last five rising yearend following two years ofweakness years accounted total turnover grew euro japanese yen yearend rates weakened million turnover established franchise products pound amounted millionrepresenting total turnover increased compared last year turnover older products less actively promoted million decline representing total turnover year continued pharmaceutical turnover therapeutic area total wellbutrinturnoverfell million wellbutrin irand srsales fell million due generic competitionbut gsks ability continue deliver pharmaceutical turnover growth largely offset strong performance wellbutrin xlup primarily due exceptionally broad product portfolio fast million growing highvalue products sales gsks largest product seretideadvairwere billion continued gain strong growth gsks epilepsy bipolar disorder treatment market shareacross regions market shareby value anti lamictalcontinued sales million driven asthma copd therapy class europe indication maintenance treatment bipolar disorder usa increase percentage points cases compared requipsales rose million q weekly new sales diabetes treatments also strong prescriptions product quadrupled usa since avandiaavandametup billion gsk launched avandia launched forrestlesslegssyndrome rls q eu final treatment type diabetes combination approval requip adartrel rls expected q product avandamet blood sugar control theproduct groupwas expanded february launch antivirals usa fixeddose combination treatment avandaryl global hiv product sales grew billion sales combines avandiawith sulfonylurea eu approval expected q new products epzicomkivexa lexiva together avandiaavandametachieved market share value doubling million offsetting performance trizivirdown oral antidiabetics europe usa million epivir million sales percentage pointsrespectively herpes treatment valtrex grew million performance driven usa million product clear market leader treatments genital herpes antibacterials antibacterial sales declined worldwide usa decline wasreflecting increased generic competition metabolic diabetes treatments avandiaavandametcontinuedto perform strongly overall sales billionup usa sales grew million avandiaavandamet also establishingstrong positionsin europe sales rising millionhelped launch avandamet sales international markets rose million two major outcome studies fast growing products lamictal epilepsybipolar involving avandiaare due report end adopt disorder billion valtrexfor herpesup investigates first line use avandiain type diabetesand dream billion coregfor heart disease billion vaccines earlier use avandiato delay prevent disease progression billion bonivabonviva new oncemonthly oral bisphosphonate addition rapid uptake number high treatment osteoporosis developed roche potential products requip restless legs syndrome sales strong launch usa andin february hada share million avodartfor benign prostatic hyperplasia sales new prescriptions oral bisphosphonates boniva injection first doubled million bonivabonvivafor treatment ever quarterly treatment osteoporosis approved usa osteoporosis waslaunched andcaptured share january received positive opinion chmp new prescriptions oral bisphosphonates us market europe th january respiratory vaccines gsk continues global leader respiratory pharmaceuticals vaccines business performed wellwith total sales rising sales three key products seretideadvair flixotideflovent billion led infanrix vaccine sales particularly strong sereventamounting billion seretideadvair usa turnover rose million helped sales rose billionin usa sales werealso strong launch two new productsfluarix boostrix european international marketswhich billion billionrespectively july gsk acquired corixa corporation million decembercompleted acquisition id biomedical corporation central nervous system cns billion approval idbs fluviralflu vaccine expected time cns sales declined billion sales declined usaand flu season europewitha small gain internationaltotal paxilsales fell million due generic competition interruption also december gsk submitted mockup dossier emea supply paxil crduring year see product supply accelerated approval potential pandemic influenza vaccine gsk partially mitigating decline strong performance ofpaxil expects begin clinical trials coming weeks hn prototype japan million pandemic vaccine using two different adjuvants alum newly developed adjuvant thegroupis discussions governments around world plans prime populations stockpile vaccine gsk expects complete filing europe gsk annual report srotcerid eht fo troper operating financial review prospects market share value seretideadvair avandiaavandamet europe usa europe usa september september year continued pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxilir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es xr zinnatceftin metabolic avandia avandamet bonvivaboniva vaccines hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac cer representsgrowth constant exchange rates represents growth actual exchange ratesturnover quarter given financial recordonpages gsk annual report srotcerid eht fo troper operating financial review prospects year continued oncology emesis pharmaceutical turnover europe region sales zofrangrew million driven us market turnover created basis million region invoiced adjustment created invoiced adjustment created cardiovascular urogenital major markets sales ofcoregfor heart diseasegrew million europe france avodartfor benign prostatic hyperplasia enlarged prostate uk strong yearwith salesdoubling millionby january italy product accounted new prescriptions us germany alpha reductase inhibitor market spain therapeutic areas poland sales zantacfell millionwith declines regions europe regional analysis adjustments gsks estimates based recent data pharmaceutical turnover geographic region independent external sources valued sterling relevant invoiced basis exchange rates management believes turnover created basis turnover reported table represents sales invoiced reporting turnover market provides better reflection gsks local entity customers local market plus co performance businesses market within europe promotion income within market total turnover europe region unaffected restatement region growth major markets total cer parallel trade occurs occasionally elsewhere worldbut usa sufficiently material affect significantly turnover data market europe presented invoiced basis france pharmaceutical turnover geographic region uk turnover created basis italy turnover market within europe adjusted effects germany parallel trade show turnover basis country spain product finally consumed product sold poland gsk europe international region growth major markets total cer asia pacific japan usa middle east africa europe latin america france canada uk italy germany cer representsgrowth constant exchange rates represents growth spain actual exchange rates poland individual governments determine pricing medicines europe countries within europe result wide price variations international product parallel trade occurs third parties exploit price asia pacific differential purchasing products inmarketswhere low prices japan enforced selling governments purchasers middle east africa markets higher prices agreed parallel trade latin america permitted single market rules european union gsk canada derive benefit profit resale higher price result management believes within european region cer representsgrowth constant exchange rates represents growth turnover market invoiced basis presented actual exchange ratesturnover quarter given financial record properly represent consumption products within pagesto market gsk employees based market instrumental promotion groups products within market thereby creating product sale final consumption market following table gives adjustments made order restate turnover markets within europe turnover created basis gsk annual report srotcerid eht fo troper operating financial review prospects year continued usa international usa reported turnover growth year despite international region reported year year turnover growth impact generic competition paxil ir wellbutrin irsr strong growth japanup chinahong kongup excluding sales products turnover grew us asia pacificupwas partly offset broadly flat sales business represented total pharmaceutical turnover canada australia canadian sales performance reflected generic competition paxil whilst australian business advairmaintained strong growth sales million negatively impacted government pricing reforms however adversely affected sales constituent products flovent serevent collectively declined flonase strong performance japan driven sales paxil indicated treatment perennial rhinitis grew serevent antiviralsup partially offset declines zantac zoviraxand tagamet sales wellbutrinproducts fell million wellbutrin irsr sales fell million result generic competition across markets international key products driving growth impact partially offset however exceptionally strong seretide grew record sales million performance wellbutrin xl new oncedaily product avandiaavandamet grew million achieved sales million vaccines franchise recorded growth achieved sales million total sales ofpaxilwere million result generic competition paxil ir sales declined product supply million paxil crgenerated sales million due following fda inspections october november supply issues cidra plant puerto rico identified possible deficiencies manufacturing practices groups facility cidra puerto rico fda halted distribution sales antivirals therapeutic area grew hiv products supplies paxil cr avandamet march site valtrex herpes grew driven patients switching engaged tableting packaging range gsk products suppression therapy primarily us market including paxil paxil cr coregavandia sales avandiaavandamet increased antibacterial sales avandamet april group reached agreement declined result generic competition began fda consent decree provides independent third quarter coregsales increased million expert review manufacturing processes site compliance continued benefit wide range indications fda good manufacturing practice requirements decree also allows potential future penalties maximum vaccines grew reflecting good performance pediarixand million year ifgsk fails meet terms launches boostrixand fluarix june group began resupplying us markets europe paxil crand avandamet sales products discussion individual market performance europe region significantly impacted interruption supply turnover created basis impact avandametwas mitigated switching patients europe region contributed pharmaceutical turnoverand avandia group also established provision grew reflected strong growth number countries external costs required rectify manufacturing issues plant full year impact acquisitions fraxiparineand arixtra details see risk factors pages noteto acquired q excluding fraxiparineand arixtra financial statements legal proceedings growth marketswhich recorded strong growth included consumer healthcare sales germany italypolandcentral europeandsouthern eastern growth europe government healthcare reforms including pricing cer reimbursement restrictions together generic competition otc medicines adversely affected turnover france uk spain analgesics major growth drivers seretide gsks largest selling product dermatological europewith growth oftheavandiaavandametfranchise gastrointestinal grew hiv thevaccines franchise respiratory tract smoking control sales herpes franchise flat comparedwith mainly natural wellness support result generic competition zovirax offset patients switching newer product valtrex oral care nutritional healthcare seroxat sales reflecting generic competitioninthe majority markets region antibacterial sales increaseddue stronger normal flu growth consumer healthcare sales billion season number southern european markets comprised otc medicines sales increase nutritional healthcare sales increase oral care sales increase gsk annual report srotcerid eht fo troper operating financial review prospectsotcmedicines due lower charges related legal mattersequal overthecounter medicine sales million growth reduction total sgaandlower sharebased payment charges analgesics respiratory tract helped offset equal decrease total sgapartly offset higher costs loss sales dermatological products divested related programmes deliver future cost savingsequal panadol growth international markets key driver increase total sga growth analgesics research development rd january fda advisory committee recommended rd expenditure percentage turnover line alli orlistat approved overthecounter use usa increased comparedwiththe previous yearpartly promote weight loss overweight adults used along result somewriteoffsofintangibleassets excluding thesewrite reduced calorie lowfat diet approved alli fda offs rd expenditure grew slightly turnover growth approved weightloss drug available overthecounter pharmaceuticals rd expenditure represented pharmaceutical turnover oral care oral care sales grew million sales sensodyneand operating income denture care brands polident poligripand corega grew operating income includes royalty income equity investment respectively helping offset lower sales toothpaste disposals impairments product disposals fair value products adjustments quest collar theravance options operating income million compared nutritional healthcare million increased income predominantly due nutritional healthcare product sales grew million increased product asset disposal gains compared lucozade continued grow strongly europe favourable fair value movement million quest operating profit collar theravance options analysis operating profit subsequent discussion operating profit compares results results overall operating profit margin increased percentage points operating profit million increased sterling terms growth constant exchange rates operating profit increased cer margin increased percentage pointsreflecting lower charges turnover relating legal mattersand sharebased paymentshigher product cost sales asset disposals increases advertising promotion selling selling general rate turnover growth partially offsetting administration items higher costs related programmes deliver future cost research savings increased rd expenditure development operating profit taxation income thediscussion compares results results operating profit gains asset disposals including associates million million costs legal matters million cost sales million charges relating costsaving programmes cost sales percentage turnover increased percentage million millionsharebased payments points constant exchange rates increase also million million percentage pointsreflecting higher costs related ongoing rectification manufacturing issues cidra site puerto rico share profitslosses joint ventures associated partly offset operating efficiencies compared undertakings previous year share profits associates arises principally groups holding quest diagnostics inc selling general administration selling general administration sga percentage disposal interest associates turnover decreased percentage points constant exchange disposals interestsin associates rates decrease percentage points reflecting flat group disposed million shares investment expenditurecomparedwith theprior year turnover increase quest diagnostics inc cash proceeds millionaprofit sga costs line overall higher million recognised groups shareholding quest advertising promotion selling expense offset lower st december general administrationexpenditure advertising promotion selling expenses increased accounted increase total sga general administration costs declined accounted areduction total sga gsk annual report srotcerid eht fo troper operating financial review prospects year continued year continued net finance costs however continues wide difference views group irs hmrc relevant taxation authorities financeincome open issues exist ultimate liability matters may vary amounts provided dependent upon outcome interestincome litigation proceedings negotiations relevant tax unwinding discount assets authorities fair value adjustments profit year growth finance costs cer interest costs profitafter taxation year unwinding discount liabilities profit attributable fair value adjustments shareholders earnings per sharepence p p earnings per adsus finance income increased compared predominantly due weighted average number higher interest rates higher cash balancesfinance costsincreased shares millions due higher interest ratesas well higher interest costs resulting issue two million bonds diluted earnings per sharepence p p diluted earnings per adsus taxation weighted average number shares millions uk corporation tax profit year million increase overseas taxation sterling terms profit attributable minority interests million profit attributable shareholders current taxation million increase sterling terms deferred taxation total earnings per share increased reflecting higher profits also reduction weighted average number shares resulting charge taxation profit amounting million groups share buyback programme interest cost represents effective tax rate tax rate programme also impacts groups earnings benefited higher tax relief actual actual rates exchangeearnings per share increased potential exercise share options employees arising favourable currency impact eps three percentage points reflects increase share price year strengthening us dollar euro average exchange rates integrated nature groups worldwide operations involving relative compares afavourable currency impact significant investment research strategic manufacture turnover difference principally arises different mix limited number locations consequential crossborder supply currencies profits compared turnover routes numerous endmarkets gives rise complexity delay dividend negotiations revenue authorities profits board declared fourth interim dividend pence per individual group companies liable taxdisagreements share resulting dividend year pence pence revenue authorities intragroup transactions increase dividend pence per share particular price goods transferred equivalent fourth interim dividend receivable adr holders group companies different tax jurisdictions produce conflicting cents per ads based exchange rate claims revenue authorities profits taxed dividend exdividend date th february record individual territories resolution issues continuing fact date th february paid th april life gsk group hassignificant open issues revenue authorities usa uk japan canada details ifrs interim dividends recognised accounts set note financial statements taxation paid declared gsk normally pays dividend two quarters quarter relates one quarter group total current tax payable liabilities st december declared consequentlythe financial statements recognise million million respect transfer dividends paid namely third fourth interim dividends pricing tax matters first second interim dividends totalling gsk uses best advice determining transfer pricing million methodology seeking manage transfer pricing issues satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments gsk annual report srotcerid eht fo troper operating financial review prospectscritical accounting policies customer rebates offered key managed care group purchasing organisations direct indirect customers consolidated financial statements prepared accordance arrangements require customer achieve certain international financial reporting standards adopted use performance targets relating value product purchased european union following accounting policies approved formulary status predetermined market shares relative board described noteto theffinancial statements accounting competitors theaccrualfor rebates estimated based policies management required make estimates assumptions specific terms agreement historical experience affect amounts assets liabilities revenue expenses product growth rates reported financial statements actual amounts results could differ estimates following considered cash discounts offered customers encourage prompt critical accounting policies adopted payment accrued time invoicing adjusted subsequently reflect actual experience turnover revenue recognised title risk loss passed historical experience customer returns gsk customer reliable estimates made relevant deductions records accrualfor estimated sales returns applying historical gross turnover reduced rebates discounts allowances experience customer returns amounts invoiced together product returns given expected given vary product market related information stock levels arrangements buying groups arrangements wholesalers anticipated price increases competitor activity purchasing organisations dependent upon submission reconciliation gross turnover net turnover us claims time initial recognition saleaccrualsare pharmaceuticals businessisas follows made time sale estimated rebates discounts allowances payable returns made based available market information historical experience amounts estimated may fully reflect final outcome gross turnover amounts subject change dependent upon amongst chargebacks things types buying group product sales mix level usgovernment accrualis reviewed adjusted quarterly light historical state programmes experience actual rebates discounts allowances given managed care returns made changes arrangements future events could group purchasing cause assumptions theaccrualsare based change organisation rebates could affect future results group cash discounts groups largest business us pharmaceuticals us market customer returns complex arrangements rebates discounts prioryear adjustments allowances following briefly describes nature items arrangements existence groups us pharmaceuticals business total deductions us medicaid programme stateadministered programme net turnover providing assistance certain poor vulnerable patients increase customer returns arosefrom product recalls medicaid drug rebate program established reduce state following manufacturing issues cidra plant increased federal expenditure prescription drugs gsk participates generic competition providing rebates states accruals medicaid rebates calculated based specific terms individual state agreements totalaccrualsfor rebates discounts allowances returns using combination historical experience product us pharmaceuticals business st december st population growth anticipated price increases impact december follows contracting strategies impact medicaid part st st arrangements seen expected affect december december level discounts given gskhas arrangements certain key parties whereby party chargebacks able buy products wholesalers lower prices usgovernment state programmes chargeback represents difference invoice price managed care group purchasing wholesaler indirect customers contractual discounted organisation rebates priceaccrualsfor estimating chargebacks calculated based cash discounts terms agreement historical experience product customer returns growth rates total gsk annual report srotcerid eht fo troper operating financial review prospects year continued year continued monthly process operated monitor inventory levels intangible assets wholesalers abnormal movements process uses gross intangible assets acquired glaxosmithkline third sales volumes prescription volumes based third party data sources parties costs acquisition capitalised licences compounds information received key wholesalers aim development amortised point maintaininventoriesat consistent level year year based available use estimated useful livesup toyears pattern consumption basis us pharmaceutical estimated useful lives reviewed annually impairment reviews inventorylevels wholesalers distribution channels undertaken events occur call question carrying st december estimated amount less one values assets brands acquired businesses capitalised month turnover calculation uses third party information independently separable longterm value accuracy totally verified believed group brands amortised estimated useful lives sufficiently reliable purpose exceeding years except end useful economic life foreseen brands amortised taxation subject annual impairment reviews impairment reviews based current tax provided amounts expected paid riskadjusted future cash flows discounted using appropriate deferred tax temporary differences tax bases assets interest rates future cash flows based business forecasts liabilities carrying amounts rates therefore inherently judgemental future events could cause enacted substantially enacted balance sheet date values intangible assets impaired would group open tax issues number revenue authorities adverse effect future results group principally relation transfer pricing disputes gsk uses best pensions postemploymentbenefits advice determining transfer pricing methodology seeking costs providing pensions postretirement benefits manage transfer pricing issues satisfactory conclusion charged theincome statementin accordance withias rover basis external professional advice continues believe period benefit derived employees services made adequate provision liabilities likely arise open costs assessed accordance advice received assessments however continues wide difference independent actuaries basis assumptions selected views open issues exist ultimate liability matters management use ifrs usgaap may vary amounts provided dependent upon assumptions include future earnings pension increases discount outcome litigation proceedings negotiations relevant rates expected long term rates return assets tax authorities disclosed innoteto thefinancial statementspensions legal disputes postemployment benefits expected long term rates return gsk provides anticipated settlement costs reasonable onbondsare determined based onthe portfolio mix indexlinked estimate may made likely outcome dispute legal governmentand corporatebondsan equity risk premium added expenses arising claims group equities discount rates arebased appropriate longterm companys directors taken legal advice established indices including theiboxxover year aaindexfor ukand provisions taking account insurance agreements moodys aa indexfor usa sensitivity analysis provided note regard relevant facts circumstances areductionin discount rate would lead matter accordance accounting requirements provisions increasein net pension deficitof approximately million product liability claims certain products made anincreasein annual pension cost approximately million incurred reported basis sufficient history claims selection different assumptions could affect future results made settlements available provisions made group unasserted claims claims reasonable estimate product rights goodwill likely outcome yet made ultimate liability addition critical accounting policies outlined pending unasserted claims may vary amounts provided accounting policy product rights goodwill deemed dependent upon outcome litigation proceedings important respect balance sheet prepared accordance investigations possible settlement negotiations us accounting principles us gaap merger glaxo impairment fixed assets wellcome smithkline beecham accounted carrying values fixed assets subject depreciation acquisition gave rise product rights billion amortisation reviewed impairment indication goodwill billion recognisedgoodwill product values assets might impaired impairment rights determined indefinite lives amortised rather determined reference higher net realisable value reviewed annually impairment impairment reviews assess value use measured reference riskadjusted future cashflows business projections prepared part groups annual discounted using appropriateinterest rates future cashflows budgeting planning process determine whether based business forecasts therefore inherently impairment invaluehas occurred business projections include judgemental future events could cause assumptions used assumptions future events changes future events could impairment reviews change consequent adverse effect cause assumptions business projections change future results group consequent adverse effect future results group reported us gaap gsk annual report srotcerid eht fo troper operating financial review prospectsfinancial position property plant equipment total cost groups property plant equipment st december billion net book value assets billion land buildings represented billion plant noncurrent assets equipment billion assets construction billion property plant equipment glaxosmithkline invested million new renewal goodwill property plant equipment mainly related large intangible assets number projects renewal improvement expansion investments associates facilities various worldwide sites property mainly held freehold joint ventures new investment financed group liquid resources st investments december group capital contractual commitments deferred tax assets future expenditure million operating lease noncurrent assets commitments million total noncurrent assets gsks business sciencebased technologyintensive highly regulated governmental authoritiesthe groupallocates significant current assets financial resources renewal maintenance property inventories plant equipment minimise risks interruption production current tax recoverable achieve compliance regulatory standards number trade receivables processes use chemicals hazardous materials liquid investments cash cash equivalents group observes stringent procedures uses specialist skills assets held sale manage environmental risks activities environmental issues sometimes dating operations modified total current assets discontinued reported responsibility environment total assets health safety note ffinancial statements legal proceedings gsk believes facilities liabilities adequate current needs current liabilities shortterm borrowings intangible assets trade payables intangible assets include cost intangibles acquired current tax payable third parties computer software cost intangible shortterm provisions assets st december million million much increase includes additions total current liabilities million arising fromthe acquisitions ofcorixa corporation id noncurrent liabilities biomedicalcorporation longterm borrowings investments deferred tax provision gsk held investmentsincludingassociates joint ventureswith pensions post carrying value st december million employment benefits millionthe market value st december million provisions million investmentsare mainly equity shares noncurrent liabilities holding derives directly groups business total noncurrent liabilities largest investments associate quest diagnostics inc total liabilities book value st december million million theinvestments include stakes companies net assets group research collaborations provide access equity biotechnology developments potential interest interests share capital companies arise business divestments share premium account trade receivables retained earnings trade receivablesinclude million million reserves derivative financial instruments held fair value shareholders equity remaining increase reflectsincreased sales impact strengthening overseas currencies translation foreign minority interests currency receivables total equity trade payables trade payables include million million derivative financial instruments held fair value remainingincreasereflects increase customer return rebate accruals andstrengthening foreign currencies gsk annual report srotcerid eht fo troper operating financial review prospects financial position resourcesfinancial position resources continued provisions share purchases group carried deferred tax provisions shortterm esop trusts make market purchases shares noncurrent provisions million st december gsk plc nil shares held trusts satisfy future million respect estimated future liabilities exercises options awards group share option million related legal disputes award schemes proportion shares held trusts respect awards rules scheme require company provision made tax legal disputes indemnified satisfy exercises market purchases rather issue disposal liabilities costs manufacturing restructuring new sharesthe shares held trusts matched options merger integration extent balance sheet date awards granted diminish dilutive effect new share issues actual constructive obligation existed could reasonably shareholdersequityand earnings estimated st december esop trusts held million gsk pensions postemployment benefits sharesagainst future exercise share options share awards group accounts pension postemployment thecarrying value lower cost expected proceeds arrangements accordance iasrthe net deficitbefore million deducted reserves allowing deferred taxationwasmillion market valueof shares wasmillion million special cash contributions million million made reduce funding deficits uk gsk repurchased billion shares treasury shares us plans expects repurchase billion exact amount timing future purchases depend market conditions net debt factors st december gsk held million shares treasury shares cost million deducted retained earnings cash cash equivalentsand liquid investments commitments contingent liabilities borrowings repayable within one year financial commitments summarised innoteto theffinancial borrowings repayable one year statements commitments contingent liabilities net debt obligations respect short longterm debt set innote thefifnancial statements contingent liabilities andnoteto net debt reduced million millionprimarily theffinancial statements net debt due increased operating profits partly offset acquisition amounts provided pensions postretirement benefits corixaand idbiomedicalfor total consideration billion restructuring integration plans legal environmental total equity disputes set innoteto theffinancial statements summary movements equityis set provisions contractual obligations commitments following table sets groups contractual obligations total equity beginning year commitments st december fall due payment implementation accounting total yr yrs yrs yrs financial instruments ias total equity beginning year adjusted loans total recognised income expense interest loans year finance lease obligations dividends shareholders operating lease ordinary shares issued commitments ordinary shares purchased cancelled intangibleassets ordinary shares purchased held property plant treasury shares equipment ordinary shares issued esoptrusts pensions sharebased payments commitments changes minority interest shareholdings total minority interests total equity atend year commitments respect future interest payable loans disclosed taking account effect interest rate swaps gsk annual report srotcerid eht fo troper operating financial review prospectsthe group entered number research collaborations cash flow develop new compounds pharmaceutical companies asummary consolidated cash flow statement set terms arrangements include upfront fees equity investments loans commitments fund specified levels research addition group often agree make net cash inflow operating activities payments future milestones achieved net cash outflow investing activities agreements relate compounds early stages development net cash outflow financing activities milestone payments continue number years compounds move successfully development process increase cash bank overdrafts generally closer product marketing approval greater exchange adjustments possibility success payments shown within intangible cash bank overdrafts beginning year assets represent maximum would paid milestones achieved number commitments made cash bank overdrafts end year licensing agreements principallywithvertex pharmaceuticals cash bank overdrafts end year inc comprise gskhas agreed trustees uk us pension schemes cash cash equivalents make additionalcontributions approximately million per overdrafts year fiveyear period ending st december orderto eliminate pension deficitson ias basisby pointthe table shows commitment basis deficits net cash inflow operating activities taxation paid st december amounts total contributions normal plus million increase million arising additional approximately million per year commitments principally due higher operating profits made past st december net cash outflow investing activities million contingent liabilities increase million reflected purchase corixa following table sets contingent liabilities comprising idbiomedical billion purchases businesses discounted bills performance guarantees items arising billion reflecting purchase fraxiparineand normal course business expected expire arixtrafrom sanofi total yr yrs yrs yrs free cash flow million increase free cash flow amount cash generated business guarantees meeting obligations interest tax dividends paid minority contingent liabilities interests capital expenditure noncurrent tangible intangible assets total free cash flow used gsks management planning normal course business group provided various reporting purposes discussions presentations indemnification guarantees respect business disposals investment analysts gsks free cash flow presented basis legal disputes subsequently arisen provision made accordance ifrs measure may directly reasonable estimate made likely outcome comparable similarly described measures used dispute included noteto theffinancial statements companies reconciliation net cash inflow operating provisions activities closest equivalent ifrs measure free cash groups policy provide settlement costs asserted flow shown claims environmental disputes reasonable estimate may reconciliation free cash flow made prior point liability recorded legal environmental costs discussed risk factors pagesto gsk uses best advice determining transfer pricing net cash inflow operating activities methodology basis external professional advice purchase noncurrent intangible assets continues believe made adequate provision purchase noncurrent tangible assets liabilities likely arise open taxation assessments ultimate disposal noncurrent tangible fixed assets liability matters may vary significantly amounts provided interest paid dependent upon outcome litigation proceedings interest received negotiations relevant tax authorities discussed dividends received joint ventures noteto theffinancial statements taxation associated undertaking dividends paid minority interests free cash flow gsk annual report srotcerid eht fo troper operating financial review prospects financial position resources continuedfinancial position resources continued reconciliation net cash flow movement net debt payment performance st december average number days purchases represented trade fixed asset creditors parent company net debt beginning year nil nil respect company uk increasein cash year subsidiaries aggregate wasdays days cash outflowinflowfrom management liquid resources treasury policies net increase longterm loans glaxosmithklineplc reports sterling pays dividends net repayment shortterm loans sterling profits role corporate treasury gskis manage exchange movements monitor groups external internal funding requirements net debt end year financial risks support group corporate objectives treasury activities governed policies procedures approved investment appraisal board monitored treasury management group gskhas formal process assessing potential investment proposals order ensure decisions aligned groups overall gsk maintains treasury control systems procedures monitor strategy process includes analysis impact profit foreign exchange interest rate liquidity credit financial risks assessment return based discounted cash flows liquidity discount rate used perform financial analysis decided internally gsk operates globally primarily subsidiary companies allow determination extent investments cover established markets group trades due groups cost capital specific investments discount rate may nature ofgsks business patent protection many adjusted take account country risk weightings products initsportfolio groups products compete largely capital expenditure financial investment product efficacy rather price selling margins sufficient cash payments tangible intangible fixed assets amounted cover normal operating costs groups operating subsidiaries million million disposals realised million substantially cash generative million cash payments acquire equity investments operating cash flow used fund investment research million million made year sales development new products well routine outflows capital equity investments realised million million expenditure tax dividends repayment maturing debt future cash flow group may time time additional demands finance group expects future operating cash flow sufficient share purchases acquisitions fund operating debt service costs satisfy normal levels gsk operates high level interest cover low levels capital expenditure meet obligations existing licensing net debt relative market capitalisation addition strong agreements meet routine outflows including tax positive cash flow normal trading activities additional liquidity dividends subject risk factors discussed pagesto readily available via commercial paper programme short group may time time additional demands term investments group also aeuropeanmedium term note finance acquisitions group access programme billion billion issue st sources liquidity banks financial institutions december group established us shelf addition cash flow operations forsuch needs registration billion st december billion billionwas issue payment policies treasury operations group companies responsible monitoring managing objective treasury activity manage posttax net working capital terms sales collections supplier payments costincome financial operations benefit group earnings reflect local commercial practice corporate treasury operate profit centregsk uses uk company uk subsidiaries policies variety financial instruments including derivatives finance ensure suppliers paid time particular uk operations manage market risks operations companies seek derivatives principally comprising forward foreign currency contracts settle terms payment suppliers agreeing terms interest rate currency swaps used swap borrowings transaction liquid assets currencies required group purposes ensure suppliers made aware agreed terms manage exposure funding risks changes foreign exchange ofpayment rates interest rates abide terms payment policy includes arrangements accelerated payment small suppliers gsk annual report srotcerid eht fo troper operating financial review prospectsfinancial position resources continued gsk balances use borrowings liquid assets regard borrowings denominated swapped foreign currencies cash flow operating activities thecurrencies match investments overseas group assets treated hedge earned tax cost intragroup distributions currencies relevant net assets business assets denominated posttax cost based composition net debt st december borrowings compared totheposttax return liquid assets appreciation sterling major currencies would result liquid assets surplus immediate operating requirements reduction groups net debt approximately million group companies generally invested managed centrally weakening sterling major currencies would result corporate treasury requirements group companies operating increase groups net debt approximately million finance met whenever possible central resources interest rate risk management external borrowings mainly managed centrally corporate treasury gsks policy interest rate risk management requires comprise portfolio long mediumterm instruments short amount net borrowings fixed rates increases ratio term finance forecast net interest payable trading profit gsk hold issue derivative financial instruments trading group uses limited number interest rate swaps purposes groups treasury policies specifically prohibit redenominate external borrowings interest rate coupon activity transactions financial instruments undertaken required group purposes duration swaps matches manage risks arising underlying business activities duration theprincipal instruments interest rate derivative speculation instruments accounted fair value cash flow hedges relevant assets liabilities funding maturity counterparty risk group invests centrally managed liquid assets government group manages centrally shortterm cash surpluses bonds shortterm corporate debt instruments minimum borrowing requirements subsidiary companies uses forward shortterm credit rating ap money market funds credit contracts hedge future repayments back originating rating aaaaaa andother structured investmentscredit ratings currency shown standard poors moodys investors services sensitivity analysis considers sensitivity groups net debt respectively hypothetical changes market rates assumes group manages net borrowing requirements variables remain constant based composition net debt portfolio longterm borrowings including bonds together financing arrangements st december taking shortterm finance us billion commercial paper consideration fixed rate borrowings place one percentage programme intwo bonds issued european point basis pointsdecrease average interest rates would result medium term note programme millionsevenyear increase groups annual net interest charge coupon bondand million yearcoupon bond approximately million groupslongterm borrowings mature dates equity risk management includea private financing although maturing equity investments classified current assets availableforsale may redeemed gsk time particular group manages disposals meet overall business event accelerating event would increase cost requirements arise group regularly monitors value funding group gsks longterm debt rating aa equity investments enters hedges selectively standard poors aa moodys investors services approval board agencies shortterm ratings paper issued groups financial assets liabilities commercial paper programme p respectively analysis net debt given noteto theffinancial statements foreign exchange risk management net debt analysis financial assets liabilities carrying gskforeign currency transaction exposure arising normal trade value fair value reconciliation net debt given note flows respect external intragroup trade theffinancial statements financial instruments related hedgedthepolicy minimise exposure overseas operating disclosures together discussion derivative financial subsidiaries transaction risk matching local currency income instruments quantitative disclosures market risk local currency costs purpose intragroup trading transactions accordance requirements ias ias matched centrally intragroup payment terms managed group continues benefit strong positive cash flow group reduce risk exceptional foreign currency cash flows hedged net debt would decreased significantly year st selectively management corporate treasury december groups purchase shares significant proportion group borrowings including market billion acquisitions approximately billion commercial paper programme us dollars benefit financial assets liabilities st december liquidity us dollar denominated capital markets certain representative treasury policies strategies gsk applied borrowings swapped currencies required consistently year significant changes group purposes group seeks denominate borrowings policies throughout year currencies principal assetsand cash flows gsk annual report srotcerid eht fo troper operating financial review prospectsoutlook risk factors outlook new product candidates may appear promising development significant investments fail reach market limited sales growth existing products launch new products commercial success result efficacy safety concerns inability key drivers gsks business performance strong growth seen obtain necessary regulatory approvals difficulty excessive costs key products seretideadvair avandiaavandametand manufacture infringement patents intellectual property gsks vaccines business expected continue eight rights others inability differentiate product adequately major development projects scheduled enter phase iii competes include oncology products casopitant pazopanibas well products alzheimers disease hiv meningitis lupus risk loss expiration patents marketing exclusivity diabetes seven product filings planned patent infringement litigation include two vaccines cervarix cervical cancer potential flu efforts generic manufacturers may involve challenges validity pandemic vaccine allermistfor allergic rhinitis eltrombopag low patent assertions alternative compounds platelet count help patients suffering thrombocytopenia infringe groups patents group successful tykerbfor breast cancer mepolizumab hypereosinophilic syndrome patent protection data exclusivity periods maintaining exclusive lamictal xr oncedaily formulation epilepsy rights market one major products particularly usa group highest turnover margins seven products expected launchedapproved groups turnover margins would adversely affected see note include rotarix rotavirus entereg postoperative bowel thefifnancial statements legal proceedings discussion disorders trexmiafor migraine avandaryl diabetes coreg crfor patentrelated proceedings group involved heart failure arranonfor cancer altabaxfor infections generic drug manufacturers seeking market generic versions typically sales existing products decline dramatically generic many groups important products including avandia competition introduced either patent expiry earlier zofran wellbutrin xl imitrexlamictal valtrex andpaxil cr prior successful challenge groups patent glaxosmithkline expiration groups patents exhibited readiness engaged legal proceedings regarding validity infringement products future generic products competitive groups patents relating many products paxil ir wellbutrin sr launched usa discussed risk factors note ffinancial respectively significant impact groups overall statements legal proceedings turnover earnings gsks published earnings guidance earnings per weakness intellectual property protection certain share growth expected around constant exchange countries rate terms countries group operates patent group net debt billion low relative protection may significantly weaker usa market capitalisation positions take advantage european union addition effort control public health opportunities might arise build business crises developing countries south africa brazil considered plans substantial reductions scope patent risks uncertainties inherent business may protection pharmaceutical products particular countries affect future performance including rd projects anticipated sales could facilitate competition within markets generic growth expected earnings growth discussed risk manufacturers would otherwise unable introduce factors competing products number years risk factors loss patent protection including abrogation patent rights compulsory licensing likely affect adversely groups risks uncertainties relevant groups business operating results national markets expected factors listed among group thinks could material group overall absence adequate patent protection cause groups actual results differ materially expected could limit opportunity look markets future sales historical results growth risk rd deliver commercially successful new products continued development commercially viable new products critical groups ability replace sales older products decline upon expiration exclusive rights increase overall sales developing new products costly lengthy uncertain process new product candidate fail stage process one latestage product candidates could fail receive regulatory approval gsk annual report srotcerid eht fo troper operating financial review prospectsoutlook risk factors continued risk substantial adverse outcome litigation antitrust litigation government investigations usa become increasingly common following see noteto fifnancial statements legal proceedings adverse outcome prosecution patent infringement actions discussion proceedings governmental investigations defendants direct indirect purchasers payers initiate group currently involved unfavourable resolution antitrust actions well claims direct indirect purchasers similar future proceedings investigations may material payers typically filed class actions relief sought adverse effect groups financial results group made may include treble damages restitution claims damages material provisions related legal adverse antitrust verdicts subject automatic trebling usa proceedings investigations reduced earnings group sales marketing regulation may also make additional significant provisions related legal group operates globally complex legal regulatory proceedings investigations future would reduce environments often vary among jurisdictions failure earnings many cases practice plaintiff bar claim comply applicable laws rules regulations jurisdictions damages compensatory punitive statutory amounts may result civil criminal legal proceedings usa bear relationship underlying harm accordingly example group responding federal state governmental potentially misleading quantify potential exposure claims investigations pricing marketing reimbursement proceedings investigations type described note prescription drug products investigations could result related recent insurance loss experience including pharmaceutical product restitution civil false claims act litigation behalf federal liability exposures increased cost narrowed state governments well related proceedings initiated coverage afforded insurance pharmaceutical companies group behalf consumers private payers generally including group proceedings may result trebling damages awarded fines respect violation law criminal proceedings may also order contain insurance costs inrecent yearsthe group initiated group companies individuals continued adjust coverage profile accepting greater degree uninsured exposure addition whereclaims made risks competition price controls limitations sales insurance policies insurers may reserve right deny coverage third party competition various grounds denial coverage ultimately upheld group operates highly competitive businesses claims could result material additional charges groups pharmaceuticals business faces competition proprietary earnings products large international manufacturers producers generic pharmaceuticals significant product innovations technical product liability litigation advances intensification price competition competitors preclinical clinical trials conducted development could adversely affect groups operating results continued potential products determine safety efficacy products consolidation pharmaceutical industry could adversely affect use humans following approval regulatory bodies groups competitive position continued consolidation notwithstanding efforts drugs vaccines among groups customers may increase pricing pressuresthe introduced marketplace unanticipated side effects may group hadproducts million annual global sales become evident group currently defendant number product liability lawsuits including class actions involve substantial claims damages related groups pharmaceutical among productsisaugmentin ir respect towhich productslitigation particularly usa inherently unpredictable groupalready generic competition zofran imitrex valtrex excessive verdicts justified evidence occur avandia wellbutrin xl respect groups class actions sweep together persons prescribed intellectual property rights usaare currently subject groups products inflate potential liability force litigation flonase fdaapprovedthe firstgeneric numbers claims pain suffering punitive damages versionin february frequently asserted product liability actions allowed represent potentially openended exposure gsk annual report srotcerid eht fo troper operating financial review prospectsoutlook risk factors continued groups major products become regulatory controls subject problem loss patent protection unexpected group must comply broad range regulatory controls side effects regulatory proceedings publicity affecting doctor testing approval manufacturing marketing many patient confidence pressure competitive products new pharmaceutical consumer healthcare products particularly effective treatment introduced adverse impact usa countries european union affect groups revenues operating results could significant cost product development also time required reach particular group faces intense competition manufacturers market uncertainty successfully sostricter regulatory generic pharmaceutical products major marketsgeneric controls also heighten risk withdrawal regulatorson products often enter market upon expiration patents data basis postapproval concerns product safety would exclusivity periods groups products introduction generic reduce revenues result product recalls product liability products typically leads dramatic loss sales reduces lawsuits groups revenues margins proprietary products addition cases group may voluntarily cease marketing expiration dates patents groups major products set product example withdrawal lotronexin shortly pageand legal proceedings involving patent challenges set initial launch usa face declining sales based noteto fifnancial statements legal proceedings concerns efficacy safety whether scientifically justified governmental payer controls even absence regulatory action development pharmaceutical products subject price controls pressures postapproval adverse event profile product product class restrictions many markets including japan germany france may major impact marketing sale product italy governments intervene directly setting prices risk interruption product supply addition markets major purchasers pharmaceutical manufacture pharmaceutical products constituent products whether governmental agencies private health care materials requires compliance good manufacturing practice providers economic power exert substantial pressure regulations groups manufacturing sites subject review prices terms access formularies approval fda regulatory agencies compliance group predict whether existing controls increase failure suppliers key materials groups manufacturing new controls introduced reduce groups margins facilities could lead product recalls seizures interruption affect adversely ability introduce new products profitably production delays approvals new products pending resolution manufacturing issues noncompliance also result example usa group highest margins fines disgorgement profits interruption supply fines sales country pricing pressures could significantly disgorgement remedy could materially adversely affect increasefollowingimplementation pharmaceutical benefit groups financial results groups cidra puerto rico facility medicare event state programmes worked resolution fda observations deficiencies control cost ofprescription drugsare adoptedas experience manufacturing practices subject compliance consent develops underthe medicare programoutpatient pharmaceutical decree entered fda referred note coverage beneficiaries us government theffinancial statements legal proceedings consequence private insurers coverage offered discussions supplies certain products manufactured enormous purchasing power program could demand cidra curtailed constrictedwhich adverse impact discounts may implicitly create price controls prescription sales drugsadditionally number states proposed implemented various schemes control prices senior citizens group undertakes business continuity planning single programs including importation countries bulk sourcing certain components bulk active materials finished purchases drugs growth number patients covered products creates risk failure supply event regulatory large managed care institutions usa likely noncompliance physical disruption manufacturing sites increase implementation medicarebenefit also increases pricing pressures groups productsthese trends may adversely affect groups revenues margins sales usa gsk annual report srotcerid eht fo troper operating financial review prospectsoutlook risk factors continued risk concentration sales wholesalers global political economic conditions usa line pharmaceutical companies group group conducts substantial portion operations outside sells products small number wholesalers addition uk groups management foreign exchange rates discussed hospitals pharmacies physicians groups sales operating financial review prospects foreign exchange three largest amounted approximately risk management fluctuations exchange rates sterling groups us pharmaceutical sales st december group currencies especially us dollar euro trade receivablesdue three wholesalers totalling japanese yen materially affect groups financial results million st december million group group control changes inflation interest rates exposed concentration credit risk respect foreign currency exchange rates controls economic wholesalers one affected financial factors affecting businesses possibility political unrest difficulty could materially adversely affect groups financial legal regulatory changes nationalisation jurisdictions results group operates factors could materially affect groups environmental liabilities future results operations environmental laws various jurisdictions impose actual accounting standards potential obligations group remediate contaminated sites new revised accounting standards rules promulgated group also identified potentially responsible party time time byus international accounting standard setting boards us comprehensive environmental response compensation could material adverse impact groups reported financial liability act number sites remediation costs relating results adoption international financial reporting groups use ownership sites failure manage properly standards ifrs changes market valuation certain financial environmental risks could result additional remedial costs instruments equity collar linked groups investment could materially adversely affect groups operations see note quest diagnostics put call options linked groups theffinancial statements legal proceedings discussion strategic alliance theravance impairments equity environmentalrelated proceedings group involved investments reflected groups reported results reliance information technology gains losses actually realised could significant impact group increasingly dependent information technology theresults given period group believes complies systems including internetbased systems internal communication appropriate regulatory requirements concerning financial well communication customers suppliers statements disclosures however companies significant disruption systems whether due computer experienced investigations potential noncompliance viruses outside incursions could materially adversely accounting disclosure requirements resulted affect groups operations significant penalties taxation human resources effective tax rate groups earnings benefits fact group approximately employees around world portion earnings taxed favourable rates subject laws regulations concerning employees jurisdictions outside uk changes tax laws application ranging discrimination harassment personal privacy respect matters transfer pricing risk double labour relations vary significantly jurisdiction jurisdiction taxation relate portion groups earnings taxed failure continue recruit retain right people maintain favourable rates could increase groups effective tax rate culture compliance could significant adverse affect adversely affect financial resultsthe group open issues group revenue authorities usa uk japan canada far largest relates glaxo heritage products respect us internal revenue service uk inland revenue made competing contradictory claims matters discussed noteto theffinancial statements taxation disruption pandemic influenza event pandemic influenza group could subject disruption range factors national governments may willing abrogate intellectual property rights medicines might otherwise short supply country afflicted pandemic flu would risk employees families affected consequence sales distribution manufacturing activities could shut supply continuity active ingredients finished goods affected gsk annual report srotcerid eht fo troper operating financial review prospects year accordance ussec disclosure requirements following pharmaceutical turnover discussion compares results year st december growth rates included review turnover constant results year st december information exchange rates cer unless otherwise stated sterling growth prepared ifrs rates may found tables pharmaceutical turnover growth rates constant exchange rates cer unless otherwise therapeutic area page stated sterling growth rates turnover product may total pharmaceutical turnover million compared found table pharmaceutical sales therapeutic area million increase cer sterling terms page turnover declined principally due weakness us dollar exchange currencies influence groups results us pharmaceutical turnover therapeutic area dollar euro japanese yen gsks ability continue deliver pharmaceutical turnover growth pound hit highest level dollar four despite generic competition several products primarily due years climbing yearend euro gained exceptionally broad product portfolio fastgrowing high sterling dollar value products second consecutive year dollar fallen value include respiratory product seretideadvairup euro due impact continued unrest iraq tension elsewhere billion diabetes treatment avandiaavandametup world concerns us economy billion lamictalfor epilepsybipolar disorder billion valtrexfor herpes billioncoregfor heart disease world market pharmaceuticals billion vaccines billion global pharmaceutical sales increased billion gsk products sales million world market value growth geographic region bn total cer respiratory usa gsk continuedto global leader respiratory pharmaceuticals europe sales three key products seretideadvair flixotideflovent germany serevent amounting billion sales france seretideadvair groups largest productgrew billion uk although contributed declines sereventand flixotide italy constituent products japan usa advairsales grew billion growth seretide asia pacific europe also strong million international latin america sales grew reflecting good growth geographic areas middle east africa canada older respiratory products ventolinand becotidecontinued decline patients converted newer products total central nervous system cns growth us market slowed remains double digits cns sales declined billion sales declined regions represents global prescription pharmaceutical market compared decade ago total sales ofpaxilwere billion result generic competition paxil ir sales declined million th september gsk held second position world mitigating decline strong performance product pharmaceutical market market share behind pfizer japan million performance paxil cr market share gsk eightofthe worlds top generated sales million pharmaceutical products augmentin avandia imigranimitrex lamictal seretideadvair seroxatpaxil wellbutrin total sales wellbutrinproducts fell million wellbutrin zofran ir sr sales fell million result generic competition impact partially offset however world market value growth exceptionally strong performance wellbutrin xl new top five therapeutic classes bn total cer daily product achieved sales million first full year cardiovascular market central nervous system strong growth gsks epilepsy bipolar disorder treatment alimentary tract metabolic lamictalcontinued sales million ongoing us antiinfectives bacterial viral growth million driven indication fungal excluding vaccines maintenance treatment bipolar disorder received respiratory note data based months thseptember gsk annual report srotcerid eht fo troper operating financial review prospectsantivirals total sales ofpaxil million result global hiv product sales rose billion sales usa generic competition paxil irsales declined increased million gsk continued grow hiv million mitigating decline performance paxil cr franchise despite launch several new products competitors generated sales million hiv performance enhanced launch epzicom new sales antivirals therapeutic area grew hiv products combination product epivirziagen usa august valtrex herpes grew driven patients switching suppression therapy sales herpes treatment valtrex exceeded million first time million performancewasdriven sales ofavandiaavandamet increased antibacterial sales usa million product clear declined result generic competition began market leader treatments genital herpes third quarter coregsales increased continued benefit wide range indications antibacterials antibacterial sales declined worldwide usa vaccines grew reflecting good performance pediarix reflecting generic competition regions europe metabolic discussion individual market performance europe region turnover created basis rather turnover invoiced basis diabetes treatments avandiaavandametcontinuedto perform see year explanation adjustments strongly overall sales billion made sales usa grew million encouragingly avandia europe region contributed pharmaceutical turnover although avandamet also grew strongly europe international overall turnover growth region good growth markets sales respectively strong recorded spain southern eastern europe government performance marketswasdriven growing acceptance healthcare reforms including pricing reimbursement restrictions amongst opinion leaders physicians benefits new adversely affected turnover france italy germany products improving control diabetic patients seretide gsks largest selling product europe grew vaccines reported notable growth spain uk seretide vaccines business strong year sales constituent products sereventand flixotidegrew billion several key productsdrovegrowth pediarixinfanrixup million priorix million fluarix decline sales herpes franchise mainly result million generic competition zovirax partially offset patients switching newer product valtrex oncology emesis sales zofran grew million driven us seroxatsales reflecting generic competition performance million uk france cardiovascular urogenital antibacterial sales declined due generic competition coregfor heart disease sales grew million throughout region therapeutic areas vaccines grew driven hepatitis franchise infanrix sales zantac fell millionwith declines regions international usa international region reported year year turnover growth usa reported flat turnover indespite significant impact strong growth asia pacificup latin americaup generic competition paxiland wellbutrin excluding sales offset flat sales australia declines subsaharan products turnover grew us business represented africa middle eastnorth africa canada total pharmaceutical turnover canada sales decline due generic erosion paxil ir excluding element canada grew advairmaintained strong growth sales million however adversely affected sales constituent japan recorded turnover growth despite routine government products floventand sereventwhich showed declines flonase price reductions implemented paxil serevent indicated treatment perennial rhinitis grew valtrex performed particularly welloffsetting small declines zantacand zovirax sales wellbutrinproducts fell million wellbutrin ir sr sales fell million result generic across markets international key products driving growth competition impact partially offset however seretide grew record sales million exceptionally strong performance wellbutrin xl new avandiaavandamet grew million daily product achieved sales million first full year vaccines franchise recorded growth achieved sales market million gsk annual report srotcerid eht fo troper operating financial review prospects year continued year continued gsk annual report srotcerid eht fo troper operating financial review prospects pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxilir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccines hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac cer represents turnover growth constant exchange rates represents growth actual exchange ratesconsumer healthcare sales operatingprofit growth analysis ofoperatingprofit subsequent discussion cer compares results results otc medicines growth analgesics cer dermatological turnover gastrointestinal respiratory tract cost sales smoking control selling general natural wellness support administration research oral care development nutritional healthcare operating income operatingprofit growth consumer healthcare sales billion comprised otc medicines sales increase oral care sales increase nutritional healthcare sales increase cost sales cost sales percentage turnover remained broadly line otcmedicines prior year reduced merger manufacturing otc medicine sales billion sales growth restructuring costs offset significant weakening us smoking control products usa europe dollar relative loss higher margin paxil irand wellbutrin helped offset decline dermatological products sr sales generics adverse product mix merger due generic competition cutivate usa manufacturing restructuring costs nil million expansion panadol brand international markets helped analgesics grow selling general administration july gsk obtained otc marketing rights usa orlistat selling general administration sga costs declined fdaapproved prescription product obesity management decline sterling terms reflecting savings general marketed roche xenical administration partly offset increased advertising oral care promotion selling costs latter costs increased oral care sales billion strong growth accounted one percentage point increase total sga international led sensodyne polidentand poligrip general administration costs declined accounted brands asixpercentage point reduction total sga due lower charges related programmes deliver future cost savings equal nutritional healthcare two percentage point reduction total sga general sales nutritional healthcare products grew billion expense reductions equal afourpercentage point decline total lucozade grew million sganet currency movements overall reduction ofpercentage points relative expenses expressed percentage turnover research development rd expenditure increased reflecting increased clinical trial activity pharmaceuticals rd expenditure represented pharmaceutical turnover year operatingincome operating income includes royalty income equity investment disposals impairments product disposals operating income million compared million reflecting lower product asset disposals gsk annual report srotcerid eht fo troper operating financial review prospects year continued year continued operatingprofit taxation overall theoperating profitmarginincreasedpercentage points asoperatingprofit million declined sterling termson uk corporation tax turnover decline constant exchange ratesoperatingprofit overseas taxation increased reflecting completion merger manufacturing restructuring programme andlower charges current taxation relating programmes deliver future cost savings partly offset deferred taxation increased rd expenditureand lower product asset disposals total share tax profitslosses associates joint charge taxation profit amounting million ventures represents effective tax rate share profits associates arises principally groups holding inquest diagnostics inc integrated nature groups worldwide operations involving significant investment research strategic manufacture disposal interest associates limited number locations consequential crossborder supply group disposed million shares routes numerous endmarkets gives rise complexity delay investment quest diagnostics inc cash proceeds million negotiations revenue authorities profits reducing groups shareholding st december individual group companies liable taxdisagreements recognising charge million goodwill previously revenue authorities intragroup transactions written reserves profit million recognised particular price goods transferred group companies different tax jurisdictions produce finance income conflicting claims revenue authorities profits interest income taxed individual territories resolution issues continuing unwinding discount assets fact life gsk group open issues revenue authorities usa uk japan canada far largest relates glaxo heritage products respect us internal revenue service irs uk inland revenue made competing financecosts contradictory claims interestcosts unwinding discount onprovisions latest position taxation see taxation year operating financial review prospects page profit taxation taking account finance income financecosts thecontribution associates business disposals profit tax million compared million anincrease decline sterlingterms gsk annual report srotcerid eht fo troper operating financial review prospectsprofit year growth cer profit taxation year profit attributable shareholders earnings per share pence p p earnings per ads us weighted average number shares millions diluted earnings per share pence p p diluted earnings per ads us weighted average number shares millions profit year million increase decline sterling terms net profits attributable minority interests profit attributable shareholders million increase decline sterling terms eps pence compared pence sterling based decline eps reflected significant weakening dollar excluding effects currency statutory eps grew reflecting completion groups merger restructuring programmes well underlying business growth partly offset higher tax rate dividend board declared fourth interim dividend pence per share making total year pence per share compared total dividend pence per share gsk annual report srotcerid eht fo troper operating financial review prospects year continuedfinancial statements section comprises directors statements responsibility independent auditors report financial statementsandthe consolidated financial statements consisting principal financial statements supporting notes prepared ifrsas adopted use european union also presentedis balance sheetof glaxosmithkline plcwhich hasbeen prepared ukgaap directors statements responsibility independent auditors report financial statements consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements presentation financial statements accounting policies new accounting policies future requirements exchange rates segment information operating income operating profit employee costs finance income financecosts associates joint ventures taxation earnings per share dividends property plant equipment goodwill intangible assets investments associates joint ventures investments noncurrent assets inventories trade receivables cash cash equivalents assets held sale trade payables pensions postemployment benefits provisions noncurrent liabilities contingent liabilities net debt share capital share premium account movementsin equity related party transactions acquisitions disposals commitments financial instruments related disclosures employee share schemes reconciliation us accounting principles principal group companies transition ifrs legal proceedings balance sheetof glaxosmithkline plc prepared ukgaap gsk annual report stnemetats laicnanifdirectors statements responsibility directors statement responsibility relation internal control consolidated financialstatements board audit committee reviewed directors areresponsible assessment risks internal control framework operates glaxosmithkline considered effectiveness system ensuring maintenance proper accounting records internal control operation inthegroup year covered disclose reasonable accuracy financial position group report date approval board directors time financial statements beprepared comply companies actand article ias combined code regulation board considers glaxosmithkline plc applies principles preparingfinancial statements financial period give combined code corporate governance financial true fair view accordance ifrs adopted use reporting council asdescribed corporate governanceon european unionof state affairs thegroup pages complied provisions except end financial period ofthe profit loss period described pages ensuring operation systems internalcontrol taking required listing rules financial services authority reasonable steps safeguard assets group auditors haveconsidered directors statement compliance preventing detecting fraud irregularities relation points combined code specified financialstatements year ended st december theirreview comprising principal statements supporting notes set infinancial statements pages report annual report directors confirm suitable accounting policies annual report year ended st december consistently applied preparation financialstatements comprising report directors remuneration report supported reasonable prudent judgements estimates financial statements additional information investors asnecessary approved board directors signed behalf responsibilities auditors relation financial statements set independent auditors report page opposite financialstatements year ended st december included annual report published hardcopy printed form made available website directors sir christopher gent responsible maintenance integrity annual report chairman website accordance uk legislation governing stmarch preparation dissemination financial statements access website available outside uk comparable legislation may different directors remuneration remuneration report pages sets remuneration policies operated glaxosmithkline disclosures directors remuneration disclosable information relating directors officers interests prepared accordance companies act complies section b combined code corporate governance going concern basis making enquiries directors reasonable expectationthat grouphasadequate resources continue operational existence foreseeable future forthis reason continue adopt going concern basis inpreparing financial statements gsk annual report stnemetats laicnanifindependent auditors report members glaxosmithkline plc audited group financial statements glaxosmithkline basis audit opinion plc year ended stdecember comprise conducted audit accordance international standards consolidated balance sheet consolidated income statement auditing uk ireland issued auditing practices board consolidated cash flow statement consolidated statement audit includes examination test basis evidence relevant recognised income expense related notes group amounts disclosures group financial statements financial statements prepared accounting policies also includes assessment significant estimates set therein judgments made directors preparation group reported separately parent company financial financial statements whether accounting policies statements glaxosmithkline plc year ended stdecember appropriate groups circumstances consistently applied information directors remuneration report adequately disclosed described audited planned performed audit obtain information explanations considered necessary order respective responsibilities directors provide us sufficient evidence give reasonable assurance auditors group financial statements free material directors responsibilities preparing annual report misstatement whether caused fraud irregularity error group financial statements accordance applicable law forming opinion also evaluated overall adequacy international financial reporting standards ifrss adoptedbythe presentation information group financial statements european union set directors statements responsibility opinion responsibility audit group financial statements opinion accordance relevant legal regulatory requirements group financial statements give true fair view international standards auditing uk ireland report accordance ifrss adopted bythe european union including opinion prepared state groups affairs stdecember companys members body accordance section profit cash flows year ended companies act purpose giving opinion accept assume responsibility purpose group financial statements properly prepared person report shown whose accordance companies act article ias hands may come save expressly agreed prior consent regulation writing separate opinion relation ifrss report opinion whether group financial statements give true fair view whether group financial explained note group financial statements group statements properly prepared accordance addition complying legal obligation comply ifrss companies act article ias regulation also adopted bythe european union also complied ifrss report opinion directors report consistent issued international accounting standards board group financial statements received opinion group financial statements give true fair view information explanations require audit accordance ifrss state groups affairs st information specified law regarding directors remuneration december profit cash flows year transactions disclosed ended review whether corporate governance statement reflects companys compliance nine provisions frc combined code specified review listing rules financial services authority report required consider whether boards statements internal control cover risks controls form opinion effectiveness groups corporate governance procedures pricewaterhousecoopers llp risk control procedures chartered accountants registered auditors read information contained annual report london consider whether consistent audited group financial stmarch statements information comprises onlythe joint statement chairman chief executive financial summary description business corporate governance statement operating financial review prospects consider implications report become aware apparent misstatements material inconsistencies group financial statements responsibilities extend information gsk annual report stnemetats laicnanifconsolidated income statement year ended st december notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income financecosts share tax profits associates joint ventures profit disposal interest associates profit taxation taxation profit disposalof businesses profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p gsk annual report stnemetats laicnanifconsolidated balance sheet st december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures otherinvestments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax provision pensions postemployment benefits provisions noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity approved board onstmarch sir christopher gent chairman gsk annual report stnemetats laicnanifconsolidated cash flow statement year ended st december notes cash flows operating activities cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment proceeds sale intangible assets purchase intangible assets purchase equity investments proceeds sale equity investments share transactions minority shareholders purchase businesses net cash acquired disposal businesses interest associates investments associates joint ventures interest received dividends associates joint ventures net cash outflow investing activities cash flow financing activities decreaseincrease liquidinvestments proceeds shares employee share options issue share capital share capital purchased cancellation purchase treasury shares redemption preference shares issued subsidiary increase longterm loans repayment longterm loans net repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders dividends paid minority interests dividends paid preference shares financing cash flows net cash outflow financing activities increase cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report stnemetats laicnanifsupplementary information cash flow year ended st december reconciliation operating profit operating cash flows notes operating profit adjustments depreciation impairment assets written amortisation intangible assets profitlosson sale property plant equipment profitlosson sales intangible assets profiton sale equity investments fair value loss inventory sold changes working capital decreaseincreasein inventories increase trade receivables increasedecreasein trade payables decreaseincreasein pension provisions sharebased incentive plans net cash inflow operating activities reconciliation net cash flow movement net debt net debt beginning year implementation accounting financial instruments ias increasein cash bank overdrafts cashinflowoutflowfrom liquid investments net increase longterm loans net repayment shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year previously adjusted analysis changes net debt reported ias exchange acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see notenet debt gsk annual report stnemetats laicnanifstnemetats laicnanif consolidated statement recognised income expense year ended st december exchange movements overseas net assets tax exchange movements fair value movements availableforsale investments deferred tax fair value movements revaluation goodwill due exchange actuarial lossesgains defined benefit plans deferred tax actuarial movementsin defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedge net losses recognised directly equity profit year total recognised income expense year implementation accounting financial instruments ias total recognised income expense total recognised income expense year attributable shareholders minority interests implementation accounting financial instruments ias attributable shareholders minority interests gsk annual report notes financial statements presentation financial statements financial statements prepared accordance groups accounting policies approved board described description business note glaxosmithkline major global healthcare group engaged creation discovery development manufacture conversion ifrs marketing pharmaceutical products including vaccines overthe first year glaxosmithkline produced financial counter otc medicines healthrelated consumer products statements ifrs adoption ifrs resulted number glaxosmithklines principal pharmaceutical products include significant adjustments previously reported results equity medicines following therapeutic areas central nervous system shareholders funds presented uk generally accepted respiratory antivirals antibacterials vaccines oncology emesis accounting principles ukgaap main changes relation metabolic cardiovascular urogenital sharebased payments pensions intangible assets deferred taxation financial instruments compliance applicable law ifrs financial statements prepared accordance ifrs firsttime adoption international financial reporting companies act article ias regulation standards permits companies adopting ifrsfor first time international accounting standards ias international financial take exemptions full requirements ifrs reporting standards ifrs related interpretations adopted transition period glaxosmithkline adopted following key use european union exemptions gsk therearenodifferencesbetween ifrs adopted use business combinations business combinations prior transition european union full ifrs published international date st january restated onto ifrs basis accounting standards board sharebased payments ifrs sharebased payment applies financial period equity instruments share options granted since th financial statements cover financial year st january november glaxosmithkline elected adopt full stdecember comparative figures financial retrospective application standard years st january st december st january financial instruments financial instruments comparative tost december periods presented annual report ie composition group recorded theukgaap basisapplicable years rather list subsidiary associated undertakings opinion accordance ias financial instruments disclosure directors principally affected amount profit net presentation ias financial instruments recognition assets group given principal group companies note measurement composition financial statements see note details consolidated financial statements drawn accordance parent company financial statements ifrs ifrs accounting presentation financial financial statements parent company glaxosmithkline statements comprise plc prepared accordance ukgaap uk consolidated income statement accounting presentation thecompany balance sheet ispresented consolidated balance sheet page consolidated cash flow statement consolidated statement recognised income expense accounting policies notes financial statements consolidation additional information accordance requirements consolidated financial statements include usgenerally accepted accounting principles us gaap included assets liabilities results cash flows notes financial statements notea statement company subsidiaries including esop trusts differences reconciliations net income shareholders equity ifrs us gaap provided groups share net assets results associates joint ventures accounting convention financial statements prepared using historical cost financial statements entities consolidated made st convention modified certain items carried fair value stated december accounting policies entities group ability exercise control accounting principles policies accounted subsidiaries group ability preparation financial statements conformity exercise joint control accounted joint ventures generally accepted accounting principles requires management group ability exercise significant influence make estimates assumptions affect reported amounts accounted associates assets liabilities disclosure contingent assets liabilities interests acquired entities consolidated effective date date financial statements reported amounts acquisition interests sold consolidated upto date revenues expenses reporting period actual results disposal could differ estimates stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued accounting policiescontinued expenditure expenditure recognised respect goods services received transactions balances subsidiaries eliminated supplied accordance contractual terms provision profit tax taken sales subsidiaries sales made obligation exists future liability respect past joint ventures associates products sold customers event amount obligation reliably outside group deferred tax relief unrealised intragroup profit estimated advertising promotion expenditure charged accounted extent considered recoverable income statement incurred shipment costs intercompany goodwill arising acquisition interestsin subsidiaries joint transfers charged cost sales distribution costs sales ventures associates representing excess purchase customers included selling general administrative consideration groups share fair values expenditure restructuring costs recognised respect direct identifiable assets liabilities contingent liabilities acquired expenditure business reorganisation plans capitalised asa separate item case subsidiaries part sufficiently detailed well advanced appropriate cost investment case joint ventures associates communication affected undertaken goodwill denominated currency operation acquired research development case acquisitions prior goodwill written research development expenditure charged income directly equity subsequent disposal assets statement period incurred development acquisitions related goodwill remains equity charged expenditure capitalised criteria recognising asset consolidated income statement business combinations met usuallywhen aregulatory filing made major restated marketand approval considered highly probable property plant results assets liabilities associates joint ventures equipment used research development depreciated incorporated consolidated financial statements using accordance groups policy equity method accounting environmental expenditure assets liabilities including related goodwill overseas environmental expenditure related existing conditions resulting subsidiaries associates joint ventures translated sterling past current operations current future rates exchange ruling balance sheet date results benefit discernible charged income statement group cash flows overseas subsidiaries associates joint ventures recognises liability sitebysite basis reliably translated sterling using average rates exchange exchange estimated liability includes groups portion total costs adjustments arising opening net assets profits also portion potentially responsible parties costs theyear retained overseas subsidiaries associates joint ventures probable able satisfy respective shares translated sterling less exchange differences arising related cleanup obligation recoveries reimbursements recorded foreign currency borrowings hedge groups net investment assets virtually certain operations taken separate component equity pensions postemployment benefits translating sterling assets liabilities results cash costs providing pensions defined benefit schemes flows overseas subsidiaries associates joint ventures calculated using projected unit credit method spread reported currencies hyperinflationary economies adjustments period benefit expected derived aremade reflect current price levels loss net monetary employees services accordance advice qualified assetsis charged consolidated income statement actuaries pension obligations measured present value estimated future cash flows discounted rates reflecting yields foreign currency transactions high quality corporate bonds foreign currency transactions group companies booked inlocal currency exchange rate ruling date transaction pension scheme assets measured fair value balance sheet foreign currency assets liabilities retranslated local date actuarial gains losses differences expected currency rates exchange ruling balance sheet date actual returns effect changes actuarial assumptions exchange differences areincluded income statement recognised statement recognised income expense year arise groups contributions defined revenue contribution plans charged income statement incurred revenue recognised income statement goods services supplied made available external customers costs postemployment liabilities calculated similar orders received title risk loss passes customer way defined benefit pension schemes spread period turnover represents net invoice value deduction discounts benefit expected derived employees allowances given accruals estimated future rebates services accordance advice qualified actuaries returns methodology assumptions used estimate rebates legal disputes returns monitored adjusted regularly light provision made anticipated settlement costs reasonable contractual historical information past experience turnover estimate made likely outcome legal disputes also includes copromotion income group records share group addition provision made legal revenue related cost sales value added tax expenses arising claims received disputes sales taxes excluded revenue gsk annual report notes financial statements continued accounting policies continued goodwill goodwill stated cost less impairments goodwill deemed respect product liability claims related products indefinite useful life tested impairment annually sufficient history claims made settlements incurred reported ibnr actuarial technique used determine fair value interest acquired entitys assets reasonable estimate groups exposure unasserted claims liabilities contingent liabilities exceeds consideration paid products provision made basis excess recognised immediately gain income statement provision made unasserted claims intangible assets obligation exists dispute possible make intangible assets stated cost less provisions amortisation reasonable estimate costs associated claims made group impairments third parties charged income statement licences patents knowhow marketing rights separately incurred acquired acquired part business combination amortised employee share plans estimated useful lives time available incentives form shares provided employees use estimated useful lives determining amortisation share option share award schemes options awards charge reviewed annually andtake account estimated fair valued grant dates cost charged income time takes bring compounds products market statement relevant vesting periods applied anydevelopment costs incurred group associated fully retrospective basis acquired licences patents knowhow marketing rights written income statement whenincurred unless criteria group provides finance esoptrusts purchase company recognition internally generated intangible asset met shares open market meet obligation provide shares employees exercise options awards costs running brands valued independently part fair value businesses esop trusts charged income statement shares held acquired third parties brand value esoptrusts deducted reserves held substantial longterm brands sold value proceeds receivable employees exercise separately rest businesses acquired brands deemed permanent impairment value reflected areamortised estimated useful lives except transfer retained earnings considered useful economic life indefinite property plant equipment prior acquired minor brands similar intangibles property plant equipment ppe stated cost purchase eliminated group balance sheet reserves year construction less provisions depreciation impairment acquisition financing costs capitalised costs acquiring developing computer software internal depreciation calculated write cost ppe excluding use internet sites external use capitalised intangible freehold land using straightline basis expected useful fixed assets software site supports significant business life normal expected useful lives major categories ppe system expenditure leads creation durable asset reviewed annually erp systems software amortised seven years computer software three five years freehold buildings years impairment noncurrent assets leasehold land lease term years carrying values noncurrent assets reviewed buildings impairment indication assets might plant machinery years impaired additionally goodwill intangible assets indefinite fixtures equipment years useful lives intangible assets yet available use ondisposal ppe cost related accumulated depreciation tested impairment annually provision impairment impairments removed financial statements charged income statement year concerned net amount less proceeds taken income statement investments associates joint ventures leases investments associates joint ventures carried leasing agreements transfer group substantially consolidated balance sheet groups share oftheir net assets benefits risks ownership asset treated finance date acquisition postacquisition retained profits leases asset purchased outright assets losses together goodwill arising acquisition included inppe computer software capital elements availableforsale investments leasing commitments shown obligations finance availableforsale investments initially recorded cost leases assets held finance leases depreciated basis remeasured subsequent reporting dates fair value unrealised consistent similar owned assets lease term shorter gains losses availableforsale investments recognised interest element lease rental included income directly equity disposal impairment investments statement leases operating leases annual rentals gains losses equity recycled income statement included income statement straightline basis equity investments recorded noncurrent assets unless lease term expected sold within one year stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued accounting policies continued derivative financial instruments hedging ias adopted group st january purchases sales equity investments accounted information relating financial instruments remains trade date purchases sales availableforsale reported ukgaap applying following policies investments accounted settlement date derivative contracts treated inception economic hedge equity investments recorded cost underlying financial instrument matching accounting inventories treatment cash flows derivative instruments longer inventories included financial statements lower cost designated hedges restated market value future including raw materials direct labour direct costs related changes value taken directly profit loss account production overheads net realisable value cost generally currency swaps forward exchange contracts used fix value determined first first basis related asset liability contract currency taxation contract rate accrued profit loss account life current tax provided amounts expected paid applying contract tax rates enacted substantially enacted gains losses foreign exchange contracts designated hedges balance sheet date forecast foreign exchange transactions deferred included deferred tax provided full using liability method measurement related foreign currency transactions temporary differences arising tax bases assets period occur gains losses balance sheet hedges liabilities carrying amounts financial statements accrued taken directly reserves except forward deferred tax assets recognised extent probable premiumsdiscounts recognised interest life future taxable profits available temporary contracts differences utilised interest differentials interest swap agreements recognised deferred tax provided temporary differences arising profit loss account adjustment interest expense investments subsidiaries associates joint ventures except life agreement timing reversal temporary difference controlled probable temporary difference new accounting policies future requirements reverse foreseeable future following ifrs ifric interpretation issued deferred tax provided using rates tax enacted iasb likely affect future annual reports substantively enacted balance sheet date deferred tax liabilities ifrs financial instruments disclosures issued august assets discounted required implemented gskfrom st january derivative financial instruments hedging new standard incorporates disclosure requirements ias derivative financial instruments used manage exposure supersedes adds quantitative qualitative market risks treasury operations principal derivative disclosures relation financial instruments instruments used glaxosmithkline foreign currency swaps ifric determining whether arrangement contains lease interest rate swaps forward foreign exchange contracts issued december required implemented gsk group hold issue derivative financial instruments st january interpretation requires arrangements trading speculative purposes may nature legal form lease derivative financial instruments initially recognised balance accounted accordance ias leases interpretation sheet cost remeasured subsequent reporting dates expected material impact group fair value hedging derivatives classified inception fair value hedges cash flow hedges net investment hedges changes exchange rates fair value derivatives designated fair value hedges recorded group uses average exchange rates prevailing income statement changes fair value period translate results cash flows overseas subsidiaries hedged asset liability joint ventures associated undertakings sterling period changes fair value derivatives designated cash flow hedges end rates translate net assets undertakings recognised equity amounts deferred equity transferred currencies influence translations income statement line hedged forecast transaction relevant exchange rates hedges net investments foreign entities accounted average rates similar way cash flow hedges us changes fair value derivative instruments euro qualify hedge accounting recognised immediately yen income statement period end rates us euro yen gsk annual report notes financial statements continued segment information groups primary segment reporting business sector geographical reporting secondary format business sectors consist pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare oral care otc medicines nutritional healthcare geographical sectors usa europe international rest world markets reflect groups significant regional markets consistent groups regional market management reporting structure business sector data includes allocation corporate costs sector appropriate basis sales business sectorsthe groups activities organised global basis geographical sector figures therefore influenced location groups operating resources particular manufacturing research variations time intragroup trading funding arrangementsturnover shown business sector location customer geographic information given location subsidiary uk segment information gives turnover location customer location subsidiary uk operating profit total assets net assets also shownwhere group copromotes product third party records sale group records share revenue copromotion income within turnover nature copromotion activities group records costs sales pharmaceutical turnover includes copromotionrevenueof million million million turnover business sector pharmaceuticals consumer healthcare turnover profit business sector pharmaceuticals consumer healthcare operating profit finance income finance costs share profits tax associates joint ventures pharmaceuticals consumerhealthcare profit disposal interest associates profit taxation taxation profit disposals businesses profit taxation year investments associates joint ventures business sector pharmaceuticals consumer healthcare investment associates joint ventures property plant equipment intangible assets business sector additions pharmaceuticals consumer healthcare total additions depreciationamortisation pharmaceuticals consumer healthcare total depreciationamortisation impairment pharmaceuticals consumer healthcare total impairment impairment reversal pharmaceuticals consumer healthcare total impairment reversal stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued segment information continued total assets business sector pharmaceuticals consumerhealthcare total operating assets investments associates liquid investments derivative financial instruments cash cash equivalents current deferred taxation tangible assets held sale total assets total liabilities business sector pharmaceuticals consumer healthcare total operating liabilities shortterm borrowings longterm borrowings derivative financial instruments current deferred taxation total liabilities turnover location customer usa europe international turnover property plant equipment intangible asset additions location usa europe international total additions total assets location usa europe international intersegment trading balances total operating assets investments associates liquid investments derivative financial instruments cash cash equivalents current deferred taxation tangible assets held sale total assets gsk annual report notes financial statements continued segment information continued uk segment purposes usgaap information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting turnover location customer turnover including intersegment turnover intersegment turnover turnover location subsidiary operating profit total assets net operating assets operating income royalties asset disposal profits income including fair value adjustments royaltiesareprincipally core recurring incomefrom outlicensing intellectual property asset disposal profits include product divestments disposals equity investments intellectual property tangible property income includes equity investment carrying value adjustments arising stock market changes fair value adjustments arising quest collar theravance put call options operating profit following items charged operating profit employee costs note advertising distribution costs depreciation property plant equipment amortisation intangibleassets net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal ofprior yearwritedown inventories operating lease rentals minimum lease payments contingent rents sublease payments audit fees fees auditors work auditors ukfirm auditors overseas firms stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued operating profit continued analysis fees auditors work advisory services related section sarbanesoxley act nonstatutory assurance services tax compliance services tax planning advice services included within audit fees fee relating company audit glaxosmithkline plc included within nonstatutory assurance services amounts related groups preparation adoption international financial reporting standards services include human resources advisory compliance treasury related services st december amount due pricewaterhousecoopers fees yet invoiced million comprising statutory audit million assurance million taxation services million employee costs wages salaries social security costs pension postemployment costssee note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial recordonpagethe average number persons employed glaxosmithkline plc nil nil compensation directors cet company secretary aggregatewas follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information directors remuneration given remuneration report pagesto gsk annual report notes financial statements continued finance income interest income unwinding discount assets interest extended credit receivables net investment hedges fair value adjustments nonhedging derivatives finance costs interest bank loans overdrafts interest loans interest respect finance leases realised losses financial instruments unwinding discount provisions fair value hedges fair value adjustments nonhedging derivatives associates joint ventures associates share tax profits quest diagnostics inc share tax losses associates share tax profitslosses joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover total profitloss taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued taxation continued reconciliation taxation rate group profits ukstatutoryrate taxation overseas taxes benefit ofspecial tax status rd credits intercompany stock profit impact share based payments tax profit associates differences prior year items tax rate group operates countries tax rate differs uktax rate profits arising fromcertainoperations singapore puerto ricoireland belgium accorded special status taxed reduced rates compared normal rates tax territories effect reduction taxation charge increased earnings per share byp p andp group required ifrs create deferred tax asset respect unrealised intercompany profit arising stock held group year end applying tax rate country stock held rather tax rate country profit originally made tax paidwhich practice ukand usgaapthe group tax rate increased decrease result reductions workinprogress finished goods integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities intragroup transactions particular price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits taxed individual territories resolution issues continuing fact life gsk group open issues revenue authorities usa uk japan canada far largest relates glaxo heritage products respect us internal revenue service irs hm revenue customs hmrc uk made competing contradictory claims gsk attempted settle us dispute first direct discussion irs subsequently discussions us uk authorities terms double tax convention two countries thesediscussions terminated july th january irs issued notice deficiency years claiming additional taxes billion nd april group filed petition us tax court disputing irs claim seeking refund billion taxes th january irs issued notice deficiency years claiming additional federal taxes billionwhich group contested filing petition us tax court th april irs filed statutory answer th june september court agreed consolidate irs claims single trial total claims periods amount billion additional federal taxes related interest st december billion net federal tax relief giving total billion groups petitions irs claims include counterclaims repayment federal taxes totalling billion based partly reference advance pricing agreement apa smithkline beecham irs covering transfer pricing tagamet rd december irs filed motion summary judgement exclude evidence relating apas court proceedings st march trial judge denied irs motion reserved ruling admissibility apa evidence full trial scheduled commence th october decision expected mid similar tax issues remain open date gsk expects receive substantial claims irs years gsk continues believe profits reported us subsidiaries period date paid taxes usa sufficient reflect activities us operations however group tax creditor balance st december billion billion includes provision estimated amountat irs dispute might ultimately settled irs follow methodology applied previously respect later years gsk estimates potential unprovided exposure respect dispute irs years amountedto approximately billion st december billion gsk continuing discussions hmrc respect uk transfer pricing matters dispute years date however little progress made past year consequently matters may become subject litigation due course gsk annual report notes financial statements continued taxation continued gsk uses best advice determining transfer pricing methodology seeking manage transfer pricing issues satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments however continues wide difference views group irs hmrc relevant taxation authorities open issues exist ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities except shown annual report provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained st december required way incremental tax arise aggregate amount unremitted profits balance sheet date approximately billion st december group recognised deferred tax asset million million respect income tax losses approximately million million losses million million due expire million million due expire million million available indefinitely st december group recognised deferred tax asset respect income tax losses approximately million million million million due expire million nil due expire million million available indefinitely group capital losses st december estimated excess billion respect deferred tax asset recognised deferred tax assets recognised insufficient evidence losses utilised payable recoverable net movement current tax account st january exchange adjustments charge profit loss account cash paid movements st december movement deferred tax assets liabilities pensions share accelerated product post legal manu stock option net deferred taxation capital intragroup business retirement tax facturing valuation award temporary assetliability allowances intangibles profit disposals benefits losses disputes restructuring adjustments schemes differences total deferred tax asset st january deferred tax liability st january st january ias adjustments st january adjusted exchange adjustments creditchargeto income creditchargeto equity transfer tofrom current tax acquisitions movements st december deferred tax asset st december deferred tax liability st december deferred taxation provided stock valuation adjustments intragroup profit temporary differences shown arecurrent deferred taxation movements arise origination reversal temporary differences net temporary differences include accrued expenses provisions stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued earnings per share p p p basic earnings per share diluted earnings per share earnings per share calculated dividing profit attributable shareholders weighted average number ofshares issue period numberof shares used calculating basic diluted earnings per share reconciledbelow weighted average number shares issue millions millions millions basic dilution share options diluted shares held esop trusts excluded trustees waived rights dividends shares held esop trusts dividends first interim second interim third interim fourth interim total total dividend dividend per share pence paidpayable th july th october th january th april total dividend dividend per share pence paid st july th september th january th april total dividend dividend per share pence paid rd july nd october th january th april ifrs interim dividends recognised financial statements paid declared gsknormally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost st january exchange adjustments additions additions business combinations disposals reclassifications transfer assets held sale cost atstdecember exchange adjustments additions additions business combinations disposals reclassifications transfer assets held sale cost st december depreciation st january exchange adjustments provision year disposals reclassifications transfer assets held sale depreciation atstdecember exchange adjustments provision year disposals reclassifications transfer assets held sale depreciation st december impairment st january exchange adjustments disposals impairment losses reversal impairments impairment atstdecember exchange adjustments disposals impairment losses reversal impairments transfer assets held sale impairment st december total depreciation impairment atstdecember total depreciation impairment st december net book value st january net book value st december net book value st december gsk annual report stnemetats laicnanifnotes financial statements continued property plant equipmentcontinued net book value st december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings st december leased assets cost million million accumulated amortisationof million million net book value million million included plant equipment vehicles st december leased assets cost million million accumulated amortisationof million million net book value million st january million impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sellor value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital adjusted appropriate country specific risksthis approximates applying pretax discount rate pretax cash flows losses charged cost sales million research development million selling general andadministration million goodwill cost st january exchange adjustments additions business combinations disposals assets written cost st december net book value st january net book value st december additions year comprisemilliononthe acquisitionof id biomedical corporationand million acquisition corixa corporationseenotefor details goodwill amortised tested impairment least annually value use calculations generally utilised calculate recoverable amount value use calculated net present value projected riskadjusted posttax cash flows cash generating unit goodwill contained applying discount rate group posttax weighted average cost capital adjusted appropriate country specific risks approximates applying pretax discount rate pretax cash flows gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued computer licences intangible assets software patents etc brands total cost st january exchange adjustments additions disposals assets written reclassificationsfrom property plant equipment cost stdecember exchange adjustments additions additions business combinations disposals assets written reclassificationsfrom property plant equipment cost st december amortisation st january exchange adjustments provision year disposals assets written reclassificationsfrom property plant equipment amortisation stdecember exchange adjustments provision year disposals assets written reclassificationsfrom property plant equipment amortisation st december impairment st january exchange adjustments impairment losses disposals impairment stdecember exchange adjustments impairment losses assets writtenoff impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value stdecember net book value st december notes financial statements continued intangible assets continued amortisation impairment charged research development selling general administration st december net book value computer software included million internally generated additions business combinations year million comprise million acquisition idbiomedical corporation million acquisition corixa corporation see noteother additions licences patents year relate purchase ofdevelopment commercialisation rightsforbotox certain territoriesacquired allergan andvarious compounds rights see note brands comprise portfolio products acquired acquisitions sterling winthrop inc block drug company net book values major brands follows panadol sensodyne polident corega poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively stable profitable market sectors size diversification market shares mean risk market related factors causing shortening brands lives considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortisedeach brand istestedannually impairment applying fair value less costs sell methodology using five year posttax cash flow forecasts terminal value calculation applying discount rate group posttax weighted average cost capitalof adjusted appropriate countryspecific risksthis approximates applying pretax discount rate pretax cash flows main assumptions include future sales prices volumes product contribution future development expenditure required maintain products marketability registration relevant jurisdiction products life assumptions reviewed part managements budgeting strategic planning cycle changes market conditions product erosion generic competition investments associates joint ventures joint associated ventures undertakings total total st january implementation accounting financial instruments ias st january adjusted exchange adjustments additions transfers disposals retained profit year st december principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million million st december group owned quest although group holds less ownership interest voting control quest group ability exercise significant influence active participationon quest board directorsand board subcommittees gsk annual report stnemetats laicnanifnotes financial statements continued investments associates joint ventures continued summarised balance sheet information respect groups associates set total assets total liabilities net assets groups share associates net assets investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiglaxosmithkline holdings lp developing specified chemical compounds glaxosmithkline shire biochem primarily comarkets combivir trizivirand epivirin certain territories investments total total st january implementation accounting financial instruments ias st january adjusted exchange adjustments additions fair value movements impairments transfers disposals st december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevantstockexchange quoted bid price investments fair value estimated reference current market value similar instruments reference discounted cash flows underlying net assets group holds number equity investments frequently entities group entered research collaborations equity investments recorded noncurrent assets unless expected sold within one year case recorded current assets noncurrent equity investments include listed investments million million offer group opportunity return dividend income fair value gains disposal investments fair value movements reclassified reserves income statement based average cost impairment losses recorded tables recognised income statement year within operating income together amounts recycled fair value reserve note recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement noncurrent assets noncurrent assets comprise sundry receivables due one year including insurance recovery receivables discounted using riskfree rates returnand derivative financial instruments inventories raw materials consumables work progress finished goods gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued trade receivables trade receivables prepaid pension contributions prepayments accrued income interest receivable employee loans advances derivative financial instruments receivables trade receivables include million million due associates joint ventures shown deducting provisions bad doubtful debts million million cash cash equivalents cash bank hand shortterm deposits commercial paper cash cash equivalents include highly liquid investments maturities three months less assets held sale land buildings plant equipment vehicles trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals derivative financial instruments dividends payable customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa provisions made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome amounts subject change dependent upon amongst things types buying group product sales mix level provision reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions provisions based change could affect future results groupgsk annual report stnemetats laicnanif notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees thesearrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length ofservice hybrid defined benefit schemes also include defined contribution sections contributions defined benefit schemes determined accordance advice independent professionally qualified actuaries pension costs defined benefit schemes accounting purposes assessed accordance independent actuarial advice using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies liabilities generally assessed annually accordance advice independent actuaries formal independent actuarial valuations groups main plans undertaken regularly normally least every three years theassets funded schemes generally held separately administered trusts insured assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment target asset allocations uk schemes equities bonds us scheme equities bonds property longer term aim increase property element consequent reduction equities actuarial movements year recognised full statement recognised income expense uk discount rate based iboxx year aaindex us discount rate based moodys aa index expected return bonds reflects portfolio mix indexlinked government corporate bonds equity risk premium added equities projected inflation rate pension increases long term predictions based yield gap long term index linked fixed interest gilts uk mortality rates calculated using pa standard mortality tables projected plan obligations increased depending individual schemes mortality experience make allowance future improvements life expectancy usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment builds full allowance future improvements life expectancy group made special funding contributions uk us pension schemes totalling million gsk agreed trustees uk us defined benefit pension schemes group would make additional contributions approximately million per year fiveyear period ending st december order eliminate deficits ias basisby point uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefitschemes merged addition group operates number postretirement healthcare schemes principal one usa following information relates groups defined benefit pension postretirement healthcare schemesnotes financial statements continued gsk annual report stnemetats laicnanif pensions postemployment benefits continued group applied following assumptions assessing liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate amounts recorded income statement statement recognised income expense three years ended st december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial losses recorded statement recognised income expense postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gainslosses recorded statement recognised income expense postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgainsrecorded statement recognised income expense total actuarial losses recorded statement recognised income expense since st january amount milliongsk annual report stnemetats laicnanif notes financial statements continued pensions postemployment benefits continued fair values assets liabilities uk us defined benefit schemes together aggregated data defined benefit schemes group follows uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value schemeobligations included noncurrent assets included pensions postemployment benefits actual return plan assets uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value schemeobligations included noncurrent assets included pensions postemployment benefits actual return plan assets uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value schemeobligations included noncurrent assets included pensions postemployment benefits actual return plan assets notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations st january exchange adjustments service cost interest cost actuarial losses scheme participants contributions benefits paid settlements curtailments obligations st december exchange adjustments service cost interest cost actuarial losses scheme participants contributions benefits paid settlements curtailments obligations st december exchange adjustments service cost interest cost actuarial losses scheme participants contributions benefits paid settlements curtailments obligations st december liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation reducing per year thereafter basis liability usscheme assessed million million million defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded gsk annual report stnemetats laicnanifnotes financial statements continued pensions postemployment benefits continued postretirement pensions benefits movements fair value assets uk usa rest world group group assets st january exchange adjustments expected return assets actuarialgains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets actuarialgains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets actuarial gains employer contributions scheme participants contributions benefits paid assets st december uk defined benefit schemes include defined contribution sections account balances totalling million st december million million information scheme assets us gaap given note employercontributions estimated approximately million respect deferred benefit pension schemes million respect postretirement benefits transition date conversion ifrsfor gsk st january therefore following historical data presented date built rolling five year record next two years postretirement pensions benefits history actuarial gains losses uk usa rest world group group actuarial gains scheme assets percentage scheme assets st december actuarial losses scheme liabilities percentage scheme obligationsat st december fair value assets present value scheme obligations deficits schemes gsk annual report stnemetats laicnanifnotes financial statements continued pensions postemployment benefits continued postretirement pensions benefits history ofactuarialgains losses uk usa rest world group group actuarialgainsof scheme assets percentage scheme assets st december actuariallossesgains scheme liabilities percentage ofof schemeobligationsat st december fair value assets present value schemeobligations deficits schemes actuarialgainslosses scheme assets percentage scheme assets st december actuariallossesgains scheme liabilities percentage ofschemeobligationsat st december fair value assets present value schemeobligations deficits schemes sensitivity analysis changes assumptions used may material impact annual defined benefit pensionandpostretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease expected rates returns assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect increase annual postretirementbenefitscost increase postretirement benefits obligation gsk annual report stnemetats laicnanifnotes financial statements continued provisions legal manufacturing merger restructuring integration disputes provisions total st january exchange adjustments additions business combinations charge year unwinding discount applied reversed unused reclassifications movements st december settled within one year settled one year st december group recognised costs previous years respect plans manufacturingandother restructuring initiated following merger glaxo wellcome smithkline beecham acquisition block drug plans largely completed costs recognised provision principally respect identified severances sites announced manufacturing activities ceaseand site closure cleaning costsare expected incurred mainlywithin next three yearscosts asset writedowns recognised impairments property plant equipment group recognised costs previous years respect plans integration glaxo wellcome smithkline beecham businesses implementation integration following merger substantially completecosts recognised provision respect identified severances expected incurred respect programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options employees exercise options discount latter provision increased million million calculated using riskfree rates return glaxosmithkline involved number legal disputes including notification possible claims provisions legal disputes include amounts relating us antitrust product liability contract terminations selfinsurance environmental cleanup property rental companys directors taken legal advice established provisions taking account insurance agreements regard relevant facts circumstances matter accordance accounting requirements provisions discounted million million using riskfree rates return effect change discount rate increase discount st december million number products history claims made settlements makes possible use ibnr incurred reported actuarial technique determine reasonable estimate groups exposure unasserted claims relation products apart ibnr provision provisions made unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters including provided using ibnr actuarial technique may subject negotiation litigation several years largest individual amounts provided expected settled within three years st december expected million million provision made legal disputes reimbursed amount included within noncurrent assets discussion legal issues refer notelegal proceedings noncurrent liabilities accruals deferred income derivative financial instruments payables gsk annual report stnemetats laicnanifnotes financial statements continued contingent liabilities st december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million st december million million financial assets pledged collateral contingent liabilities discussion tax issues refer note taxation legal issues refer note legal proceedings net debt current assets liquid investments cash cash equivalents shortterm borrowings us us medium term note eurobond us notes commercial paper bank loans overdrafts loans obligations finance leases longterm borrowings us notes us us medium term note european medium term note european medium term note european medium term note european medium term note us us medium term note european medium term note european medium term note us us medium term note loan stock bank loans loans private financing obligations finance leases net debt current assets liquid investments classified availableforsale investments atst december theyincludedredeemableshareswhichwerefully collateralised highly rated bonds billion millionthe billion redeemable preference shares held st december redeemed yearthe effective interest rate liquid investments st december wasapproximately effective interest rate cash cash equivalents st december wasapproximately gsk annual report stnemetats laicnanifnotes financial statements continued net debt continued shortterm borrowings commercial paper comprises us billion programme million million issue st december million million backed committed facilities days duration million million million million renewable annually liquid investments cash cash equivalentsas shown table weighted average interest rate commercial paper borrowings st december weighted average interest rate current bank loans overdrafts st december longterm borrowings two bonds issued european medium term note programme million year coupon bondand million year coupon bond loans due one yearare repayable various periods follows one two years two three years three four years four five years five years loans repayable five years carry interest effective rates betweenand repayment dates range fromto average effective interest rate ofall notesatst december wasapproximately secured loans loans amounting million million secured charges noncurrent current assets finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations gsk annual report stnemetats laicnanifnotes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised st december st december st december share capital issued fully paid st january issued share options schemes purchased cancelled st december issued share option schemes purchased cancelled st december issued share option schemes st december st december st december st december number shares issuable outstanding optionsnote number unissued shares option st december issued share capitalshares held esop trustshares held treasury shares andshares free issue issued shares fully paid atotal billion spent company since buying shares cancellation held treasury shares whichbillion spent exact amount timing future purchases extent repurchased shares held treasury shares rather cancelled determined company dependent market conditions factors shares purchased period st january th february period th february th february furthermillion shares purchased cost millionall purchases publicly announced buyback programme table sets monthly purchases share buyback programme average share price excluding number shares commission stamp duty month january nil february march april nil may june july nil august september october november december total shares purchasedin held treasury shares details substantial shareholdings refer substantial shareholdings gsk annual report stnemetats laicnanifnotes financial statements continued movementsin equity shareholders equity share share retained minority total capital premium earnings reserves total interests equity st january recognised income expense year distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary sharestransferredby esop trusts writedownof shares held esoptrusts sharebased incentive plans atst december recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares purchased held treasury shares ordinary sharestransferredby esoptrusts writedownof shares held esoptrusts sharebased incentive plans st december implementation accounting financial instruments ias st january adjusted recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased held treasury shares ordinary sharestransferredby esoptrusts writedownof shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december retained earnings reservesamounted million st december million million million million million relates company million million million relates joint ventures associated undertakingsthe cumulative translation exchange equityat st december sincest january million million million share based incentive plans million includes million relating associate undertaking gsk annual report stnemetats laicnanifnotes financial statements continued movementsin equity continued reserves analysed follows cash flow esop trust fair value hedge shares reserve reserve reserves total st january ordinary shares purchased cancelled ordinary shares transferred esop trusts writedown shares held esop trusts atstdecember ordinary shares purchased cancelled ordinary shares transferred esop trusts writedown shares held esop trusts sharebasedincentive plans st december implementation accounting financial instrumentsunder ias st january adjusted recognised income expense year ordinary shares transferred esop trusts writedown shares held esop trusts st december reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million million related party transactions glaxosmithkline held aninterest quest diagnostics inc st december group quest diagnostics parties longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide quest diagnostics provided services million million group st december balance payable glaxosmithkline quest diagnostics million million group shionogi co ltd entered transactions usjoint venture company support research development activities conducted joint venture company glaxosmithkline provided services joint venture million million st december balance due glaxosmithkline joint venture million million dr shapiro nonexecutive director glaxosmithkline plc received fees form adss subsidiary company membership groups scientific advisory board fees included within annual remuneration remuneration report pagesto dr barzach former nonexecutive director glaxosmithkline plc received fees subsidiary company healthcare consultancy provided included within annual remuneration remuneration report aggregate compensation directors cet company secretary given note employee costs gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures businesses given acquisitions th december group acquired issued share capital idbiomedical corporation biotechnology company based canada specialising development manufacture vaccines particularly influenza vaccines cash consideration million transaction accounted purchase method accountingthe goodwill arising acquisition results benefits separately quantified recorded including immediate access additional flu vaccines manufacturing capacity particularly event pandemic skilled workforce good relations us canadian governments regarding supply flu vaccines idbiomedical corporation turnover million million loss million loss millionfor year million turnover million loss related period since acquisition andareincluded group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets deferred tax provision liabilities goodwill total consideration total consideration included directly attributable costs million th july group acquired issued share capital corixa corporation biotechnology company specialising developing vaccine adjuvants immunology based products cash consideration million investment increased groups holding corixa group number business relationships corixa prior acquisition date principally relation adjuvant developed corixa used groups vaccines transaction accounted purchase method accounting existing investment corixawith book value million previously classified availableforsale investmentand nowforms part investment subsidiarythe existing issued share capital acquired previous years cash consideration million corixa corporation turnover million loss million year million turnover million loss related period since acquisition andareincluded thegroup accounts book fair value fair value adjustment value net assets acquired intangible assets assets liabilities goodwill existing investment total consideration total consideration included directly attributable costs million gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals continued euclid sr partners lp additional million invested euclid srpartners lp associatein group interest glaxosmithkline consumer healthcare limited april anindiansubsidiary grouppurchased share capital held byminorityshareholders cash consideration million glaxosmithkline pharmaceuticals limited may june anindiansubsidiary grouppurchased share capital held byminorityshareholders cash consideration million glaxosmithkline biologicals shanghailimited achinese subsidiary grouppurchased share capital held minority shareholdersfor cash consideration million disposals ideapharm sa december group disposed ofideapharm sa subsidiary located romania cash proceeds million received january net assets disposed inthe yearincluded cash million aseptic technologies sa april group disposed aseptic technologies sa societe regionale dinvestissement de wallonie sa cash proceeds million gsk gsk gsk biologicals aseptic pharma consumer euclid id shanghai tech ceuticals healthcare ideapharm sr corixa biomedical cash flows total cash consideration cash cash equivalents acquired net cash payment acquisitions cash cash equivalents disposed net cash proceeds disposals gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals continued acquisitions fraxiparine fraxodi arixtra september group acquired fraxiparine fraxodiand arixtra andrelated assets including manufacturing facility cash consideration million book fair value net assets value adjustment acquired intangible assets tangible fixed assets inventory provisions onerous contracts euclid sr partners lp additional million invested euclid sr partners lp associate company group interest disposals quest diagnostics inc group disposed million shares investment quest diagnostics inc cash proceeds million reducing groups shareholding st december aprofit million recognised glaxosmithkline vehicle finance ltd group disposed employee vehicle financing subsidiary resulting loss million glaxosmithkline pharmaceuticals chongqing ltd group disposed glaxosmithkline pharmaceuticals chongqing ltd group subsidiary located china million profit disposal million realised beeyar investments pty ltd july group disposed beeyar investments pty ltd subsidiary located south africa cash proceeds million realising profit million optilead srl year part groups holding associated undertaking optilead srl sold resulting loss million fraxiparine gsk gsk fraxodi quest vehicle pharmaceuticals beeyar arixtra euclid sr diagnostics finance chongqing investments total cash flows cash consideration paid net cash proceeds disposals gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals continued acquisitions europharm group completed buyout minority interests europharm holdings sa group subsidiary located romania million giving rise goodwill million capitalised book fair value net assets goodwill cost values adjustments acquired capitalised acquisition europharm iterfi sterilyo payment million made pursuant acquisition agreement based financial performance acquired company amount included deferred compensation disposals sb clinical laboratories additional cash refund million received respect indemnified liabilities arising sb clinical laboratories disposal occurred refund follows successful outcome case uscourt appeal iterfi sb clinical sterilyo europharm laboratories total cash flows cash consideration paid net cash proceeds disposals commitments contractual obligations commitments contracted provided financial statements intangible assets plant property equipment pensions commitments interest loans number commitments made licensing agreements principally vertex pharmaceuticals inc commitments related intangible assets include milestone payments dependent successful clinical development represent maximum would paid milestones achieved gsk agreed trustees ukand uspension schemes make additional contributions approximately million per year fiveyear period ending st december order eliminate pension deficits ias basis point table shows commitment basis deficits st december amounts total contributions normal plus additional approximately million per year commitments made past st december group also commitments relating revenue payments made licences alliances principally exelixis inc commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments operating lease gsk annual report stnemetats laicnaniffinancial instruments related disclosures borrowings denominated swapped foreign currencies match investments overseas group assets treated hedge financial risk management relevant net assets glaxosmithkline plc reports sterling pays dividends sterling profits role corporate treasury gsk manage st december group outstanding contracts sell monitor groups external internal funding requirements purchase foreign currency total gross notional principal financial risks support group corporate objectives treasury amount million million majority activities governed policies procedures approved contracts periods months less board monitored treasury management group based composition net debt st december gsk maintains treasury control systems procedures monitor appreciation sterling major currencies would result foreign exchange interest rate liquidity credit financial risks reduction groups net debt approximately million weakening sterling major currencies would result gsk uses variety financial instruments including derivatives increase groups net debt approximately million finance operation manage market risks operations financial instrumentsincludecash liquid resources interest rate risk management borrowings spot foreign exchange contracts gsks policy interest rate risk management requires amount net borrowings fixed rates increases ratio number derivative financial instruments used manage forecast net interest payable trading profit market risks treasury operations derivative instruments principally comprising forward foreign currency contractsandinterest group uses limited number interest rate swaps rate currency swaps used swap borrowings liquid redenominate external borrowings interest rate coupon assets currencies required group purposes manage required group purposes duration swaps matches exposure funding risks changes foreign exchange rates duration principal instruments interest rate derivative interest rates instruments accounted fair value cash flow hedges relevant assets liabilities gsk balances use borrowings liquid assets regard tothe cash flow operating activities thecurrencies group manages centrally shortterm cash surpluses earned tax cost intragroup distributions currencies borrowing requirements subsidiary companies uses forward business assets denominated posttax cost contracts hedge future repayments back originating currency borrowings compared totheposttax return liquid assets sensitivity analysis considers sensitivity groups net debt liquid assets surplus immediate operating requirements hypothetical changes market rates assumes group companies generally invested managed centrally variables remain constant based composition net debt corporate treasury requirements group companies operating financing arrangements st december taking finance met whenever possible central resources consideration fixed rate borrowings placea one percentage point basis pointsdecreasein average interest rates would result external borrowings mainly managed centrally corporate treasury increase groups annual net interest charge comprise portfolio long mediumterm instruments short approximately million term finance market risk financial assets gsk hold issue derivative financial instruments group invests centrally managed liquid assets government trading purposes groups treasury policies specifically bonds shortterm corporate debt instruments minimum prohibit activity transactions financial instruments shortterm credit rating ap money market funds undertaken manage risks arising underlying business credit rating aaaaaa structured investmentscredit activities speculation ratings shown standard poors moodys investors foreign exchange risk management servicesrespectively theseinvestments classified available gsk foreign currency transaction exposure arising normal trade forsale flows respect external intragroup trade equity investments classified availableforsale investments hedged gsks policy minimise exposure overseas group manages disposals meet overall business requirements operating subsidiaries transaction risk matching local currency arise group regularly monitors value equity income local currency costs purpose intragroup trading investments enters hedges selectively approval transactions matched centrally intragroup payment terms board managed reduce risk exceptional foreign currency cash flows hedged selectively management corporate treasury credit risk usa line pharmaceutical companies group significant proportion group borrowings including sells products small number wholesalers addition commercial paper programme us dollars benefit hospitals pharmacies physicians groups sales liquidity us dollar denominated capital markets certain three largestwholesalersamounted approximately borrowings swapped currencies required groups us pharmaceutical sales st december group group purposes group seeks denominate borrowings trade receivables due three wholesalers totalling currencies principal assetsand cash flows million st december million gsk annual report stnemetats laicnanif notes financial statements continuedfinancial instruments related disclosures equity investments investments traded active market continued determined reference relevant stock exchange quoted bid price investmentsdeterminedby reference current group exposed concentration credit risk respect market value similar instruments reference discounted wholesalers one affected cash flows underlying net assets financial difficulty could materially adversely affect groups cash cash equivalents approximates carrying amount financial results liquid investments based quoted market pricesin case group believe exposed major concentrations marketable securities based principal amounts case credit risk onother classes offinancial instruments group nonmarketable securities short repricing periods exposed creditrelated losses event nonperformance shortterm loans overdrafts approximates carrying counterparties financial instruments expect amount short maturity instruments counterparties fail meet obligationswhere group longterm loans based quoted market prices case significant investments single counterparty collateral eurobonds fixed rate borrowings approximates obtained order reduce risk carrying amount case offloating rate bank loans loans group applies boardapproved limits amount credit forward exchange contracts based market prices exchange exposure one counterparty employs strict minimum credit rates balance sheet date worthiness criteria choice counterparty currency swaps based market valuations balance liquidity sheetdate group operates globally primarily subsidiary companies quest equity collar theravance put call options based established markets group trades due option pricing model uses significant assumptions nature groups business patent protection many respect price volatility dividend yield interest rates products groups portfolio groups products compete interest rate instruments based net present value largely product efficacy rather price selling margins discounted cash flows sufficient toexceednormal operating costs groups operating receivables payables approximates carrying amount subsidiaries substantially cash generative provisions approximates carrying amount lease obligations approximates carrying value operating cash flow used fund investment research development new products well routine outflows capital year ended st december total amount expenditure tax dividends repayment maturing debt change fair valuesestimated usingvaluation techniques referred group may time time additional demands finance resulted credit income statement million forshare purchases acquisitions fair value investments ingskshares gsk operates high level interest cover low levels atst december esop trusts held gsk ordinary shares net debt relative market capitalisation addition strong carrying valueof million million positive cash flow normal trading activities additional liquidity fair value million million based quoted readily available via commercial paper programme short market price shares represent purchases esop trusts term investments group also aeuropeanmedium term note satisfy future exercises options awards employee programme billion billion issue st incentive schemes thecarrying value lower cost december march group established us shelf expected proceeds shares recognised registration billion st december billion deduction reservesat st december gsk held billionwas issue treasury shares cost million million deducted retained earnings fair value financial assets liabilities table pagepresents carrying amounts ifrs committed facilities fair values groups financial assets liabilities st group committed facilities back commercial paper december comparative information presented table programme million million million page carrying amounts st december million days duration renewable annually st december recorded uk gaap basis applicable date rather undrawn committed facilities totalled million accordance ias ias described note million million million fair values financial assets liabilities included atthe amount instrument could exchanged current transaction willing parties forced liquidationsale following methods assumptions used estimate thefair values gsk annual report stnemetats laicnanif notes financial statements continuedgsk annual report stnemetats laicnanif notes financial statements continued financial instruments related disclosures continued ifrs disclosures group adopted ias ias st january following disclosures included st december meet requirementsof ias classification fair values financial assets liabilities following table sets classification financial assets liabilitiesreceivables payables included extent classified financial assets liabilities accordance ias provisions included contractual obligation settle cash appropriate currency interest rate swaps presented alongside underlying principal instrument carrying amounts instruments adjusted effect currency interest rate swaps acting hedges carrying fair value value st december liquid investments cash cash equivalents current asset financial instruments notes bonds usnotesbondsand private financing notes bonds swapped us currency swaps interest rate swaps notesswapped yen currency swaps notes interest rate swap othershorttermborrowings otherlongterm borrowings total borrowingsand related swaps equity investments receivables payables provisions otherderivatives assets otherderivatives liabilities financial assets financial liabilities total financial assets liabilities total financial assets total financial liabilities reconciliation net debt liquid investments cash cash equivalents total borrowings lessnet effect ofinterest rate currency swaps net debt notes financial statements continued gsk annual report stnemetats laicnanif financial instruments related disclosurescontinued interest rate profiles financial assets liabilities following tables set exposure financial assets andliabilities either fixed interest rates floating interest rates orno interest rates maturity profile financial assets liabilities exposed interest rate risk tables indicates contractual repricing maturity dates instruments cash st december liquid cash financial investments investments equivalents receivables assets total financial assets less one year one two years two three years three four years four five years greater five years total interestearning analysed fixed rate interest floating rate interest total interest earning noninterestearning total effect obligations st december interest rate finance financial debt swaps leases payables provisions liabilities total financial liabilities less one year one two years two three years three four years four five years greater five years total interest bearing analysed fixed rate interest floating rate interest total interest bearing noninterest bearing total maturity analysis interestearning financialassets maturity analysis interestearning financial assets isequivalent maturity analysispresented interest rate profile tableabove maturity analysis interest bearing financialliabilities st december finance financial debt leases payables liabilities total financial liabilities within one year demand one two years two three years three four years four five years five years gsk annual report stnemetats laicnanif notes financial statements continued financial instruments related disclosures continued currency profiles financial assets liabilities groups currency exposures give rise net currency gains losses recognised income statement arise principally companies sterling functional currency table sets exposures financial assets liabilities held currencies functional currencies group companies effect currency swaps st december sterling us euro yen total financial assets investments cash cash equivalents receivables st december sterling us euro yen total financial liabilities debt obligations finance lease payables provisions derivativefinancial instruments table sets net principal amount fair value derivative contracts held gsk fair value contract underlying principal amount assets liabilities currency interest related instruments foreign exchange contracts cross currency swaps interest rate swaps equity related instruments options warrants equity collar embedded derivatives total derivative financial instruments gskhedged part equity value holdings largest equity investment quest diagnostics inc series variable sale forward contracts contracts equity collar structured five series one million quest shares mature group entered put option agreement whereby theravances shareholders sell half theravance shares gsk predetermined price given maximum number shares subject put option groups obligation capped million st december option recorded liability ofmillion million st december maximum potential exposure gsk fair value movements options therefore approximatelymillion expiry date august group entered call option agreement whereby purchase half outstanding theravance shares issue pre determined price st december option recorded asset ofmillion million st december maximum potential exposure gsk fair value movements option thereforemillion expiry date july notes financial statements continued financial instruments related disclosures continued following table sets principal amount andfair values derivative contracts qualify hedge accounting treatment contract underlying fair value principal amount derivative contract cash flow hedges cross currency swaps fair value hedges foreign exchange contracts interest rate swaps cross currency swaps net investment hedges foreign exchange contracts cross currency swaps cash flow hedges group entered cross currency swap designated cash flow hedge converting fixed euro coupons payable annually fixed yen payments bond matures risk hedged variability cash flows arising currency fluctuations fair value hedges foreign exchange contractsdesignated fair value hedgeshavebeen enteredin order hedge foreign currencyrisk associated intercompany loans deposits commercial paper borrowings andother liabilities group designated interest rate swapsand interest element cross currency swapsas fair value hedges risk hedged variability ofthe fair value bondsarising frominterest rate fluctuations net investment hedges foreign exchange contracts currency element cross currency swaps designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment usdollar euro yen foreign operations uk gaap disclosures group exercised ifrs exemption record financial instruments comparative period existing uk gaap basis following disclosures included st december meet requirements financial reporting standard derivatives financial instruments disclosures uk gaap accounting policy derivative financial instruments group hold issue derivative financial instruments trading purposes derivative financial instruments used manage exposure market risks treasury operations principal derivative instruments currency swaps forward foreign exchange contracts interest rate swaps derivative contracts treated inception economic hedge underlying financial instrument matching accounting treatment cash flows derivative contracts havea high correlation specific financial instrument hedged inception throughout hedge period derivative instruments longer designated hedges restated market value future changes value taken directly income statement currency swaps forward foreign exchange contracts used fix value related asset liability contract currency contract rate accrued income statement life contract gains losses foreign forward exchange contracts designated hedges forecast foreign exchange transactions deferred included measurement related foreign currency transactions period occur gains losses balance sheet hedges accrued taken directly reserves except forward premiumsdiscounts recognised interest life contracts interest differentials interest swap agreements recognised income statement adjustment interest expense life agreement gsk annual report stnemetats laicnanifnotes financial statements continued financial instruments related disclosures continued classification fair values financial assets liabilities following table sets classification financial assets liabilities provides reconciliation group net debt note short term payables receivables excluded financial assets liabilities provisions included contractual obligation settle cash appropriate currency interest rate swaps presented alongside underlying principal instrument carrying amounts instruments adjusted effect currency interest rate swaps acting hedges st december carrying fair value value net debt liquid investments cash cash equivalents current asset financial instruments notes bonds usnotes bonds private financing notes bonds swapped us currency swaps interest rate swaps notesswapped yen currency swaps notes interest rate swap otherlongterm borrowings shortterm loans overdrafts total borrowingsand related swaps total net debt equity investments receivables payables provisions foreign exchange derivatives nonhedging derivatives total financial assets liabilities total financial assets total financial liabilities gsk annual report stnemetats laicnanifnotes financial statements continued financial instruments related disclosures continued currency interest rate risk profile financial liabilities financial liabilities taking account currency interest rate swaps analysed total financial liabilities comprise total borrowings million longterm payables millionand provisions million exclude shortterm payables foreign exchange derivatives million benchmark rate determining interest payments floating rate financial liabilities tables libor noninterest fixed rate floating rate bearing weighted weighted average average weighted st december interest years average rate rate years total currency fixed maturity us sterling euro yen currencies currency interest rate risk profile financial assets total financial assets comprise investments million liquid investments million cash cash equivalents million longterm receivables million benchmark rate determining interest receipts floating rate assets tables libid noninterest fixed rate floating rate bearing weighted weighted average average st december fixed interest years rate rate rate total currency fixed us sterling euro yen currencies gsk annual report stnemetats laicnanifnotes financial statements continued financial instruments related disclosures continued currency exposure net monetary assetsliabilities groups currency exposures give rise net currency gains losses recognised income statement arise principally companies sterling functional currency monetary assets liabilities denominated overseas functional currency borrowings designated hedge overseas net assets excluded table st december functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us euro yen finance total debt leases maturity financial liabilities within one year demand one two years two five years five years gains losses net hedges unrecognised gains losses beginning year unrecognised gains losses arising previous years recognised year unrecognised gains losses arising year total unrecognised gains losses end year expected recognised within one year expected recognised one year total unrecognised gains losses end year unrecognised gains losses represent difference carrying amount fair value currency swaps interest rate swaps equity collar foreign exchange derivatives impact ias ias adoption comparative information nature main adjustment would make comparative information comply ias ias would therecognition fair valueof financial instrumentsclassified fair valued profit loss availableforsale gsk annual report stnemetats laicnanifnotes financial statements continued employee share schemes group operates share option schemes whereby options granted employees acquire shares adss glaxosmithkline plc grant price share award schemes whereby awards granted employees acquire shares adss glaxosmithkline plc cost subject tothe achievement group specified performance targets group introduced new share award scheme restricted share plan whereby awards granted employees acquire shares adss glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options certain employees cost schememore readily equates potential gain made employee group operates share option schemes savingsrelated share option schemes grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving options share option schemes normally granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price marketprice ruling date grant share options awarded tothe directorsand effect grant cetare subject performance criteria laid remuneration report option pricing purposes valuing options arrive stockbased compensation charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option schemes years years years weighted average share pricefor grants year ordinary shares adss volatility determined based three year share price historythe fair value performance share plan grants take account market conditionsexpected lives options determined based weighted average historic exercises options stockbased compensation charge recorded income statement follows cost sales selling general administration research development options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st january options granted options exercised options cancelled st december options granted options exercised options cancelled st december options granted options exercised options cancelled st december range exercise prices average share price gsk annual report stnemetats laicnanifnotes financial statements continued employee share schemes continued order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expiry options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted latest weighted latest latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options exercisable except options shares adss granted savingsrelated share options granted change effective exercise price outstanding options year options exercisable share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period performance conditions consist two parts applies award awards granted first part condition compares glaxosmithklines total shareholder return tsr period tsr companies ukftse index period awards granted subsequent yearsthe first part condition compares glaxosmithklines tsr period tsr pharmaceutical companies comparator group period second part performance condition compares glaxosmithklines earnings per share growth increase ukretail prices index three year performance period awards granted directors members cet th december subject single performance condition compares glaxosmithklines tsr period tsr companies comparator group period gsk annual report stnemetats laicnanifnotes financial statements continued employee share schemes continued shares weighted adss weighted number shares adss issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december restricted share plan group operates restricted share plan whereby awards grantedin form shares certain employees cost awards vest three years performance criteria attached shares weighted adss weighted number shares adss issuable number fair value number fair value atst january awards granted st december awards granted awards exercised awardscancelled st december employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares onthe open market finance provided group way loans contributionscosts running esop trusts charged income statement shares held esoptrusts deducted reserves held value proceeds receivable employees exercise deemed permanentdiminutionin value reflected transfer retained earnings shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esoptrusts gsk annual report stnemetats laicnanifreconciliation usaccounting principles like ifrs sfas requires goodwillmust notbe amortised annual impairment tests goodwill must undertaken analyses reconciliations presented note represent implementation sfas year earlier financial information prepared basis us generally accepted groups transition ifrs results goodwill balances acquired accounting principles usgaap rather ifrs reflecting one year less amortisation summary material differences ifrs us usgaap ifrs gaap ifrscosts incurred integrating restructuring acquisition smithkline beecham wellcome smithkline beecham block drug businesses following group exercised exemption available ifrs first acquisitions respectively charged timeadoption ifrs restate business combinations prior income statement post acquisition similarly integration date transition groups reporting gaap uk restructuring costs arising respect acquisitions ofcorixa generally accepted accounting principles ukgaap ifrs idbiomedical charged income statement therefore combination glaxo wellcome plc ifrs usgaap certain ofthesecostsareconsidered smithkline beecham plc continues accounted merger allocation purchase consideration thereby affecting pooling interests accordance withukgaapat time goodwill arising acquisition us gaap business combination qualify pooling interests accounting glaxo wellcome deemedto inprocessresearch development iprd accounting acquirer purchase business combination ifrs iprd projects acquired business combination capitalised remain balance sheet subject accordingly net assets smithkline beecham recognised impairment writedownsamortisation charged assets fair valueas date acquisition result fair value estimated useful lives point whenthe assets became available exercise increases values smithkline beechams inventory useunder usgaap assets recognised opening property plant equipment intangible assets investments balance sheet writtenoff immediately income pension obligations recognised fair market values statementas technological feasibility iprd yet attributed internallygenerated intangible assets mainly product established alternative future use ifrs rights inclusive patents andtrademarks inprocess research deferred tax provided iprd assets acquired business development together appropriate deferred taxation combination usgaap provide deferred tax effects difference cost acquisition fair assets resulting reconciling adjustment deferred tax value assets liabilities smithkline beechamisrecorded goodwill goodwill iprd acquired transactions business combinations capitalised interest discussed underintangible assets ifrs group capitalise interest usgaap requires interest incurred part cost constructing fixed assetto intangible assets capitalised amortised life asset ifrs certain intangible assets related specific compounds products purchased third party developed goodwill commercial applications capitalised subject group exercised exemption available ifrs amortisation regulatory approval obtained usgaap restate business combinations prior date transition payments madein respect ofthese compounds products groups reporting gaap ukgaap ifrs ukgaap still development yet received regulatory approval goodwill arising acquisitions accounted charged directly theincome statement purchase method eliminated equity ifrs futuredisposal closure business goodwill previously taken ifrs intangible assets amortised estimated useful directly equity former gaap charged economic life except case certain acquired brands income ukgaap goodwill arising acquisitions end useful economic life brand foreseen capitalised amortised period exceeding years us gaap implementation sfas goodwill date groups transition ifrs st january intangible assets intangible assets including amortisation ceased accordance ifrs business brands amortised finite life implementation sfas combinations group must instead identify value reporting intangible assets deemed indefinite lives units purpose assessing least annually potential longer amortised result difference accounting impairment goodwill allocated reporting unit permitted treatment prior implementation sfas carrying business combinations exemption available ifrs valuesofindefinite lived brandsare affected byamortisation charged amortisation arising prior reversed usgaap us gaap goodwill arising acquisitions prior th june capitalised amortised period exceeding years july financial accounting standards board fasb issued statement financial accounting standard sfas goodwill intangible assets gsk annual report stnemetats laicnanif notes financial statements continuedreconciliation us accounting principles proceeds sale marketable securities usgaap continued million year ended st december proceeds include rollover liquid funds shortterm deposit gross restructuring costs gains losses reflected consolidated income statement ifrs restructuring costs incurred following acquisitions respect marketable securities weremillion andnil respectively charged profit loss account post acquisition usgaap purposes certain costs recognised liabilities upon pensions postretirement benefits acquisition opening balance sheet key differencebetween ifrs usgaap method recognition actuarial gains losses gsk opted underifrs restructuring costs recorded provision ifrswhen recognise actuarial gains lossesin statement recognised restructuring plan announced usgaap provision income expense year arise usgaap may recognised criteria met liability actuarial gains losses recognised using corridor incurred therefore adjustments made eliminate approach deferred actuarial gains losses amortised provisions restructuring costs meet usgaap therefore pension liability recognised ifrs greater requirements usgaap marketable securities stockbased compensation marketable securities consist primarily equity securities certain ifrs sharebasedpayment share options fair valued liquid investments principally government bonds short grant dates cost charged income statement term corporate debt instrumentsunder sfas accounting relevant vesting periods usgaap group applies certaininvestments indebt andequitysecurities securities sfas accounting forstockbasedcompensation related considered availableforsaleand carried fair value accounting interpretations accounting option planswhich unrealised gains losses net tax recorded separate also require options fair valued grant date included component shareholders equity ifrstheseare accounted inthe income statementover vesting period options availableforsale financial assetsin accordance withias differences arise result application differing financialinstruments recognition andmeasurement measurement basesin respect performance conditions attaching accounting treatment marketable securities usgaap sharebased payments treatment lapsed grants ifrs issimilar however differences arise principallyas result derivative instruments category marketable securities defined sfas sfas accounting derivative instruments hedging smaller category availableforsale financial assets activities amended sfas sfas interpreted defined ias investments marketable securities derivatives implementation group adopted group sfas definition accounted cost less effect st january sfas establishes accounting impairments usgaap rather fair value reporting standards derivative instruments including certain group adopt ias st january derivative instruments embedded contracts collectively accordance exemption available ifrs presented referred derivatives hedging activities sfas requires financial instruments comparativeperiods accordance entity recognise derivatives either assets liabilities ukgaap therefore securities stated lower consolidated balance sheet measure instruments fair cost net realisable value value changes fair value period recorded current earnings unless hedge accounting obtained sfas prescribes marketable securities reviewed leastevery six monthsfor requirements designation documentation hedging temporary impairment equity securities factors relationships ongoing assessments effectiveness order considered include qualify hedge accounting investees current financial performance future prospects group also evaluates contracts embedded derivatives general market condition geographic industry area accordance sfas requirements embedded derivatives investee operates clearly closely related host contract accounted duration extent market value separately host contract derivatives cost key differences ifrs groups financial gross unrealised gains losses marketable securities statements prepared usgaap groups application million millionrespectivelyat st december respective requirements million millionrespectively fair value marketable securities unrealised losses st december ismillion certain derivatives designated group hedging million marketable securities instruments ias designated hedging continuous loss position less monthsdeferred tax instruments sfas accordingly hedge accounting provided unrealised gains losses st december applied usgaap respect arrangements million million gains million reclassified ofaccumulatedothercomprehensive income income statement disposals equity investments year gsk annual report stnemetats laicnanif notes financial statements continuednotes financial statements continued reconciliation us accounting principles continued following adjustments also included reconciliations definition derivatives within scope sfas excludes computer software ifrs group capitalises costs incurred instruments liquid market leads certain acquiring developing computer software internal use items recognised balance sheet although software supports significant business system accounted derivatives ifrs notably call option expenditure leads creation durable asset us gaap theravance shares group applies sop accounting costs computer software developed obtained internal use restricts ias exemption requirement recognise categories costs capitalised embedded foreign currency derivatives currency commonly used economic environment host contract guarantor obligations usgaap group applies sfas grant similar exemption group fasbs financial interpretation fin guarantors identifies separately accounts embedded derivatives accounting disclosure requirements guarantees including us gaap ifrs indirect guarantees indebtedness others requires group recognise certain guarantees issued measured fair group exercised exemption available ifrs value ifrs guarantor obligations recognised present financial instruments comparativeperiods accordance additional criteria met liability incurred ukgaap ukgaap derivative instruments used hedges recognised balance sheet matching variable interest entities fasbs interpretation principle used match gain loss hedging revised fin r consolidation variable interest entities certain contracts foreign currency transaction profits entities known variable interest entities vies must relatedgains losses related fair value adjustments consolidated primary beneficiary entity primary derivative instruments therefore reconciling items beneficiary generally defined majority risks group designate derivatives qualifying hedge rewards arising vie additionally vies instruments sfas significant majority variable interest held certain disclosures required group completed review fair value book value derivative instruments st potential vies consequence consolidated theravance december disclosed classification fair value inc may see note c page vies financial assets liabilities table note group primary beneficiary identified valuation derivative instruments fixed asset inventory impairments reversals impairments fair value derivative instruments sensitive movements previously recorded carrying value assets permitted underlying market rates variables group monitors ifrs certain circumstances usgaap permit fair value derivative instruments least quarterly basis reversals impairments derivativesincluding interest rate swaps crosscurrency swaps valued using standard valuation models counterparty valuations various othersmalladjustments third party valuations standard valuation models used consolidated summary statement cash flows group consider relevant discount rates market yield curve usgaap cash flow statement reportsthree categories cash valuation date forward currency exchange rates counterparty flows operating activities including tax interest investing risk significant rates variables obtained market activities including capital expenditure acquisitions disposals sources valuations based remaining term maturity together cash flows availableforsale current asset instrument investments andfinancing activities including dividends paid foreign exchange contracts valued using forward rates observed summary statement ofcash flows presented page quoted prices relevant markets possible group comprehensive income statement assumes parties longterm contracts economically viable requirement sfas reporting comprehensive income reserves right exercise early termination rights economically provide comprehensive income statement met ifrs beneficial rights exist contract statement recognised income expense page dividends ifrs gsk plcs quarterly dividends recognised payment usgaap dividends recognised financial statements declared gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles recent fasb pronouncements continued november fasb issued sfas inventory costs amendment arb chapter sfas clarifies recent financial accounting standards board fasb abnormal amounts idle facility expense freight handling costs pronouncements wasted materials spoilage recognised current fsp fin r period charges requires allocation fixed production march fasb issued fasb staff position fsp fin r overheads inventory based normal capacity implicit variable interests fasb interpretation r production facilities sfas effective fiscal years beginning consolidation variable interest entities fsp requires reporting th june enterprise consider whether holds implicit variable interest thevieor potential vie determination whether implicit december fasb issued sfas exchanges non variable interest exists involves determining whether enterprise monetary assets amendment apb opinion amends may indirectly absorbing receiving variability entity apb opinion accounting nonmonetary transactions fsp effective first reporting period beginning rd eliminate exception nonmonetary exchanges similar march adoption fsp group productive assets replaces general exception impact overall results operations financial positionunder exchanges nonmonetary assets commercial us gaap substance sfas effective nonmonetary asset exchanges occurring fiscalyearsbeginning th june eitf june emerging issues task force eitf reached consensus march fasb published fasb staff position fsp fin issue determining amortisation period leasehold accounting conditional asset retirement obligations improvements purchased lease inception acquired interpretation fasb statement clarifies business combination eitf requires leasehold improvements application sfas accounting obligations associated acquired business combination amortised shorter retirement longlived assets respect conditional asset useful life assets term includes required lease retirement obligations fsp effective first period beginning periods renewals deemed reasonably assured date th december acquisition additionally issue requires improvements placed november fasb issued fsp fsp service significantly contemplated near meaning otherthantemporary impairment application beginning lease term amortised shorter certain investments nullify certain requirements eitf useful life assets term includes required lease periods supersede eitf fsps provide guidance identifying renewals deemed reasonably assured date impaired investments new disclosure requirements leasehold improvements purchased investments deemed temporarily impaired fsps eitf effective immediately adoption eitf effective fiscal years beginning th december amaterial impact groups consolidated financial position november fasb issued fsp fin provide results operations cash flowsunder us gaap clarification respect application fin guarantors sfas rand related fsps accounting disclosure requirements guarantees including december fasb issued sfas revised share indirect guarantees indebtedness others fsp fin includes based payment sfas r replaces sfas supersedes apb within scope provides guidance concerning application sfas r requires cost resulting sharebased fin guarantee granted business owners payment transactions recognised financial statements fair entitys revenue revenue specified portion entity value excess tax benefits reported financing cash meet minimum amount referred minimum revenue inflow rather reduction taxes paid sfas r effective guarantee group st january effective date group expect adoption compensation cost recognised based requirements sfas pronouncements material impact consolidated r new sharebased awards based requirements financial position results operations cash flows us gaap sfas awards granted prior effective date sfas r remain unvested effective date may sfas accounting changes error corrections replacement apb opinion sfas issued sfas fasb issued fsp rfsp r fspr changes accounting reporting change accounting fsps detail various aspects implementation principle requiring retrospective application prior periods sfas rgsk process assessing impact financial statements changes accounting principle unless adoption sfas r groups consolidated financial position impracticable sfas effective accounting changes made results operations cash flows us gaap fiscal years beginning th december group determine impact sfas depends part upon future changes us accounting principles gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued following summary material adjustments profit shareholders funds would required us gaap applied instead ifrs profit notes profit taxation year ifrs profit attributable minority interests profit attributable shareholders ifrs usgaap adjustments amortisation impairment intangible assets b acquisition disposal product rights b writeoff inprocess rd acquired business combinations b capitalised interest disposal interestsin associates subsidiaries investments pensions postretirement benefits f stockbased compensation derivative instruments hedging fair value put option granted minority shareholders c restructuring tax benefits exercise stock options deferred taxation net incomeunder usgaap earnings per share usgaap p p p basic net income per share diluted net income per share earnings per ads usgaap basic net income per ads diluted net income per ads equity shareholders funds notes total equity ifrs minority interests shareholdersequityunder ifrs usgaapadjustments goodwill product rights b pension intangible asset f property plant equipment capitalised interest marketable securities investments pensions postretirement benefits f restructuring costs derivative instruments hedging fair value put option granted minority shareholders c dividends deferred taxation e shareholders equity us gaap gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued consolidated statement cash flows usgaap net cash provided operating activities net cash used investing activities net cash used financing activities net increase cash cash equivalents exchange rate movements cash cash equivalents beginning year cash cash equivalents end year notes profit equity shareholders funds reconciliations goodwill following tables set ifrs usgaap adjustments required ifrs balance sheet respect goodwill including goodwill respect associated undertakings balance sheet goodwill ifrs goodwill usgaap ifrs usgaap adjustments million millionusgaap goodwill balance st december million million respect goodwill arising acquisition smithkline beecham glaxo wellcome following tables present changes goodwill allocated groups reportable segments consumer pharmaceuticals healthcare total atst january asset written exchange adjustments st december additions disposals exchange adjustments st december b intangible assets following tables set ifrsto usgaap adjustments required ifrs income statement balance sheet respect intangible assets income statement amortisation charge ifrs amortisation charge usgaap ifrsto usgaap adjustment amortisation impairment charge ifrs impairment charge usgaap ifrs usgaap adjustment impairment addition adjustments amortisation impairments ifrs usgaap adjustments arose year million million million respect acquisition disposal inprocess rd licences patents etc capitalised ifrs charged directly research development expense usgaap nil million million nil respect disposals product rights higher carrying value usgaap ifrs gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued balance sheet product rights intangible assets ifrs product rights intangible assets usgaap net ifrsto usgaap product rights adjustments product rights intangible assets usgaap analysed follows acquired licenses brands subject indefinite products patents etc amortisation lived brands total cost accumulated amortisation impairment carrying value cost accumulated amortisation impairment carrying value acquired products pharmaceutical products principally arising acquisition smithkline beecham plc book values net accumulated amortisation impairment follows avandia seroxatpaxil augmentin fluviral havrix infanrix coreg twinrix engerixb hycamtin others acquired products intangible assets usgaap indefinite lived brands relate large number consumer healthcare products principally arising acquisitions ofsmithkline beecham plc including products previously acquired smithkline beecham sterling winthrop inc block drug company book values follows panadol aquafresh lucozade horlicks ribena nicorette odol tums sensodyne nicoderm others indefinite lived brands intangible assets us gaap gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued brands considered indefinite life given strength durability brand level marketing support brands relatively stable profitable market sectors size diversification market shares mean risk market related factors causing shortening brands lives considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortisedeach brand tested annually impairment applying fair value less costs sell methodology using five year posttax cash flow forecasts terminal value calculation applying discount rate group posttax weighted average cost capital approximates applying pretax discount rate pretax cash flows carrying values certain intangibles subject amortisation reviewed impairment million million recorded million nil relates pharmaceutical products million million consumer healthcare products impairment charge respect consumer healthcare intangible assets subject amortisation million recognised nil discussed notelegal proceedings number distributors generic drugs filed applications market generic versions number groups products prior expiration groups patents generic versions products launched future periods earlier dates group currently expects impairments carrying value products may arise estimated future amortisation expense next five years intangible assets subject amortisation st december follows year total inprocess rd million nil nil arising acquisitions idbiomedical corixa corporation written valued basis intangible assets acquired relates various development projects pre approval stage technological feasibility projects established point acquisition c theravance may group formed strategic alliance theravance inc develop commercialise novel medicines across variety important therapeutic areas terms alliance theravance received million significant part related groups purchase theravance shares group call option increase ownership significant premium price paid transaction theravances shareholders put option lower exercise price cause glaxosmithkline acquire half outstanding stock given maximum number shares subject put option groups obligation capped million group exclusive option license potential new medicines theravances programmes august upon exercising option theravance programme group responsible relevant development manufacturing commercialisation activities depending success programmes theravance receive clinical regulatory commercial milestone payments royalties subsequent sales medicines based assessment performed groupwas primary beneficiary theravance defined fin r result theravance consolidated groups us gaap financial statements may net assets acquired measured fair value principal adjustment carrying value net assets theravances balance sheet prior acquisition recognition inprocess research development iprd valuation million iprdwas writtenoff immediately acquisition accordance usgaap purchase accounting effect consolidating theravance including reversal fair value gains recorded investment ifrshas decrease shareholders equity million million net income million million additionally group accounted theravance put option discussed accordance sfas accounting certain financial instruments characteristics liabilities equity requires group record fair value put option liability fair value theravance put option st december million million accordance sfas accounting derivative instruments hedging activities call option recognised financial statements readily convertible cash gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued taxation total tax expense ifrs current tax expense deferred taxcreditexpense total tax expense us gaap current tax expense deferred tax credit total tax expense ifrsto usgaap adjustments current tax expense deferred tax credit total tax expense ifrs usgaap adjustment respect current tax expense includes million million million groups share tax expense associates recognised taxation charge income statement usgaap recorded share tax profits associates income statement presented accordance ifrs e deferred taxation usgaap classification gsks deferred taxation liabilities assets us gaap follows liabilities stock valuation adjustment timing differences current deferred taxation liabilities accelerated capital allowances product rights product business disposals pensions postretirement benefits timing differences total deferred taxation liabilities assets intragroup profit stock valuation adjustment timing differences current deferred taxation assets accelerated capital allowances product business disposals pensions postretirement benefits tax losses restructuring legal disputes share option award schemes timing differences valuation allowances total deferred taxation assets net deferred taxation us gaap net deferred taxation ifrs ifrs usgaap adjustment gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued f pensions postretirement costs usgaap uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs disclosures include additional information required sfas r pension costs uk us major overseas defined benefit pension plans restated following tables accordance us gaap minor retirement plans pension costs million million million recalculated accordance requirements sfas excluded net periodic pension cost major retirement plans service cost interest cost expected return plan assets amortisation prior service cost amortisation transition obligation amortisation net actuarial loss net periodic pension cost us gaap termination benefits curtailment costs major assumptions used computing pension costs pa pa pa rates future pay increases discount rate expected longterm rates return plan assets aggregate average international plan assumptions vary significantly us assumptions estimated future benefit payments gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued change benefit obligation benefit obligation atst january amendments service cost interest cost plan participants contributions actuarial loss benefits paid termination benefits curtailment costs exchange adjustments benefit obligation atst december benefit obligation atst decemberfor pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation st december million st december million change plan assets fair value plan assets atst january actual return plan assets employer contributions plan participants contributions benefits paid exchange adjustments fair value plan assets atst december fair value plan assets end year pension plans accumulated benefit obligations excess plan assets plan assets consist primarily investments uk overseas equities fixed interest securities indexlinked securities property st december uk equities included million gsk shares million shares market value million million analysis percentage total plan assets major category disclosed note analysis includes assets valued million minor retirement plans excluded tables funded status funded status unrecognised net actuarial loss unrecognised prior service cost unrecognised transition obligation net amount recognised amounts recognised statement financial position prepaid benefit cost accrued pension liability intangible asset accumulated comprehensive income net amount recognised gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued postretirement healthcare usgaap postretirement healthcare costs uk us major overseas postretirement healthcare schemes restated following tables accordance usgaap minor healthcare plans costs million nil million recalculated excluded net healthcare cost service cost interest cost amortisation prior service cost amortisation net actuarial loss net healthcare cost major assumptions used calculating net healthcare cost pa pa pa rate future healthcare inflation discount rate rate future healthcare inflation reflects fact benefits certain groups participants capped change benefit obligation benefit obligation atst january service cost interest cost plan participants contributions actuarial loss benefits paid exchange benefit obligation atst december change plan assets fair value plan assets atst january employer plan participants contributions benefits paid fair value plan assets atst december funded status funded status unrecognised net actuarial loss unrecognised prior service cost accrued postretirement healthcare cost decrease increase impact variation rate future healthcare inflation effect total service interest cost postretirement healthcare effect obligation postretirement healthcare medicare gross subsidy net estimated future benefit payments gsk annual report stnemetats laicnanifstnemetats laicnanif notes financial statements continued principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group stdecember details given principal country operation location headquarters business segment business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary undertaking segment activity england brentford glaxosmithkline holdings onelimited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limited ph h greenford glaxo operations uk limited ph p brentford glaxo wellcome international bvi phch h brentford glaxo wellcome investments bvi phch h stockley park glaxo wellcome uk limited ph h p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uklimited ph p brentford smithkline beecham investments limited phch f brentford smithkline beecham swg limited ch e brentford smithkline beecham research limited ph brentford staffordmiller limited ch p greenford wellcome foundation limited ph p austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph e p r rixensart glaxosmithkline biologicals manufacturing sa ph h guernsey st peter port smithkline beecham limited phch denmark ballerup glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch germany buehl glaxosmithkline consumer healthcare gmbh cokg ch h p r munich glaxosmithklinepharmagmbh ph h greece athens glaxosmithkline aebe phch h hungary budapest glaxosmithklinemedicine healthcare products limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare sp ch h luxembourg mamer glaxosmithkline international luxembourg sa phch f h gsk annual report stnemetats laicnanif notes financial statements continued principal group companies continued europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p warsaw glaxosmithkline consumer healthcare spzoo ch e portugal lisbon glaxosmithklineprodutos farmaceuticos limitada ph republic dublin glaxosmithkline consumer healthcare ireland limitedii ch ireland carrigaline smithkline beecham cork limitedii ph p carrigaline smithkline beecham manufacturinglimitedii ph p spain tres cantos glaxosmithklinesa ph mp alcala de henares smithkline beecham sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch h muenchenbuchsee glaxosmithkline ag ph zug adechsa gmbh ph e usa usa philadelphia smithkline beecham corporation phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h p wilmington glaxosmithkline financial inc ph f wilmington glaxosmithkline holdings americas inc phch h americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc phch p r vancouver idbiomedical corporation ph p r asia pacific australia boronia glaxo wellcome australia pty ltd phch e p r china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ph p r india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limitediii ch p malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan limited ph p gsk annual report notes financial statements continued principal group companies continued japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk phch p r latin america argentina buenos aires glaxosmithkline argentina sa phch p brazil rio de janeiro glaxosmithkline brasil ltda phch p colombia bogota glaxosmithkline colombia sa phch mexico delegacion tlalpan glaxosmithkline mexicosade cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph san juan sb pharmco puerto rico inc ph p venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty ltd phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa location associated undertaking business usa teterboro quest diagnostics incorporatediv clinical testing incorporated netherlands ii exempt provisions section companies amendmentact ireland iii consolidated subsidiary undertaking accordance section companies act grounds dominant influence iv equity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business segment ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r researchs service full details group subsidiary associated undertakings attached companys annual return filed registrar ofcompanies stnemetats laicnanif gsk annual report notes financial statements continued transition ifrs ifrs adjustments summary principal differences uk gaap ifrs background apply togskis set financial effect shown ifrs project pagesto june council european union adopted customer allowances regulation requiring listed companies member states prepare adjustment reclassification turnover expenses consolidated financial statements accordance profit cash flow effect ifrs detailed rules relation international financial reporting standards ifrs certain marketing promotional expenditure glaxosmithkline annual report year ending st deducted turnover rather recorded expense however december first annual report prepared ifrs rules exist us gaap eitf accounting consideration given vendor customer requires earliest year full ifrs financial statementsare marketing advertising promotion payments made customers presented annual report transition date ifrs deducted turnover significant impact glaxosmithkline st january normallyaccounting changes consumer healthcare business payments large retailers nature would require full retrospective application gsk instore advertising preferential shelfspace product listings etc taken advantage exemptions available ifrs transitional commonplace rulesto applycertainrequirementsonlywith effect transition date st january case financial instruments gskbelieves reflects best practice revenue recognition st january hence absence detailed guidance ifrs decided adopt revenue recognition policy ifrs line financial instruments eitf thereforethereis expected anydifference gsk adopted ias endorsed european union turnover reported ifrs turnover reported however one exemptions available ifrs relaxes us gaap adjustment impact profit tax eps requirement comparative information presented annual report comply ias ias glaxosmithkline sharebased payments taken advantage exemption financial thepreviousuk gaap approach sharebased paymentswasto instruments accounted presented uk gaap basis record intrinsic loss grant suffered company means share options granted market price therewasno st january adjustment million charge income statement shares options opening balance sheet reflect movements uk gaap granted cost employee eg longterm incentive carrying values ias values many financial plans income statementwascharged amount equal instruments fair value market price date award spread financial instruments concerned performance period usually three years held fair value ifrs movements recorded equity ifrs sharebased payment ukgaap equivalent frs equity investments sharebased payment came force liquid investments require fair value equity instruments issued charged derivatives classified cash flow hedging instruments income statementthe grouphas chosen recognise unvested options awards retrospectively held fair value ifrs movements recorded income statement gsk receives tax credit appropriate relates share equity collar linked groups investment quest diagnostics options awards exercised based gains holders inc make dependent tax rules country put call options linked groups strategic alliance deduction claimed deferred tax asset represents estimate theravance inc future tax relief gain based potential gains derivatives classified hedging instruments including available option award holders balance sheet date embedded derivatives movement deferred tax asset one balance sheet derivatives classified fair value hedges together next may result either tax credit tax charge recorded hedged element relevant asset liability income statementthe amount tax credit recognised income statement capped cumulative amount tax presentation differences effect sharebased payment charge excess credit taken nonequity minority interests repaid equity ias valuation rules applied would adjustment reducedprofit tax million charge profit tax largest elements million earnings million million arise quest collar million million eps pence pence theravance put call options million nil valuations inherently unpredictable changes fair values financial instruments could material impact future results financial position gsk stnemetats laicnanif gsk annual report notes financial statements continued transition ifrs continued pensions postemployment benefits glaxosmithkline accountedunder uk gaap pensions thesharebased payments chargereducedtoamore normal level postemployment benefits opebs accordance ssap millionin considerably higher charge spreadthe costs providing benefits estimated average arises two main factors relatively share options service lives employees granted gwsb merger finalised full catchup grant early year ias employee benefitsrecognises surpluses deficits followed normal annual grant november addition accounts accordance transitional provisions ifrs grants made average share price excess surpluses deficits recognised full balance share optionsbecame exercisable therefore sheet transition date st january addition following fellout charge nowreflectsmore current share amendment ias issued iasb december prices normal grant levels permitted recognise movements surpluses deficits immediately balance sheet outside income statement coreg capitalisation amortisation statement recognised income expensethis means north american rights coregwere acquired time cases balance sheet reflects full surplus deficit gwsb merger partial consideration required disposal positions funds kytril roche uk gaap accounted exchange assets value attributed coregon groups policy charge operating businesses balance sheet ifrs however requires acquired rights coregto service cost element pension charge gets reported added intangible assets fair value date within cost sales selling general administrative expenditure acquisition million amortised remaining research development appropriate charge useful life eight years adjustment reduces profit element related funding deficit reported inselling tax million million eps pence general administrative expenditure ias service pence cost element total charge considerably higher ssap funding deficit element lower thishas ledto intangible assets amortisation additional reclassification adjustment income statement uk gaap gskamortisedintangible assets estimated expense headings expected useful lives acquisition whichwasup maximum years ifrs permits amortisation commence overall impact adjustments pensions opebs asset becomes available use annual impairment testing wasa decrease profit tax million increase required point gskhas determined point million decrease eps pence nil amortisation productrelated assets commences ifrs share profits associates normally regulatory approval majority groups ukgaap share profits associateswasreported within intangible assets relates acquisition rights compounds profit tax group however ifrs requires share development reached point amortisation profits net profit attributable group ie interest commences led reduction amortisation charge tax minority interests associate led likely reverse future compounds reach reclassification adjustment removing share associates regulatory approval amortisation charged shorter interest tax minority interests lines income period profit tax increasedby million statement netting together share profits million eps pence pence associates line adjustment reduced profit tax goodwill amortisation million million butdidnot affect eps uk gaap required goodwill amortised estimated deferred tax intercompany profit expected useful life gskhad determined normally uk gaap deferred tax provision intercompany profit longer years ifrs however goodwill considered held inventory calculated supplying companys effective tax indefinite life amortised subject annual rate ifrs however takes balance sheet approach recognition impairment testing adjustment therefore reverses goodwill deferred tax results tax rate company holding amortisation charged uk gaap including recorded inventory balance sheet date applied provision profit share associates line relating acquisition proportions groups inventory held specific locations groups interest quest diagnostics inc business change significantly one balance sheet date next combinations exemption ifrs goodwill previously written could significant change value deferred tax asset direct reserves uk gaap recycled income reflected tax charge year statement disposal partdisposal subsidiary associate would uk gaap adjustment increases profit tax million million eps pence pence stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued transition ifrs continued amortisation goodwill ukgaap prior date transition ifrs st january reversed adjustments accordingly goodwill recognised ifrs balance sheet lower number minor adjustments reclassifications respect would gsk taken including advantage business combinations exemption computer software recorded intangible asset unless sharebased payments ifrs sharebased payment applies forms integral part operating system tangible fixed equity instruments share options granted since th asset november glaxosmithkline elected adopt full deferred tax brands acquired company retrospective application standard difference fair value brands acquisition financial instruments financial instruments comparative tax value taxable temporary difference arises periods presented annual report ie cash equivalents reclassification liquid investments arerecognised measuredon theuk gaap basisapplicable maturities less three months acquisition included years rather accordance ias financial within cash cash equivalents instruments recognition measurementas result certain derivative instruments recognised comparative provisions reclassification elements provisions expected periods ifrs hedge accounting applied comparative paid within one year balance sheet date periods hedged borrowings recorded amortised cost rather exception pensions opebs presented within current fair value also availableforsale financial assets liabilities equity investments liquid investments recorded cost less cash flow statement impairments rather fair value move ukgaap ifrs change cash flows group ifrs cash flow format similar ukgaap presents various cash flows different categories different order ukgaap cash flow statement ifrs accounting adjustments net within cash generated operations except intangible assets reclassification inclusion liquid investments maturity less three months acquisition together related exchange adjustments within cash cash equivalents ifrs ifrs exemptionsand elections ifrs firsttime adoption international financial reporting standards permits companies adopting ifrs first time take exemptions full requirements ifrs transition period make elections apply ifrs full retrospective effect required gskhas adopted following key exemptionsand elections business combinations business combinations prior transition date st january restated onto ifrs basis merger glaxo wellcomeand smithkline beecham restated onto ifrs basis would accounted acquisition fair value adjustments net assets acquired company would required including recognition significant intangible asset balances product rights relating marketed products inprocess rd recognised merger accounting significant goodwill balance would also recorded goodwill writtenoff reserves prior old ukgaap written back goodwill business combinations exemption taken additional goodwill balances relating acquisitions prior would havebeen recognised ifrs balance sheet gsk annual report notes financial statements continued transition ifrs continued ifrs consolidated income statement months months uk gaap adjustments ifrs ukgaap adjustments ifrs turnover cost sales gross profit selling general administration research development operating income operating profit finance income financecosts share profitslosses associates joint ventures profit disposal interests associates profit taxation taxation lossprofit disposal businesses profit taxation year profit attributable minority interests profit attributable shareholders earnings per sharepence p p p p p p diluted earnings per sharepence p p p p p p ifrs consolidated statement recognised income expense st december st december ukgaap adjustments ifrs ukgaap adjustments ifrs exchange movements overseas net assets tax exchange movementsand unrealised gains goodwill written back revaluation goodwill due exchange unrealisedlossprofiton disposal intellectual property actuarial gainslosses defined benefit plans deferred tax actuarial movements ondefinedbenefit plans net lossesgainsrecognised directly equity profit year total recognised income expense year gsk annual report stnemetats laicnanifnotes financial statements continued transition ifrs continued ifrs consolidated balance sheet st december st december ukgaap adjustments ifrs ukgaap adjustments ifrs noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax provision pensions postemployment benefits provisions noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests totalequity gsk annual report stnemetats laicnanifnotes financial statements continued transition ifrs continued analysis ifrs adjustments income statement year ended st december share intangible share customer based coreg assets goodwill pensions profits ifrs allowances payments amortisation amortisation amortisation opebs associates adjustments turnover cost sales gross profit selling general administration research development operating income operating profit finance income financecosts share profitslosses associates jointventures profit disposal interests associates profit taxation taxation profit disposal businesses profit taxation year profit attributable minority interests profit attributable shareholders earnings per sharepence p p p p p p p reconciliation opening equity component equity st january share total share premium retained shareholders minority total capital account reserves earnings equity interests equity uk gaap ifrs adjustments net tax pensions deferred profit stock dividends deferred tax onindefinite life assets coreg intangible assets sharebased payments tax sharebased payments total ifrs adjustments ifrs gsk annual report stnemetats laicnanifnotes financial statements continued transition ifrs continued analysis ifrs balance sheet adjustments st december coreg capitalisation intangible goodwill dividend sharebased assets amortisation pensions ifrs deferred payments amortisation amortisation reversal opebs adjustments noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax provision pensions postemployment benefits provisions noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings group holds us patents relating advairwhich affected reissue application including compound patent group involved significant legal administrative related active ingredient salmeterol affords protection proceedings principally product liability intellectual property tax anti august giving effect expected grant trust governmental investigations related private litigation paediatric exclusivity fdaandvarious patents relating group makes provision proceedings regular basis diskusdevice expire period summarised notesand group may make additional significant provisions legal proceedings required avandia avandamet event developments matters consistent august group filed action us district court generally accepted accounting principles litigation particularly district new jersey teva pharmaceuticals usa inc usa inherently unpredictable excessive awards may infringement groups patent relating maleate salt form justified evidence may occur group could future rosiglitazone active ingredient avandia expires incur judgments enter settlements claims could result september group filed comparable action payments exceed current provisions amount court dr reddys laboratories alleging infringement would material adverse effect groups financial patent actions filed response condition results operations andor cash flows abbreviated new drug application anda filings fda dr reddys laboratories teva certifications groups intellectual property claims include challenges validity maleate salt patent invalid fda approval andas stayed groups patents various products processes assertions earlier november resolution respective noninfringement patents loss cases could patent infringement actions result loss patent protection product issue consequences loss could significant decrease sales teva subsequently filed additional certification challenging product could materially affect future results operations validity groups basic compound patent rosiglitazone group january group commenced action teva court infringement patent basic compound legal expenses incurred provisions related legal claims patent currently expires giving effect patent term charged selling general administration costs provisions restoration paediatric exclusivity made taking appropriate legal advice reasonable estimate made likely outcome dispute january group filed action us district court group established actuarially determined provision product district new jersey teva infringement liability claims incurred yet reported described note two patents basic compound maleate salt patents st december groups aggregate provision legal rosiglitazone teva filed anda fda generic disputes including tax matters described version avandametwith certification patents invalid taxation note billion ultimate liability infringed fda approval anda stayed earlier legal claims may vary amounts provided dependent june resolution patent infringement action since upon outcome litigation proceedings investigations avandametis protected patents avandia earlier possible settlement negotiations holding invalidity avandiacases would dispositive avandametas well significant matters described imitrex intellectual property december group commenced action us district advair court southern district new york dr reddys september group applied us patent laboratories alleging infringement one two primary trademark office uspto reissue combination patent compound patents sumatriptan active ingredient imitrex advair inhaled combination salmeterol fluticasone patent issue affords protection february propionate expires september followed giving effect grant paediatric exclusivity fda internal review concluded language patent may defendant filed anda fda sumatriptan oral accurately describe circumstances invention tablets certification invalidity compound patent may claim invention precisely could objective certify invalidity noninfringement theothercompound seeking reissuance strengthen protection afforded patent expires june giving effect paediatric patent january uspto issued final office action exclusivity rejecting application group seek reconsideration rejection response uspto expected first half march group commenced infringement action year application reissue remains pending cobalt pharmaceuticals transferred us patent remains force listed register pharmaceutical district court southern district new york defendant patents maintained us food drug administration fda filed anda forsumatripan oral tablets certification orange book invalidity noninfringement compound patent issue dr reddys case final pretrial conference consolidated dr reddys cobalt case scheduled may gsk annual report stnemetats laicnaniflegal proceedings continued group filed actions apotex us district court eastern district pennsylvania february group commenced infringement action infringement additional groups patents december us district court district delaware spectrum judge granted part denied part summary pharmaceuticals defendant filed anda injectable judgment motions filed apotex result issues validity sumatriptan certification invalidity noninfringement infringement three fouradditionalpatents remained compound patent issue dr reddys cobalt trial july judge certified patent cases trial date case set november held invalid appeal tothe cafcin february cafc affirmed judges ruling invalidity patent lamictal august group commenced action us district group also commenced actions us district court court district new jersey teva pharmaceuticals usa eastern district pennsylvania geneva alphapharm andrx inc alleging infringement groups compound patent pharmaceuticals zenith teva pharmaceuticals connection lamotrigine active ingredient lamictaloral tablets patent anda filings paxiland basf sumika fine chemicals affords protection january giving effect grant connection supply paroxetine hydrochloride use paediatric exclusivity fda teva filed anda andas lawsuits settled stayed pending resolution fda certification invalidity groups patent parties appeals apotex caseapotex launched generic product reached settlement agreement pursuant group usa september additional generic products granted teva exclusive royaltybearing license distribute launched defendants march usa generic version lamotrigine chewable tablets addition groups us patent litigation synthon bv settled teva granted exclusive right manufacture sell tevas december enabling us marketing synthons paroxetine generic version lamotrigine tablets usa mesylate product followed settlement august expected launch date groups nonus patent litigation synthon paxilseroxat consequence synthon free market paroxetine usa number distributors generic drugs filed applications mesylate product many markets globally obtained fda market generic versions paxilseroxatparoxetine marketing authorisations resolution damages respect several hydrochloride prior expiration giving effect country markets remains outstanding paroxetine mesylate grant paediatric exclusivity fda groups patent different salt form paroxetine used marketed form paroxetine hyrdrochloride hemihydratethesedistributors sought seroxatpaxil certain markets litigation synthon ongoing bring market anhydrate versions paroxetine synthon asserting counterclaims unfair competition hydrochloride one case paroxetine mesylate response group group filed actions distributors infringement generic products containing anhydrate form paroxetine various groups patents basis generic anhydrate hydrochloride market european countries versions infringe contain andor convert whilst products subject continuing litigation hemihydrate form andor infringe group patents actions settled expected july gsk filed action apotex us district settled future uk litigation several years standing court northern district illinois infringement group apotex culminated appeal court groups patent paroxetine hydrochloride hemihydrate apotex decision groups anhydrate process patent valid filed anda fda seeking approval introduce generic infringed result litigation apotex enjoined form paxil following trial february judge ruled gsks launching product one year market patent valid infringed apotexs product groups damages enquiry relating injunction ongoing settlement appealthe us court appeals federal circuit cafc damages claim reached one apotexs local hears appeals us district courts patent matters ruled distributors groups patent infringed invalid based upon public use paxil cr clinical trials prior filing date usa group filed november mylan pharmaceuticals filed anda paxil cr petition cafc rehearing appeal full court paroxetine hydrochloride controlled release formulation april full cafc vacated judgment remanded certification invalidity noninfringement several patents listed matter panel concurrently entry decision fda orange book certification invalidity panel issued new opinion ruling patent invalid noninfringement patent covering paroxetine hydrochloride alternative theory groups request rehearing full hemihydrate mylan admitted active ingredient court panels new decision denied group filed product patent expires june giving effect grant petition review us supreme court paediatric exclusivity fda group file patent infringement action mylan within day period provided hatchwaxman month stay fda approval mylan anda conduct patent litigation gsk annual report stnemetats laicnanif notes financial statements continuednotes financial statements continued legal proceedings continued zofran august group commenced action us district requip court district new jersey reddycheminor dr april group commenced action us district reddys laboratories dr reddy certified invalidity three patents court district delaware teva pharmaceutical usa ondansetron active ingredient zofrantablets including inc alleging infringement groups compound patent compound patent expired july two method use ropinirole hydrochloride active ingredient requip patents later expires december method use patent treatment parkinsons disease instances taking account extension paediatric exclusivity listed fda orange book compound patent july group filed action dr reddys laboratories expires december method use patent may district court infringement groups patents defendant filed anda fda certification related orally disintegrating tablet presentation zofran invalidity noninfringement patents fda approval october group filed action westward anda stayed earlier august resolution pharmaceuticals inc district court infringement patent infringement action case progressing groups patents related injectable presentation zofran discovery stage dr reddy disintegrating tablet case westward case valtrex consolidated earlier dr reddy case may group commenced action us district prior trial reddycheminor westward withdrew court district new jersey ranbaxy laboratories challenge compound patent trial infringement alleging infringement groups compound patent valaciclovir validity groups method use process patents active ingredient valtrex patent expires completed june closing arguments heard may defendant filed anda fda certification date report decision groups compound patent invalid infringed august announced ranbaxy filed motion partial summary judgment grounds patent invalid public use march group filed similar action teva one year filing patent application pharmaceuticals usa inc us district court district group filed motion patent invalid delaware alleging infringement two method use patents groundsin march court ruled groups favour ondansetron teva certified invalidity noninfringement patent invalid grounds discovery substantially two method use patents teva challenge compound completed patent trial judge ruled groups favour upholding validity method use patents following appeal teva wellbutrin xl cafc parties reached settlement agreement terms december biovail commenced actions us district court confidential central district california anchen pharmaceuticals us district court southern district florida january group commenced action kali abrika pharmaceuticals case alleging infringement biovail laboratories par pharmaceutical company us district formulation patents wellbutrin xl april biovail filed court district new jersey involving orally disintegrating action us district court eastern district pennsylvania zofrantablets trial judge denied kalis summary judgment motion impax laboratories infringement patents granted groups summary judgment motions june patents expire anchen abrika impax july affirming validity groups method use filed anda fda certification invalidity non patents holding kalis proposed generic product would infringement biovail patents group licensee infringe patents kali filed notice appeal cafc patents hearing abrikas motion summary judgment ruling date report hearing date heard november date report appeal announced decision announced trial date biovails action june group commenced action us district anchen set th september group court district new jersey faulding party actions september biovail commenced pharmaceutical company mayne pharma inc alleging actions us district court southern district new york infringement two method use patents ondansetron watson laboratories alleging infringement biovail faulding challenge compound patent case formulation patents group remains third party counterclaim date report stayed pending decisions defendant based listing activities associated fda orange reddywestward case book additional actions remain pending generic distributors december andrx pharmaceuticals filed action asserting products infringe groups patent group us district court southern district florida reduced crystal size ondansetron expires march alleging manufacture importation sale mg taking account extension paediatric exclusivity wellbutrin xlproduct infringes patent issued andrx june asserting invalidity noninfringement groups asking treble damages attorneys fees group compound patents emesis use patent others acting concert enjoined case early stages gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued federal cases consolidated multidistrict litigation proceeding us district court district washington productliability judge responsible proceedings denied class certification paxil struck class allegations federal personal injury group received lawsuits claims filed behalf patients consumer refund class actions class certification denied alleging suffered symptoms discontinuing treatment california state court pennsylvania state court putative class paxilparoxetine separately group received lawsuits action dismissed leaving putative class actions pending claims patients commenced paxiltreatment committed group litigation substantial number cases attempted commit suicide andor acts violence also group manufacturers defendants reached private consumer lawsuits alleging group concealed trial state federal courts manufacturers part misrepresented data paediatric clinical trials paxil received favourable outcomes trial group received lawsuits filed state federal courts baycol usa canada behalf thousands plaintiffs including august bayer ag withdrew baycolcerivastatin sodium purported class actions alleging paroxetine active ingredient worldwide light reports adverse events including deaths paxil addictive causes dependency withdrawal reactions involving rhabdomyolosis gsk participated marketing plaintiffs sought remedies including compensatory punitive baycolin usa pursuant copromotion agreement bayer statutory damages cost fund medical monitoring licence holder manufacturer product federal judge us district court central district california denied class action certifications nationwide class following withdrawal bayer gsk named california statewide class cases filed federal court defendants thousands lawsuits filed state federal courts district subsequently petition plaintiffs counsel federal usa behalf individuals putative classes former court cases transferred district court consolidation baycolusers number suits allege plaintiffs multidistrict litigation mdl january group concluded suffered personal injuries including rhabdomyolosis use settlement pending claims based baycol others claim persons took baycol although symptoms discontinuing paxiltreatment pending injured may risk future injury may suffered economic purported class actions dismissed part settlement damages purchasing using baycol plaintiffs seek remedies group part settlement admit liability including compensatory punitive statutory damages creation respect allegations suits litigation respect funds medical monitoring balance lawsuits including purported class action gsk bayer corporation principal us subsidiary bayer ag california state court continues signed allocation agreement bayer corporation group received numerous claims lawsuits alleging agreed pay settlements compensatory damages treatment paxil caused homicidal suicidal behaviour judgments party retaining responsibility exhibited users product none purport attorneys fees punitive damages federal cases class actions january fda approved black box warning consolidated multidistrict litigation proceeding us aboutsuicidal thoughts behaviourin paediatric patients district court district minnesota numerous cases strengthened warnings selective serotonin reuptake inhibitor ssri scheduled trial state federal courts datetwo products including paxil class statewide class actions certified medical monitoring case pennsylvania consumer fraud deceptive business avandia practices act case illinois medical monitoring action group received lawsuits claims filed state federal dismissed court summary judgment another class action courts usa behalf numerous patients alleging gsk named defendant certified rosiglitazone active ingredient avandia caused congestive oklahoma substantial number claims death serious injury heart failure liver damage none cases purports class settled many others alleging muscle aches pains action cases early stages voluntarily involuntarily dismissed phenylpropanolamine following report yale haemorrhagic stroke project found suggestion association first use phenylpropanolamine ppa decongestant haemorrhagic stroke group manufacturers voluntarily withdrawn consumer healthcare products ppa active ingredient since ppa product withdrawal group named defendant numerous personal injury class action lawsuits filed state federal courts alleging personal injury increased risk injury use products containing ppa unfair deceptive business practices plaintiffs seek remedies including compensatory punitive damages refunds gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued sales andmarketing andregulation marketing andpromotion fenphen february gsk received subpoena us attorneys fda became aware reports cardiac valvular office colorado regarding groups sales promotional problems individuals fenfluramine dexfenfluramine practices relating nine largest selling products period alone combination phentermine prescribed part january present particular government regimen weight reduction requested voluntary inquired alleged promotion drugs offlabel uses withdrawal fenfluramine dexfenfluramine market well group sponsored continuing medical education programmes reports cardiac valvular problems subsequent speaker events special issue boards advisory boards speaker withdrawal products fromthe market spawned numerous training programmes clinical studies related grants fees travel product liability lawsuits filed manufacturers entertainment although original subpoena issued distributors fenfluramine dexfenfluramine phentermine us attorneys office colorado scope inquiry one number manufacturers phentermine group nationwide group cooperating investigation remains defendant approximately two hundred several providing requested information group earlier responded thousand lawsuits filed various state federal district october letter fdas division drug marketing courts usa group defendants advertising communication requesting information lawsuits seek relief including combination groups alleged promotion wellbutrin srfor offlabel use compensatory punitive damages medical monitoring refunds june group pharmaceutical manufacturers purchases drugs judicial panel multidistrict received letter senate finance committee litigation issued order consolidating transferring federal committee expressed concern educational grants actions district court eastern district pennsylvania improperly used promote drug products requesting court approved global settlement proposed defendant company provide detailed information documents use wyeth sold fenfluramine dexfenfluramine settlement educational grants january group subsequently approved third circuit court appeals manufacturers received second letter committee asking include phentermine defendants including group additional information groups internal grant approval individual plaintiffs may elect opt class settlement process grants medicalphysicianprofessional organizations pursue claims individually tens thousands plaintiffs academic institutions state agencies support journal articles elected wyeth continues settle individual state court publications grants patient education advocacy cases trial group continues dismissed groups group cooperating committees investigation lawsuits settled wyeth providing requested information thimerosal nd february fda approved anda filed roxane gsk along number pharmaceutical companies laboratories generic form flonasenasal spray denied two named defendant numerous individual personal injury citizens petitions filed group concerning lawsuits state federal district courts usa alleging regulatory criteria applied determining whether thimerosal preservative used manufacture vaccines causes proposed generic products bioequivalent neurodevelopmental disorders injuries including autism quality control standards asflonase rd february usdistrict three cases purported class actions although court district maryland granted temporary restraining determination whether cases permitted order suspending fdas approval roxane andafor ten proceed class action number purported class actions days group file motion preliminary injunction jurisdictions withdrawn dismissed plaintiffs seek continue interim relief granted temporary restraining order remedies including compensatory punitive statutory damages request ruling motion temporary cost fund medical monitoring research restraining order may extended additional ten date report cases scheduled trial days expires lotronex february verona public prosecutor commenced criminal following voluntary withdrawal lotronex usa investigation gsks sales marketing practices italy specific november number lawsuits filed areas investigation include medical education programmes clinical group state federal district courts including individual personal studies congresses well interaction gsk injury actions purported class actions asserting product liability representatives physicians similar issues investigated consumer fraud claims plaintiffs seek remedies including bari public prosecutor ussecurities exchange compensatory punitive statutory damages class previously commission secstaff initiated informal investigation certified west virginia decertified action allegations group cooperating withall theseinvestigations dismissed large number claims brought following withdrawal settled lotronexwas reintroduced usa february group received subpoena sec subject risk management planimposing additional protections respect groups participation united nations oil food around prescribing dispensing lotronex programme group cooperating sec providing documents responsive subpoena gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued paxilseroxat following announcement new york state attorney generals average wholesale price officeofthe states lawsuit subsequently settled august gsk responded subpoenas office inspector alleging failure disclose data use paxilin children general us department health human services hhs adolescents similar cases purport class actions us department justice states texas california filed state federal canadian courts private connection allegations pharmaceutical companies plaintiffs group responding discovery requests cases including gsk violated federal fraud abuse laws federal false claims act respect texas california uk investigation remains pending uk medicines comparable state laws result way average wholesale price healthcare products regulatory agency mhra determine awp determined reported certain drugs way whether group complied pharmacovigilence medicare medicaid programs reimburse drugs obligations reporting data clinical trials seroxatpaxilin september group reached civil settlement us children adolescents department justice us attorney district cidra puerto rico manufacturing site massachusetts office inspector general hhs following fda inspections october november group agreed pay government civil settlement resulted observations possible deficiencies million part settlement corporate integrity agreement manufacturing practices groups manufacturing facility cidra group signed april connection prior puerto rico march fda halted distribution supplies government investigation medicaid rebate issues amended paxil cr avandamet due manufacturing issues fda address issues raised course investigation observations related certain aspects production controls process subsequent initial subpoenas several states validation laboratory investigations respective attorneys general several counties new york state cidra site engaged tableting packaging range filedcivil lawsuits state federal court gsk several gsk products primarily us market including paxil paxil cr drug companies actions claim behalf states coreg avandiaand avandamet april group reached payers behalf instate patients consumers damages agreement fda consent decree consent decree restitution due awpbased price reporting undefined set provides independent expert review manufacturing pharmaceutical products covered states medicaid programs processes site compliance fda good manufacturing addition private payer class action lawsuits filed practice gmp requirements provided consent decree gsk several federal district state courts federal cases group provided report fda deficiencies identified consolidated multidistrict litigation proceeding review setting corrective plan timetable completion us district court district massachusetts august fda inspectors recently conducted general gmp inspection judge mdl proceeding granted part denied part followup groups report january fda issued privatepayer plaintiffs motion class certification thereby form listing five observations made narrowing scope class claim fact discovery inspection group responded february proceeding closed group end august observations consistent findings independent expert discovery way discovery proceeding expert effectively already included part groups suits filed state attorneys general state courts remediation plan site group remains fully committed nominal pricing working cooperatively fda address issues timely group responded two letter requestsfrom ussenate fashion group resumed manufacture products site committee finance dated april february financial penalties imposed consent decree documents information relating nominal price exception consent decree allows potential future penalties best price reporting requirements medicaid drug maximum million year group fails meet terms rebate program activity connection thedecree inquiry committee group since september may group advised us department justice group also required post bond ensure product investigating certain groups nominal pricing previously seized fda appropriately destroyed arrangements determine whether arrangements qualify reconditioned group met requirements bond exception best price reporting requirements violate expires march civil statutes laws group cooperating thatinvestigation april group received subpoena usattorneys provided documents information department office boston requesting production records regarding justice regarding nominal pricing arrangements number manufacturing cidra site covering type information groups products collected usgovernment puerto rico gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued relafen august us district court district massachusetts antitrust ruled groups patent nabumetone relafen invalid paxilseroxat anticipatory art unenforceable grounds inequitable paroxetine patent infringement actions brought group conduct august cagc issued decision affirming described intellectual property apotex alphapharm district court judgment invalidity declining rule basfand sumike filed antitrust unfair competition judgment inequitable conduct counterclaims group usdistrict court eastern district ofpennsylvania based allegations group following district court decision antitrust claims alleging monopolised market forpaxilby bringing allegedly sham patent competitive injury overcharges filed teva eon litigation allegedly abusing regulatory procedures pharmaceuticals generic manufacturers nabumetone listing patents fdaorange book whilst apotex matter purported classes direct indirect purchasers payers remains discovery stage three actions individual retail chains aspects litigation stayed concluded exception appeal taken certain indirect purchasers trial judges order giving final approval november us federal trade commission ftc staff settlement class appeal pending us circuit advised group conducting nonpublic court appeals first circuit investigation determine whether group violating section federal trade commission act monopolizing canadian importation attempting monopolize market paroxetine hydrochloride group along eight pharmaceutical companieshas preventing generic competition paxiland requested group named seven purported class action lawsuits following submit certain information connection investigation groups actions reduce illegal importation prescription october ftc closed investigation basis drugs canada lawsuits alleged companies entered finding action warranted unlawful conspiracy prevent canadian pharmacies selling products us customers lawsuits following public reference ftc investigation regarding paxil consolidated one action us district court purported class actions filed us district court district minnesota groups motion dismiss consolidated eastern district pennsylvania behalf indirect purchasersbased action granted court decision appealed allegations similar antitrust counterclaims brought us circuit court appeals eighth circuit date apotex similar actions filed city new york report date oral argument announced eastern district pennsylvania indirect purchasers florida california minnesota pennsylvania class actions relation matter minnesota state attorney general settled class settlements approved although filed civil investigative demand subsequently complaint certain objectors appealed approval indirect purchaser alleging group violated state antitrust commercial settlement city new york action settled action laws group filed motion dismiss complaint oral minnesota one california actions dismissed argument motion completed november florida action another california action stayed date report decision announced group also settled similar threatened claims group group also named defendant along thirteen chain drug stores conditionally settled threatenedclaims drug companies state court action california state attorneys general remains seen many states plaintiffs independent pharmacies allege defendants join settlementsimilar class actions filed unlawfully conspired keep prices artificially high usa provincial courts canada behalf direct indirect purchasers detriment plaintiffs parties involved extensive cases early stages discovery trial date set th september october competition directorate european wellbutrin sr commission initiated inspection concerning allegations december january february lawsuits several group abused dominant position marketplace concerning purported class actions filed us district enforcement intellectual property rights litigation surrounding court eastern district pennsylvania group regulatory approvals marketing seroxatin europe group behalf direct indirect purchasers wellbutrin sr cooperating fully commission complaints allege violations us antitrust laws sham litigation fraud patent office group obtaining enforcing patents covering wellbutrin sr complaints follow introduction generic competition wellbutrin srin april district appellate court rulings generic manufacturer infringe groups patents oral argument groups motion dismiss completed february date report decision announced gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued commercial corporate relenza may biota holdings limited filed complaint victorian supreme court australia alleging group failed tofulfil development promotion production obligations zanamivir relenza terms licence agreement group biota biota seeking substantial cash damages group believes adhered obligations licence agreement parties involved extensive discovery securities class action september attorneys representing purported class purchasers gsk shares american depositary shares adss filed second amended securities class action complaint group us district court southern district new york alleging group violated us securities laws failure disclose unfavourable clinical data studies paxil misrepresentation remaining patent protection paxiland augmentinand violation federal false claims act basis groups recent awp settlement government group filed motion dismiss environmental matters gsk notified potential responsibility relating past operations past waste disposal practices certain sites primarily usa matters subject litigation including proceedings initiated us federal state governments waste disposal site remediation costs tort actions brought private parties gsk advised may responsible party approximately sites appear national priority list created comprehensive environmental response compensation liability act superfund proceedings seek require operators hazardous waste facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs instances gsk involved alleged generator hazardous waste although sites gsk involved current former operator facility although superfund provides defendants jointly severally liable cleanup costs proceedings frequently resolved basis nature quantity waste disposed site generator gsks proportionate liability cleanup costs substantially determined sites referred gsks potential liability varies greatly site site cost investigation study remediation sites could time substantial gsk routinely accrues amounts related share liability matters tax matters pending tax matters including disclosure tax liability billion billionare described note taxation gsk annual report stnemetats laicnanifdirectors statements responsibility directors statement responsibility relation going concern basis companys financial statements making enquiries directors reasonable directors expectationthat company adequate resources continue operational existence foreseeable future forthis reason responsible ensuring maintenance proper accounting continue adopt going concern basis inpreparing financial records disclose reasonable accuracy financial statements position company time financial statements prepared comply companies combined code act board considers glaxosmithkline plc applies principles required law prepare financial statements financial combined code corporate governance financial period give true fair view state affairs reporting council asdescribed corporate governance company end financial period ofthe profit pages complied provisions except loss period described pages responsible also ensuring operation systems required listing rules financial services authority internalcontrol taking reasonable steps safeguard auditors haveconsidered directors statement compliance assets company preventing detecting fraud relation points combined code specified irregularities theirreview balance sheet year ended st december supporting notes set pagestoof report directors confirm suitable accounting policies consistently applied preparation financial statements supported reasonable prudent judgements estimates asnecessary applicable accounting standards followed financial statements prepared going sir christopher gent concern basis chairman st march responsibilities auditors relation financial statements set independent auditors report annual report published hardcopy printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different directors remuneration remuneration report pages sets remuneration policies operated glaxosmithkline disclosures directors remuneration disclosable information relating directors officers interests prepared accordance companies act complies section b combined code corporate governance gsk annual report stnemetats laicnanif glaxosmithkline plcgsk annual report stnemetats laicnanif glaxosmithkline plc independent auditors report members glaxosmithkline plc audited parent company financial statements basis audit opinion glaxosmithkline plc year ended st december conducted audit accordance international standards comprise balance sheetand related notes parent auditing uk ireland issued auditing practices board company financial statements prepared audit includes examination test basis evidence relevant accounting policies set therein also audited amounts disclosures parent company financial information directors remuneration report described statements part directors remuneration report audited audited also includes assessment significant estimates judgments made directors preparation parent reported separately group financial statements company financial statements whether accounting policies glaxosmithkline plc year ended st december appropriate companys circumstances consistently applied respective responsibilities directors auditors adequately disclosed directors responsibilities preparing annual report planned performed audit obtain directors remuneration report parent company financial information explanations considered necessary statements accordance applicable law united kingdom order provide us sufficient evidence give reasonable accounting standards united kingdom generally accepted assurance parent company financial statements part accounting practice set statement directors directors remuneration report audited free responsibilities material misstatement whether caused fraud irregularity responsibility audit parent company financial statements error forming opinion also evaluated overall part directors remuneration report audited adequacy presentation information parent company accordance relevant legal regulatory requirements financial statements part directors remuneration international standards auditing uk ireland report report audited including opinion prepared opinion companys members body accordance section opinion companies act purposewe giving opinion accept assume responsibility purpose parent company financial statements give true fair view person report shown whose accordance united kingdom generally accepted accounting hands may come save expressly agreed prior consent practice state companys affairs st december writing report opinion whether parent company parent company financial statements part financial statements give true fair view whether directors remuneration report audited properly parent company financial statements part directors prepared accordance companies act remuneration report audited properly prepared accordance companies act also report opinion directors report consistent parent company financial statements company kept pricewaterhousecoopers llp proper accounting records received chartered accountants registered auditors information explanations require audit london information specified law regarding directors remuneration st march transactions disclosed read information contained annual report consider whether isconsistent audited parent company financial statements information comprises onlythejoint statement chairman chief executive financial summary description business corporate governance statementand operating financial review prospectswe consider implications report become aware apparent misstatements material inconsistencies parent company financial statements responsibilities extend informationcompany balance sheet uk gaap atst december restated notes investmentin subsidiary companies fixed assets debtors e cash bank current assets creditors amounts due within one year f net current liabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board onst march sir christopher gent chairman gsk annual report stnemetats laicnanif glaxosmithkline plcgsk annual report stnemetats laicnanif glaxosmithkline plc notes company balance sheet uk gaap atst december apresentation financial statements taxation current tax provided amounts expected paid applying description business tax rates enacted substantially enacted glaxosmithkline plc parent company gsk major global balance sheet date healthcare group engaged creation discovery development manufacture marketing pharmaceutical company accounts taxation deferred accelerated products including vaccines overthecounter otc medicines reason timing differences originated reversed healthrelated consumer products balance sheet date deferred tax assets recognised extent considered recoverable future taxable preparation financial statements profits financial statements drawn accordance uk generally accepted accounting principles ukgaap uk deferred tax measured average tax rates expected accounting presentation st december comparative apply periods timing differences expected figures st december reverse deferred tax liabilities assets discounted permitted companies act profit loss cnew accounting policies account company presented annual report accounting standards board asb issued financial reporting accounting convention standards stanard frs share based payments april although balance sheet prepared using historical cost company incur charge standard issuance convention complies applicable uk accounting standards company subsidiaries grant companys accounting principles policies options represents additional capital contributions company preparation balance sheet conformity generally subsidiaries additional investment subsidiaries results accepted accounting principles requires management corresponding increase shareholders equity additional capital make estimates assumptions affect reported amounts contribution based fair value grant issued allocated assets liabilities disclosure contingent underlying grants vesting period assets liabilities date balance sheet actual amounts theasb issuedfrs events balance sheet date may could differ estimates standard replacedstatement standard accounting balance sheet prepared accordance practice accounting post balance sheet events main companys accounting policies approved board described effect change prohibit recording provision note b proposed dividend dividend declared balance sheet date frs applicable accounting periods beginning baccounting policies st january therefore final dividends recognised profit loss account shareholders foreign currency transactions approved amount interim dividends recognised foreign currency transactions recorded exchange rate ruling paid date transaction forward rate hedged forward exchangecontract foreign currency assets liabilities year company also adopted frs effects translated rates exchange ruling balance sheet date changes foreign exchange rates frs financial instruments forward rate disclosure presentation frs financial instruments measurement frs corresponding amounts adoption dividends paid received standards material impact companys dividends paid received included accounts period balance sheet related dividends actually paid received expenditure expenditure recognised respect goods services received supplied accordance contractual terms provision made obligation exists future liability respect past event amount obligation reliably estimated investments subsidiary companies investments subsidiary companies held cost less provision permanent diminution valuenotes company balance sheet uk gaap st december dfixed assets restated shares glaxosmithkline finance plc shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited capital contribution relating share based payments subsequent yearend company formed new subsidiary glaxosmithkline holdings limited sold entire share holding glaxosmithkline finance plc glaxosmithkline holdings limited issued new shares company consideration edebtors amounts due within one year corporate tax amounts owed group undertakings fcreditors restated amounts due within one year dividends payable amounts owed group undertakings creditors gshare capital share premium account share ordinary shares p premium number share capital authorised st december st december share capital issued fully paid st january issued share option schemes purchased cancelled st december issued share option schemes st december st december st december number shares issuable outstanding options number unissued shares option st december issued share capitalshares held esop trust shares held treasury shares andshares free issue issued shares fully paid stnemetats laicnanif glaxosmithkline plc gsk annual report gsk annual report stnemetats laicnanif glaxosmithkline plc notes company balance sheet uk gaap st december profit hreserves reserves loss account total restated restated restated atstjanuary previously reported prior year adjustment implementation frs prior year adjustment implementation frs atstjanuary profit attributable shareholders dividends shareholders ordinary shares purchased cancelled ordinary shares purchased held treasury shares capital contribution relating share based payments st december profitattributable shareholders dividends shareholders ordinary shares purchased held treasury shares capital contribution relating share based payments st december profit glaxosmithkline plc year million million dividends million million gave retainedlossof million profit million cost shares purchased cancelled nil millionandshares purchased held treasury shares million million profit loss account reserve st december stood million million million unrealised millionnoitamrofni rotsevni investor information section includes financial record presenting historical information analysed accordance current reporting practice transition date ifrs gsk st january therefore information included five year record accordance ifrs information accordance ukgaap provide link ifrs uk gaapinformation presented also ukgaap accounting policies used preparation ukgaap information disclosed annual report information prepared ifrs directly comparable information prepared uk gaap fiveyearrecord also presents information accordance us gaap section also discusses shareholder return form dividends share price movements provides information shareholders financial record quarterly trend five year record shareholder information taxation information shareholders gsk annual report financial record quarterly trend gsk annual report noitamrofni rotsevni unaudited analysis provided quarter group results sterling financial year analysis comprises statutory results pharmaceutical sales therapeutic area income statement months q cer cer turnoverpharmaceuticals consumer healthcare total turnover cost sales selling general administrative expenditure research development expenditure operating income operating profit finance income financecosts share tax profitslosses joint ventures associated undertakings profit disposal interests associates profit taxation taxation tax rate profitafter taxation period profit attributable minority interests profit attributable shareholders earnings per share p p diluted earnings per share p pfinancial record continued gsk annual report noitamrofni rotsevni q q q cer cer cer p p p p p pfinancial record continued gsk annual report noitamrofni rotsevni pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es xr zinnatceftin metabolic avandia avandamet bonvivaboniva vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover includes copromotion incomefinancial record continued pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es xr zinnatceftin metabolic avandia avandamet bonvivaboniva vaccines hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover includes copromotion income gsk annual report noitamrofni rotsevnifinancial record continued gsk annual report noitamrofni rotsevni pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es xr zinnatceftin metabolic avandia avandamet bonvivaboniva vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover includes copromotion incomefinancial record continued pharmaceutical turnover international q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir ageneraselexiva epzicomkivexa herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es xr zinnatceftin metabolic avandia avandamet bonvivaboniva vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover includes copromotion income gsk annual report noitamrofni rotsevnifinancial record continued five year record record financial performance provided analysed accordance current reporting practice transition date ifrs glaxosmithkline st january therefore information included fiveyearrecord accordance ifrsas adopted use european unionfor gsk differences ifrs adopted use european union full ifrs published international accounting standards boardthe information accordance ukgaap provide link ifrs uk gaap information also presented uk gaap accounting policies used preparation uk gaap information disclosed annual report information prepared ifrs directly comparable information prepared uk gaap fiveyearrecord also presents information accordance us gaap turnover business segment ifrs pharmaceuticals consumer healthcare turnover business segment ukgaap pharmaceuticals consumer healthcare pharmaceutical turnover therapeutic area ifrs respiratory central nervous system antibacterials antivirals metabolic vaccines oncology emesis cardiovascular urogenital others pharmaceutical turnover therapeutic area ukgaap respiratory central nervous system antibacterials antivirals metabolic vaccines oncology emesis cardiovascular urogenital others pharmaceutical turnover geographic area ifrs usa europe international asia pacific japan middle east africa latin america canada international gsk annual report noitamrofni rotsevnifinancial record continued pharmaceutical turnover geographic area ukgaap usa europe international asia pacific japan middle east africa latin america canada international pharmaceutical turnover includes copromotion income consumer healthcare turnover ifrs otc medicines oral care nutritional healthcare consumer healthcare turnover ukgaap otc medicines oral care nutritional healthcare financial results ifrs turnover operating profit profit taxation profitafter taxation basic earnings per share pence p p diluted earnings per share pence p p weighted average number shares issue basic diluted return capital employed financial results ukgaap turnover operating profit profit taxation profitafter taxation basic earnings per share pence p p p diluted earnings per share pence p p p weighted average number shares issue basic diluted return capital employed return capital employed calculated statutory profit taxation percentage average capital employed year gsk annual report noitamrofni rotsevnifinancial record continued amounts accordance us gaap turnover net incomeloss basic net incomeloss per share pence p p p p p diluted net incomeloss per share pence p p p p p information presented accordance us gaap derived financial information prepared ifrs adopted use european union uk gaap information presents us gaap net incomeloss net incomeloss per share results yearended st december adjusted reverse amortisation expense goodwill indefinitelived intangible assets sfas also applied years adjusted net incomeloss adjusted basic net incomeloss per share pence p adjusted diluted net incomeloss per share pence p exchange rates guide holders adrs following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates last day month year feb jan dec nov oct sept high low noon buying rate th february us number employees usa europe international asia pacific japan middle east africa latin america canada international manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed glaxosmithkline contract basis gsk annual report noitamrofni rotsevnifinancial record continued balance sheet ifrs noncurrent assets current assets totalassets current liabilities noncurrent liabilities total liabilities net assets equity shareholdersequity minority interests balance sheet uk gaap fixedassets current assets totalassets current liabilities noncurrent liabilities total liabilities net assets equity shareholdersequity minority interests amounts accordance us gaap total assets net assets longterm borrowings shareholders equity gsk annual report noitamrofni rotsevnishareholder information share price st january high year low year st december increasedecrease table sets middle market closing prices derived london stock exchange daily official list companys share priceincreased byin price st january st december compares anincreasein ftse index year market capitalisation market capitalisation based shares public issue glaxosmithkline st december billion date gsk thefourthlargest company market capitalisation ftse index smithkline beecham plc floating rate unsecured loan stock loan stock listed exchange holders may require smithkline beecham plc redeem loan stock par ie every loan stock held first business day march june september december holders wishing redeem part loan stock complete notice back loan stock certificate return registrar arrive least days relevant redemption date taxation general information concerning uk us tax effects share ownership set 'taxation information shareholders ' page dividends glaxosmithkline pays dividends quarterly details dividends declaredthe amount payment dates given note dividends per share table sets dividends per share paid last five years year pence gsk annual report noitamrofni rotsevni dividends per ads table sets dividends per ads paid us dollars last five years translated us dollars applicable exchange rates year us dividend calendar fourth quarter exdividend date th february record date th february payable th april first quarter exdividend date th may record date th may payable th july second quarter exdividend date nd august record date th august payable th october third quarter exdividend date st november record date rd november payable th january internet information company including details share price available gsks website wwwgskcom information made available website constitute part annual report investor relations investor relations may contacted follows uk great west road brentford middlesex tw gs tel fax usa one franklin plaza po box philadelphia pa tel toll free tel outside usa fax shareholder information continued analysis shareholdings number total total number analysis shareholdings st december accounts accounts shares shares holding shares totals held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline totals bank new yorks holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value th february number holders record shares usa holdings shares thenumberof registered holders adrs holdings adrs certain shares adrs held brokers nominees result number holders record registered holders usa representative number beneficial holders orofthe residence beneficial holders control company far known company directly indirectly owned controlled one corporations government thecompany know arrangements operation might result change control company major shareholders voting rights per share shareholders substantial shareholdings th february company received notification following interests shares issue excluding treasury shares bnynominees limited holds shares representing shares held behalf holders adrs evidence adss legal general investment management limited holds shares representing barclays plc holds shares representing far known company person owner shares issue excluding treasury shares company directors officers interests directors officers company defined thecompanies act share options company given remuneration report pages exchange controls limitations affecting securityholders currently uk laws decrees regulations restricting import export capital affecting remittance dividends orother payments holders companys shares nonresidents uk limitations relating nonresidents uk english law companys memorandum articles association right tobe holder tovote respect companys shares documents display memorandum articles association company documents referred annual report available inspection registered office company publications late march gsk publish website corporate responsibility report covering performance areas including community investment ethics integrity access medicines rd environment health safety gsk annual report noitamrofni rotsevnishareholder information continued nature trading market annual general meeting ordinary shares company listed london stock queen elizabeth ii conference centre th may exchange th december shares also listed broad sanctuary westminster new york stock exchange nyse inthe form american depositary london swp ee shares adss date annual general meeting company 's principal forum following tables set periods indicated high communication private shareholders addition formal low middle market closing quotations pence shares business presentation chief executive officer london stock exchange high low last reported sales performance group future development prices us dollars adss thenyse opportunity questions board chairmen board 's committees take questions matters relating glaxosmithkline pence per share committees high low investors holding shares company nominee service quarter ended st march arrange nominee service appointed february corporate representative proxy respect shareholding january order attend vote meeting december november adr holders wishing attend meeting must obtain proxy october bank new york enable attend meeting september vote business transacted adr holders may instruct quarter ended st december bank new york way shares represented quarter ended th september adrs voted completing returning voting quarter ended th june card provided bank accordance instructions given quarter ended st march quarter ended st december financial reporting quarter ended th september financial reporting calendar quarter ended th june quarter ended st march announcement st quarter results april year ended st december announcement nd quarter results july year ended st december announcement rd quarter results october year ended st december preliminary announcement annual results february publication annual reportreview march us dollars per ads high low results announcements quarter ended st march results announcements issued london stock exchange february available news service shortly afterwards january issued media made available website sent december ussecurities exchange commission nyse november october financial reports september company publishes annual report investor quarter ended st december needing full detail report annual review quarter ended th september available date publication website quarter ended th june annual review sent shareholders date quarter ended st march publication shareholders may also elect receive annual report quarter ended st december writing companys registrars alternatively shareholders may quarter ended th september elect receive notification email publication financial quarter ended th june reports registering wwwshareviewcouk quarter ended st march year ended st december copies previous financial reports available website year ended st december printed copies obtained registrar uk year ended st december customer response center usa toth february gsk annual report noitamrofni rotsevnigsk annual report noitamrofni rotsevni shareholder information continued ordinary shares companys shares listed london stock exchange registrar companys registrars lloyds tsb registrars causeway worthing west sussex bn da wwwshareviewcouk tel inside uk tel outside uk registrars also provide following services glaxosmithkline investment plan glaxosmithkline individual savings account glaxosmithkline corporate sponsored nominee shareview service shareview dealing service share dealing service hoare govett operate postal dealing service companys ordinary shares enables investors buy sell shares competitive commission charges details may obtained telephoning glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel provision details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser american depositary shares companys shares listed nyse form american depositary shares evidenced american depositary receipts adrs one represents two ordinary shares general nyses rules permit company follow uk corporate governance practices instead apply usa provided company explains significant variations explanation provided companys website adr programme administrator adr programme administered bank new york shareholder relations po box church street station new york ny wwwadrbnycom tel toll free tel outside usa customer response center tel toll free administrators also provide global buydirect direct ads purchasesale dividend reinvestment plan adr holdersgsk annual report noitamrofni rotsevni taxation information shareholders information shareholders gift disposal subject uk inheritance tax us estate gift tax estate gift tax convention would summary main tax consequences holders shares generally provide tax paid usa credited tax adrs citizens residents uk usa set payable uk complete analysis possible tax consequences purchase ownership securities intended stamp duty general guide holders advised consult advisers uk stamp duty stamp duty reserve tax sdrt subject certain respect tax consequences purchase ownership exemptions payable purchase shares rate shares adrs consequences state local tax purchase price minimum charge laws usa implications new ukus income tax stamp duty liability arises convention us shareholders statement based upon uk us tax laws practices date report following summary certain uk taxation usa federal income tax considerations may relevant usholder new ukus income tax convention came force st shares adrs summary applies shareholder holds march provisions new treaty apply uktax shares adrs capital assets citizen resident usa purposes st april ukcorporation tax th april domestic corporation otherwise subject united states uk income tax capital gains tax st may federal income taxation net income basis respect shares withholding taxes ustax purposes provisions new adrs resident uk uktax purposes treaty apply st may withholding taxes st january hold shares purposes trade profession vocation ustaxes however holders shares adrs carried uk branch agency ability elect continue use provisions previous treaty months following new treatys entry force taxation dividends election must made advance first event new gross amount dividends receivedwithout reduction uk treaty would apply withholding tax treated foreign source dividend income us tax purposes eligible dividend received deduction us holders adrs generally treated owners allowed us corporations dividends adrs payable us underlying shares purposes current usauk double dollars dividends shares payable sterling dividends paid taxation conventions relating income gains income tax pounds sterling included income us dollar amount convention estate gift taxes estate gift tax convention calculated reference exchange rate day dividends purposes us internal revenue code received holder subject certain exceptionsfor short amended code term hedged positions individual eligible us holder following analysis deals dividends paid th april subject us taxation maximum rate respect advance corporation tax act abolished qualified dividends received shareholders advised consult tax advisers confirm eligibility uk shareholders taxation capital gains taxation dividends generally us holders subject uk capital gains tax th april rate tax credits reduced one ninth subject us tax capital gains realised sale result compensating reductions rate tax dividend disposal shares adrs income increase tax borne uk resident individual estate gift taxes shareholders tax credits however longer repayable estate gift tax convention us shareholder shareholders tax liability less associated tax credit generally subject uk inheritance tax taxation capital gains stamp duty uk shareholders may liable uk tax gains disposal uk stamp duty sdrt subject certain exemptions payable shares adrs may also entitled indexation relief issue transfer shares adr custodian depository taper relief sales indexation relief calculated market rate price issued amount value shares st march cost subsequent consideration provided transferred sale value purchases date purchase indexation relief transferred consideration individual shareholders ceased th april taper relief available individual shareholders hold deemed hold sdrt would payable transfer adr uk stamp shares least three years sold duty payable transfer adr provided instrument transfer executed remains times outside inheritance tax uk stamp duty transfer adr would payable individual shareholders may liable inheritance tax transfer rate consideration transfer sale shares adrs tax may charged amount underlying shares would result liability uk stamp duty value shareholder 's estate reduced result transfer case may sdrt rate minimum charge way gift disposal less full market value stamp duty liability arisesgsk annual report noitamrofni rotsevni glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation advance corporation tax act advance payment uk tax made dividends paid direct us equivalent american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares adss ordinary shares registered new york stock exchange basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc creditors accounts payable currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates debtors accounts receivable defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy share based employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements bymaking offsetting commitments intangible fixed assets assets without physical substance brands licences patents knowhow marketing rights purchased outside parties nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue shares outstanding statement recognised income expense statement comprehensive income stocks inventories subsidiary undertaking affiliate glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenuegsk annual report noitamrofni rotsevni index accounting policies independent auditors report accounting presentation intellectual property achieve commercial operational excellence interest rate risk management acquisitions disposals internal control framework annual general meeting inventories assets held sale investments associates joint ventures associates joint ventures investor information best place best people best work legal proceedings board movements equity build best product pipeline industry net debt cash cash equivalents new accounting policies future requirements combined code nonexecutive director terms conditions fees commitments nonexecutive directors remuneration committee reports notes financial statements community investment operating financial review prospects consolidated balance sheet operating profit consolidated cash flow statement intangible assets consolidated income statement investments consolidated statement recognised income expense noncurrent assets consumer healthcare noncurrent liabilities contact details operating income contingent liabilities provisions corporate executive team outlook risk factors corporate governance pensions postemployment benefits corporate responsibility pharmaceutical turnover critical accounting policies presentation financial statements description business principal group companies dialogue shareholders products competition directors senior management remuneration property plant equipment directors interests quarterly trend directors interests contracts reconciliation us accounting principles directors statements responsibility regulatory environment dividends related party transactions earnings per share remuneration report employee costs report directors employee share schemes responsibility environment health safety exchange rates risk factors executive director terms conditions remuneration segment information finance costs share capital share premium finance income share options financial instruments related disclosures shareholder information financial position resources strategy financial record taxation financial statements taxation information shareholders financial summary total equity financial trends ratios trade payables five year record trade receivables foreign exchange risk management trademarks global manufacturing supply transition ifrs glossary terms treasury policies goodwill us law regulation governance policy world economy ifrs adjustments world market pharmaceuticals improve access medicines incentive plans discovering important medicines eradicating diseases improving quality peoples lives making medicines available greater number people matters people jp garnier left sir christopher gent rightannual report corporate website brochure us meeting global challenges products commitment innovation health access medicines responsibility therapy areas community mission research development would better future investors like know media centre careers gsk wwwgskcom corporate annual responsibility review report human access medicines interview research innovation chairman ceo ethical conduct focus patient annual employees year vaccine human rights growing brands report environment powering performance community investment performance highlights business operating review summary remuneration report interview corporate governance chairman ceo summary financial statements financial summary shareholder information description business chairman ceos corporate governance closing letter remuneration report operating financial review prospects financial statements notes financial statements investor information feel better live longer head office registered office glaxosmithkline plc great west road designed cgi london brentford middlesex tw gs printed midas press uk paper used united kingdom production document made pulps harvested tel sustainable forests also using sawmill residues wwwgskcom forest thinnings elemental chlorinefree feel better live longer glaxosmithkline annual report